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Abstract
Adenylate cyclase toxin (CyaA) toxin is an important virulence factor of Bordetella 
pertussis, the causative agent of whooping cough, and a potential component of 
acellular pertussis vaccine. The work involved the production of three purified forms of 
CyaA with different enzymic and invasive properties. These were: the native 
enzymatically-active, invasive toxin (CyaA), an invasive derivative lacking AC 
enzymic activity (CyaA*) and a non-acylated, non-invasive form of CyaA (proCyaA). 
These were expressed in E. colt BL21/DE3 as recombinant proteins. After purification 
by a combination of chromatographic methods (Q-and Butyl-Sepharose) their properties 
were investigated by several assays. The LPS content of these preparations was very 
low. The AC enzymic activity was assayed by a conductimetric method. CyaA and pro­
CyaA had a high level of enzymic activity but that of CyaA* was very low. The 
cytotoxic properties of CyaA* and pro-CyaA towards J774.2 cells were similar and 
were 100-fold less than that of CyaA, but these differences were shown to some extent 
to be Ca^^ -dependent for CyaA*. Caspase 3/7 activities were measured over a range of 
toxin concentrations. At these concentrations, neither urea buffer alone nor CyaA* 
induced any significant increase in caspase 3/7 from different mammalian cells. The 
greatest effect of CyaA was observed on J774.2 and RBL-2H3 cells where increasing 
concentration of toxin gave increasing activity. Different concentrations of CyaA and 
CyaA* were used to investigate dose-dependent effects of the toxins on phagocytosis 
and the oxidative burst in U937 human monoblastic cells, J774.2 mouse macrophage­
like cells and fresh human granulocyte cells (whole blood used). Significant effects 
were seen with CyaA on both phagocytosis and oxidative burst, but CyaA* did not have 
a significant effect on either. The results of this first part of the study showed that both
enzymatic and invasive functions are required for the cytotoxic effects of adenylate 
cyclase toxin.
In the second part of the work, CyaA was formulated as protein-coated microcrystals 
(PCMCs) on the surface of microcrystals of DL-valine. The aims of this formulation 
were to remove the urea, normally used to stabilize the protein, and to determine the 
stability of the enzymic and cytotoxic activities of the protein in this form, as a dry 
powder and when the PCMCs were redissolved in aqueous solution. The CyaA in the 
PCMCs was shown not to be readily soluble in aqueous buffers, but could be 
resolubilised in urea buffer and retained high AC and cytotoxic activity. Many different 
types of PCMC formulation were prepared in attempts to increase solubility of PCMCs 
in aqueous solution. PCMCs were made with CyaA coprecipitated with different 
combination of CaM, BSA, CaCE or ATP and crystals were dissolved in different 
buffers at various pHs. The most promising results were obtained with CyaA-CaM- 
BSA-PCMCs where the highest levels of both AC enzymic and cytotoxic activities 
were seen when the PCMCs were dissolved in lOOmM Bicine (pH 8). CaM alone 
preserved only the AC enzymic activity of PCMCs when coprecipitated with CyaA and 
DL-valine. AC and cytotoxic activities of CyaA were stable in PCMCs for up to a week 
at 37°C.
CyaA-CaM-BSA-PCMCs induced a strong serum IgG response to CyaA and BSA 
when injected subcutaneously into mice. The results indicated that CyaA-CaM-BSA- 
PCMCs offer a promising way to preserve the activity and antigenicity of CyaA in a 
non-aqueous formulation. Neutralisation tests proved that the antibody generated from 
mice immunised with CyaA-B SA-CaM-PCMCs was able to neutralise the AC enzymic 
and cytotoxic activities. Such PCMCs could have application for presentation of protein 
antigens that normally require cold storage for stability.
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Introduction
Chapter 1 
Introduction
1-1 The genus Bordetella
There are nine named species of the genus Bordetella, B. pertussis, B. pat'apertussis, B. 
bronchiseptica, B. avium, B. holmesii, B. trematum, S. hinzii, B. petrii and B, ansorpii. 
They are mostly obligatory parasites and inhabit the surface of the respiratory tract of 
humans and waim-blooded animals, including birds (Roberts and Parton, 2001; Ko et 
a l,  2005). B. pertussis infects only humans and causes the acute respiratory disease 
known as whooping cough (Yeh et al, 2003). 5. parapertussis strains can be divided 
into two genetically distinct types, those which infect humans causing a pertussis-like 
disease and those which cause respiratory infection in sheep (Cullinane et a l ,  1987). B. 
bronchiseptica is a common respiratory tract coloniser in wild and domesticated 
mammals where it generally causes chronic and persistent respiratory disease and 
asymptomatic infection (Woolfrey and Moody, 1991). It has also been occasionally 
described as a cause of pneumonia and bacteraemia in humans (Reina, 1991; Dorittke et 
a l, 1995; Gueirard et a l,  1996). B. avium causes an upper respiratory tract infection 
called bordetellosis in turkey poults and other birds but it has rarely been reported to 
cause infection in humans (Vandamme et a l ,  1995). B. hinzii was proposed as the 
species for some strains isolated from poultry with respiratory disease, but the 
aetiological role of the organism was unclear. Recently it was reported as being a 
causative agent of septicaemia (Vandamme et a l ,  1995; Kattar et a l,  2000). B. holmesii 
has been isolated from human sputum and nasophaiyngeal specimens from patients with 
symptoms similar to pertussis. Recently, B. holmesii was isolated from a patient with 
sickle cell anaemia (Tang et a l, 1998; Mazengia et a l, 2000; Njamkepo., et al 2000).
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B. trematum  contains isolates from human wound and ear infections but never from the 
respiratory tract and was described originally as atypical Bordetella or unidentified 
(Vandamme et a l, 1996). von Wintzingerode et al. (2001) described a novel Bordetella 
species which was isolated from an anaerobic, dechlorinating bioreactor culture 
enriched from river sediment. Comparative 16S rDNA sequence analysis and DNA- 
DNA hybridisation experiments demonstrated that B. petrii was the first member of the 
genus Bordetella to be isolated from the environment. It is capable of anaerobic growth 
and also has the ability to reduce selenate to selenium. Ko et a l  (2005) have reported a 
Gram-negative bacillus (SMC-8986^) which was isolated from an epidermal cyst. 
Genotypic and phenotypic characteristics of this bacterium with regard to 16S rRNA 
sequence, analyses of cellulai* fatty acid composition and two protein-coding genes 
{risk  and ompA) led to the proposal that SMC-8986^ should be recognised as a member 
of the Bordetella genus, B. ansorpii.
1-2 The species Bordetella pertussis
Before the introduction of the genus Bordetella by Moreno (1952), the first three 
recognised species were grouped in the genus Haemophilus. Later, after several changes 
of name, it was classified in its own genus, Bordetella, which was named in honour of 
Jules Bordet. In 1640, the French physician De Baillou noted an epidemic with the 
chai'acteristic symptoms of whooping cough in Paris in 1587 and made the first cleai* 
description of the disease. Although the aetiological agent had probably been observed 
independently by several physicians during the last decades of the 19^ ^^  century, the 
modern history of the disease clearly started in 1904 with the cultivation of the 
organism by Bordet and Gengou (Bordet and Gengou, 1906). In 1931, before 
vaccination against whooping cough was introduced, a standard textbook of 
Bacteriology stated that the disease might be one of the major causes of death in
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civilised countries. Now it remains a ubiquitous, serious infectious disease causing, 
world-wide, an estimated 40 million cases and 360,000 deaths each year, 90 percent of 
which occur in developing countries (Ivanoff and Robertson, 1997). B. pertussis is a 
small (0.2 to 0.5 x 1pm), non-motile Gram-negative coccobacillus. It is strictly aerobic 
with an optimal growth temperature of 35-37“ C, having a respiratory metabolism 
(Porter et a l ,  1994). Although B. pertussis is the most fastidious of the Bordetella 
genus, the organism can be cultured in a buffered simple salts medium containing 
several amino acids, an organic sulphur source, and some growth factors such as 
nicotinic acid (an essential vitamin for the micro-organism), L-glutamic acid and 
ascorbic acid (Rowatt, 1957; Stainer, 1988). Essential amino acids are L-glutamic acid 
and one of the sulphur containing amino acids such as L-cysteine. Supplementation of 
the medium with heptakis (2,6-O-dimethyl) (3-cyclodextrin and casamino acids not only 
improves the growth but also greatly enhances the yield of surface antigens such as 
pertussis toxin (PT), fimbriae (FIM), filamentous haemagglutinin (FHA) and adenylate 
cyclase toxin (CyaA) in the culture supernatant (Hozbor et a l ,  1994).
1-2-1 Clinical significance
B. pertussis is a strict human pathogen, and there is no evidence for the existence of an 
animal or environmental reservoir (Cotter and Miller, 2001; Chen-y and Heininger, 
2004). It colonises the human respiratory tract and is transmited through the aerosolised 
droplets produced by coughing. Whooping cough is acute, with severe coughing which 
can progress to vomiting, convulsions, coma and death (Mattoo and CheiTy, 2005). 
After an incubation period of 7-14 days, it manifests itself initially in the new host as a 
cold or mild cough, with little fever (Hewlett, 1997). The clinical course of whooping 
cough can be divided into three stages, 1) catanhal, 2 ) paroxysmal and 3 ) convalescent. 
The first stage is characterised by an irriating cough, slight fever and sneezing, lasting
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for 1-2 weeks (Friedman, 1988). Coughing becomes more prominent in the paroxysmal 
stage with disjointed attacks, whooping and vomiting lasting 2 to 6  weeks (CheiTy et al., 
1988). The convalescent stage is marked by decreased paroxysms, persistent cough and 
secondary bacterial infections. Severe consequences of pertussis infection include 
encephalopathy, iiTeversible brain damage, and pneumonia. Moreover, physical damage 
such as the rupture of the frenulum of tongue, rectal prolapse and inginal hernia can 
result from paroxysmal coughing (Hewlett, 1995; 1997). Pertussis may occur at any 
age, but most cases of serious disease and the majority of fatalities are observed in early 
infancy (Edwards et at., 1999). In adults, the main manifestation is a persistent 
paroxysmal cough, which is largely unresponsive to treatment. Typical pertussis occurs 
mainly during primary infection in unimmunized children, but 25 to 30% of such 
children present with mild or atypical pertussis. They may not be suspected of suffering 
from pertussis but will spread the disease. Also, adults play an important role in 
transmission (Isacson and Trollfors, 1993). Secondary infections, such as pneumonia 
and otitis media, may accur during pertussis particularly in infants, resulting from 
impairment of clearance mechanisms by B. pertussis (CheiTy, 1996; Hewlett, 2000).
1-2-2 Epidemiology of B. pertussis
It is believed that the transmission of B. pertussis occurs via aerosol droplets expelled 
by severe coughing that pass directly from the respiratory tract of infected individuals to 
those of susceptible hosts (Hewlett, 1997). Before the introduction of vaccines and in a 
population in which immunisation is not peifoiTned, pertussis is one of the ten most 
common causes of death and is an epidemic disease with cycles every 2-5  years. 
Although the incidence has decreased significantly since the widespread use of 
vaccination, outbreaks of pertussis occur periodically (Cattaneo et a l, 1996). It appears 
that B. pertussis infections aie endemic in adults and adolescents even when they have
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mild or unrecognised disease, therefore these infections might serve as the source of the 
epidemic cycles involving unvaccinated children (Rappuoli, 1994; Black, 1997). Now 
that acellular vaccines are available, it may be possible to give booster immunization to 
adults to attempt to eliminate the reservoir of infection (Cherry, 1997).
1-2-3 Diagnosis
Isolation of B. pertussis from clinical specimens is the gold standard for the diagnosis of 
pertussis (Muller et a l,  1997). The standard laboratory method for the diagnosis of B. 
pertussis infection is culture of the organism from a nasophaiyngeal swab. Clinical 
diagnosis of B. pertussis is often possible due to the characteristic and prolonged 
paroxysmal coughing in the typical disease. However, clinical features tend to vary with 
age and immune status, in adolescents and adults (Hallander et a l,  1999). 
Unfortunately, the catarrhal stage of the pertussis resembles a common cold, meaning 
that diagnosis may not be possible until the second stage (paroxysmal stage). 
Laboratory methods include direct detection of B. pertussis from nasopharyngeal 
aspirates and then by culture (Muller et a l ,  1997). PCR assay has been used as an 
additional method for detecting and differentiation of B. pertussis and B. parapertussis. 
This method is highly sensitive and more rapid than culture to detect B. pertussis in 
specimens containing only a few cells (Aoyama et a l,  1997; Sloan et a l,  2002). PCR is 
particularly useful for pertussis diagnosis in pre-vaccinated infants. A number of 
serological tests, such as agglutination, complement fixation, fluorescent antibody test 
and the ELISA are available for diagnosis of B. pertussis (Hallander, 1999). The 
success of culture and serology is limited, especially among pre-vaccinated and 
recently-vaccinated children. In pre-vaccinated infants with whoop and less than 2 
weeks of cough, PCR testing should be implemented promptly (Bamberger et al, 2005).
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1-2-4 Treatment
Despite a dramatic reduction in the incidence of pertussis caused by universal 
immunization, outbreaks still continue to occur in countries with a high level of vaccine 
coverage. Treatment of infection with antibiotics may improve symptom severity during 
the catarrhal phase of pertussis but has no effect on established paroxysms, vomiting, or 
apnea if given during the paroxysmal or convalescent phases (Langley et al, 2004). The 
treatment for pertussis is primarily supportive, with nursing supervision during the 
paroxysmal and convalescent stages of illness. Antimicrobial therapy of B. pertussis 
established that several antibiotics are effective. Erythromycin is recommended for 
treatment of pertussis to prevent transmission of infection, but it is poorly tolerated 
because of gastrointestinal side effects. In addition, chloramphenicol, trimethoprim- 
sulphamethoxazole and tetracycline are effective. However, antibiotic treatment has 
limited value because the illness is usually unrecognised during the peak of 
contagiousness (Hoppe, 1996). It has been found recently that azithromycin is as 
effective as erythromycin estolate for the treatment of pertussis in children. 
Gastrointestinal adverse events were much more common with erythromycin treatment 
than azithromycin (Langley et a l ,  2004).
1-3 Regulation of virulence
It was recognised that certain members of the Bordetella genus share a genetic locus 
B vghS  that encodes a biological switch enabling them to mediate transition between 
different phases (Bvg* ,^ Bvg^ and Bvg") that are characterised by distinct patterns of gene 
expression. Although in the laboratory BvgAS activity can be inhibited by low 
temperature (<25°C), nicotinic acid and sulphate ions, the true signals sensed in nature 
or in the mammalian hosts are unknown (Deora et al, 2001; Mattoo et a l  2001). The 
BvgAS signal transduction system controls a highly-regulated programme of gene
introduction
expression in response to environmental stimuli. This regulatory cascade mediates the 
co-ordinated expression of almost all of the known or suspected colonisation and 
virulence factors currently associated with the infectious cycle of Bordetella. Studies on 
the bvgAS  locus have shown that its transcript is controlled by a 350 bp DNA sequence 
having four promoters (Figure 1.1) promoters Pi, P2 and P3 are responsible for the 
transcription of the bvg locus, whereas the fourth, P4 directs the synthesis of an 
antisense RNA of unknown function (Scarlato et al, 1990). Ppha promoter, located near 
the bvg locus is responsible for the transcription of the adhesion factor FHA of B. 
pertussis. P fha"^ has also been shown to express low levels of the FHA precursor 
protein, FhaB, in vitro (Boucher et a l, 1997).
BvgA and BvgS are members of a group of two-component regulatory signal- 
transducing proteins that communicate by a four-step His-Asp-His-Asp phosphorelay. 
According to the studies of Cotter and Jones (2003) and Deora (2004), phosphorylated 
BvgS can phosphorylate BvgA, which is then able to activate or repress transcription of 
the cognate genes. Akerley and Miller (1993) demonstrated that whilst BvgAS is 
activated, Bordetella are in the Bvg^ phase, characterised by the expression of a number 
of Bvg-activated protein factors, including the adhesins and toxins encoded by the vag 
genes (Bvg-activated genes). They also reported that inactivation of BvgAS by 
modulating signals or by mutation results in the transition to the Bvg” phase. In this 
phase, the vag genes are repressed and vrg genes (Bvg-repressed genes) are expressed. 
The role of the Bvg^ phase in Bordetella infection is unclear but it has been suggested 
that this intermediate phase might be involved in aerosol transmission (Cotter and 
Miller, 1997).
Figure 1.1 Schematic representation of BvgAS of B. pertussis
Schematic representation of the genetic region comprising the bvg operon and the fhoE  
gene. The genes encoding BvgA, BvgS, BvgR and FhaB are shown (coloured boxes) and 
the direction of transcription from each promoter is shown by arrows (Adapted from 
Cotter and Allison 2003)
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BvgS is a 135 kDa periplasmic sensor protein which resides in the cytoplasmic 
membrane and autophosphorylates using the y-phosphoryl group of ATP (Boucher et al, 
1994). It is often termed an unorthodox sensor protein because it contains a number of 
extra functional domains. BvgS consists of a periplasmic input domain and several 
cytoplasmic domains, the linker, transmitter, receiver and the C-terminal domain (Roy 
et al,, 1990; Ui and Miller, 1995). It was shown that deletion of these extra domains 
made BvgS non-functional. BvgA, a response regulator, is a 23-kDa cytoplasmic 
protein comprising a N-terminal receiver and a C-terminal output domain, which 
contains a helix-turn-helix (HTH) DNA binding motif. The transfer of a phosphate 
group from the C-terminal output domain of BvgS activates BvgA. A heptameric 
sequence-specific BvgA binding site, TTTCCTA, first proposed by Roy and Falkow 
(1990), is present as either direct or inverted repeats upstream of various 6vg-regulated 
genes. These heptameric repeats are involved in the binding of BvgA to virulence- 
activated promoters, as shown by DNase I protection studies (Boucher and Stibitz, 
1995; Marques and Carbonetti., 1997). Merkel and Stibitz (1998) recognised that the 
bvgA gene product is responsible for repression of the bvg-repressed genes. A locus 
required for expression of repressor activity was identified, designated as bvgR, that is 
located immediately downstream of the bvgS gene (Merkel et a l,  1995). The BvgR 
protein was shown to be responsible for the regulation of the vrg genes whose functions 
aie unknown. It was speculated that the ^vgR locus might be involved in the 
establishment or persistence of B. pertussis in the host (Merkel et a l ,  1998). The results 
from studies with a ZivgR-defective mutant strain indicated that Z?vgR-mediated 
regulation of gene expression contributed to respiratory infection of mice. A recent 
study demonstrated that expression of BvgR is activated by binding of phosphorylated 
BvgA to the bvgR promoter (Merkel et a l,  2003).
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A second two-component regulatory system has been identified in B. bronchiseptica, 
which is required for the expression of certain 6vg-repressed genes. This locus was 
designated risAS due to its association with reduced intracellular survival of B 
bronchiseptica within eukaryotic cells (Jungnitz et a l,  1998). Recently, it was found 
that RisA was essential for expression of vrg-repressed genes and that the RisA protein 
binds to the promoter region of both the yrg6  and vrg lS  genes (Croinin et a l ,  2005), 
but that, the risS gene does not encode a functional RisS protein (Stenson et a l,  2005).
1-4 Virulence factors of Bordetella pertussis
B. pertussis produces several potential virulence factors which play an important role in 
pathogenesis. These factors can be grouped into two major categories: adhesins, such as 
filamentous haemagglutinin, pertactin and fimbriae, and toxins, such as pertussis toxin, 
adenylate cyclase toxin, dermonecrotic toxin and tracheal c y to toxin (Figure 1.2). The 
adhesins and toxins act in concert to establish infection. The bacteria bind to ciliated 
epithelial cells in the upper respiratory tract. Once attachment is initiated, toxins 
produced by the bacterium enable colonisation to proceed by interfering with host 
clearance mechanisms (Goodwin and Weiss, 1990; Smith et a l ,  2001). Other virulence 
factors of B. pertussis, which include LPS and the products of serum resistance loci, 
also need to be considered. As Kerr and Matthews (2000) observed, the 
pathophysiological sequence consists of attachment, evasion of host defences, local 
effects and systemic effects. Our understanding of Bordetella virulence at the molecular 
level has led to the development of new acellular vaccines against whooping cough. In 
the following pages, the properties of B, pertussis virulence factors will be explained.
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Figure 1.2 Virulence factors of B. pertussis
Some important virulence factors of B.pertussis are shown in the Figure and their 
properties are described in the text pages (Adapted from Weiss, 1997).
FHA: filamentous haemagglutinin 
TCF: tracheal colonisation factor 
BrkA: Bordetella resistance to killing protein 
TCT: tracheal cytotoxin
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1-4-1 Filamentous haemagglutinin
The major adhesion protein is FHA, a 220kDa protein expressing at least three different 
binding activities 1) carbohydrate binding, 2) heparin sulphate binding and 3) integrin 
binding via an RGD site which comprises the amino acid sequence Arg-Gly-Asp (Locht 
et ah, 1993). Carbohydrate binding mediates attachment to ciliated cells present in the 
respiratory epithelium that is the main binding site for B, pertussis in the respiratory 
tract (Tuomanen and Weiss, 1985). FHA also binds to sulphated carbohydrates of 
sulphatides and peptidoglycans on the surface of epithelial cells or in the extracellular 
matrix (Brennan et a l, 1991; Menozzie et a l,  1994). The hepaiin binding activity of 
FHA may allow the bacterium to adhere to non-ciliated cells as demonstrated using 
WiDr (human colon carcinoma cell), Hela and Vero cells (Hazenbos, et al, 1993; 1995). 
The FHA tail region contains an RGD sequence, which is present in a number of other 
bacterial adhesins and is a region of attachment of many eukaiyotic integrin-binding 
proteins. It has been realised that it is this RGD tripeptide which facilitates binding to 
the integrin receptor CR3 which might allow entry of B, pertussis into phagocytes 
without an oxidative burst (Relma/r et al; 1990).
FHA is initially produced as a large 367 kDa precursor FhaB, which undergoes both 
amino-terminal (Lambert-Buisine et a l, 1998) and carboxy-terminal maturation 
(Renauld-Mongenie et a l, 1996). FHA is present on the surface of B. pertussis and is 
also secreted into the medium in liquid culture (Roberts and Parton, 2001). FHA is also 
associated with the outer membrane of the bacterial surface where it is thought to be 
responsible for autoagglutination of the bacteria by FHA-FHA homotypic interaction 
(Menozzi et a l, 1994). The synthesis of FHA depends on an outer-membrane- 
associated accessory protein named FhaC (Jacob- Dubuission and Hamel, 1999). FhaC 
is a pore-forming outer-membrane protein that interacts with FhaB, allowing for
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secretion of the FhaB. An FhaC mutant exhibited a slight, transient defect in 
colonisation of the nasal cavity and trachea of mice (Geuijen et ah, 1997).
FHA is also highly immunogenic in humans and is a protective antigen in animal 
models (Shahin et a l,  1992; Amsbaugh et a l, 1993; Cahill et a l, 1993). McGuirk and 
Mills (2000) demonstrated that interaction of FHA with receptors on macrophage 
results in suppression of synthesis of the pro-inflammatory cytokine, interkeukin-12  
(IL-12), via an IL-10 dependent mechanism. These data reveal a role for FHA in 
facilitating persistence by curbing protective T hl immune responses (Zaretzky et a l,
2002). FHA along with CyaA was recently shown to be necessary to inhibit monocyte- 
dependent T-cell proliferation in vitro (Boschwitz et a l,  1997). A recent study showed 
that a direct physical association can occur between CyaA toxin and FHA. It was 
suggested that FHA might play a role in CyaA toxin retention on the surface of B. 
pertussis and raises the possibility of an involvement of adherence mediated by FHA in 
delivery of AC toxin from the bacteria to the target cells (Zaretzky et a l ,  2002). 
Furthermore, as a dominant adherence factor it may play a role in human host species 
tropism and receptor recognition.
1-4-2 Fimbriae (FIM)
B. pertussis has two antigenetically distinct types of fimbriae, features of serotype 2 and 
serotype 3 strains, each of which are made up of major and minor subunits and are 
believed to cause persistency of infection (Locht et a l, 1992; Willems et a l, 1992). The 
main body of each fimbria is composed of a major subunit protein, Fim2 or Fim3 also 
known as agglutinogens (AGG2 and AGG3), of 22.5 kDa or 22 kDa encoded by 
unlinked chromosomal loci fim 2  and fim3, respectively (Livey et a l,  1987). The same 
40 kDa minor fimbrial protein, FimD, is present at the tip of both types of fimbriae
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(Geuijen et al., 1997). Different strains of B. pertussis express fim2 and fim3 singly or 
together or not at all. A third unlinked locus,/im X, is expressed only at very low levels 
in B. pertussis and recently a fourth fimbrial locus, //mN was identified in B. 
bronchiseptica (Kania et al, 2000). It was reported that a fifth gene, fim h , was 
identified in B. parapertussis and B. bronchiseptica, located immediately upstream of 
the fimbrial biogenesis operon fimBCD  and 3 ’ of fhaB , that is expressed and capable of 
encoding a fimbrial subunit type, FimA (Boschwitz et a l ,  1997).
The major fimbrial subunits Fim2 or Fim3 bind to sulphated sugars which are 
ubiquitous in the respiratory tract, whereas the minor subunit FimD shows affinity for 
VLA-5, an integrin that is found on macrophages (Geuijen et a l, 1996). Fimbriae 
stimulate agglutinating antibodies and there is evidence that agglutination elicited by 
whole-cell vaccines is correlated with immunity against pertussis in humans (Medical 
Research Council 1954). Binding of fimbriae to monocytes results in activation of CR3 
(complement receptor type3), the monocyte receptor of FHA, reflecting their synergistic 
action during infection (Menozzi et al., 1991). 7n vivo studies have shown that Fim' B. 
pertussis strains are unable to multiply in the nasopharyx and trachea of mice (Mooi et 
a l, 1992; Geuijen et a l,  1997). It has been shown that fimbriae are protective 
immunogens in mice and that a five-component acellular B. pertussis vaccine 
containing Fim2 and Fim3 is very efficacious in the human infant (Jones et a l, 1995; 
Steffen et a l, 1996; Willems et a l, 1998). Another study showed that when vaccine 
containing Fim2, Fim3, FT, FHA and PRN was compared with vaccine containing PT, 
FHA and PRN the first vaccine displayed significantly greater efficacy (Olin et al, 
1997). It has been shown by Mattoo et a l  (2000) that fimbriae are essential components 
for persistence of B. bronchiseptica in the trachea in mouse and rat models.
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1-4-3 Pertactin (PRN)
Autotransporters are outer-membrane proteins which are secreted by gram-negative 
bacteria. They consist of an N-tenninal signal sequence, to direct translocation across 
the inner membrane, a passenger domain to be delivered to the cell surface and a C- 
terminal transporter domain that is proposed to mediate secretion across the outer 
membrane. A number of related surface-associated proteins belong to the 
.autotransporter secretion family (Henderson and Nataro, 2001). PRN was the first 
member of this family identified and characterised in Bordetella and its expression is 
under the control of the bvg locus. It is partly responsible for the adhesion of the 
bacteria to host cells (Montaraz, et al, 1985; Gotto et a l ,  1993).
The PRN gene (prn) of B. pertussis encodes a large precursor of 93.5 kDa which is 
processed at both the N-and C-terminal ends to generate mature PRN. PRN was 
originally referred to as P69 or 69kDa protein, a size determined by SDS-PAGE 
analysis. Similar molecules are produced as proteins of 68  and 70-kDa by B. 
bronchiseptica and B. parapertussis respectively (Kobisch and Novotny, 1990). PRN is 
an outer membrane protein and one of the agglutinins of B, pertussis which has also 
been observed to contribute to the binding to target cells, at least in part by its RGD 
sequence (Leininger et a l, 1991). Studies on Chinese hamster ovary (CHO) cells using 
purified PRN in the presence of synthetic peptides containing RGD sequences showed 
that these three residues were critical for cell adhesion as the synthetic peptides 
decreased the ability of PRN to adhere to the cell surface. A mutant deficient in PRN 
was 30-40% less adhesive than wild type B. pertussis to HeLa and CHO cells 
(Leininger era/., 1991).
PRN is one of the few B. pertussis proteins that exhibit antigenic vaiiation, and 
antigenic divergence between vaccine strains and clinical isolaties has been observed in
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a number of vaccinated populations (Mooi et al., 1998; Mastrantonio et al., 1999). 
According to Hewlett (1997), 3-component acellular vaccines containing FHA, PT, and 
PRN have been shown to be significanttly more effective than 2-component vaccines 
with FHA and PT. Serological analysis has shown that pertactin is highly immunogenic 
in human infants and also may be the most important component when used in acellular 
pertussis vaccines (CheiTy et al., 1998; Hewlett, 1998; Storsaeter et a l, 1998). It has 
been reported to protect mice against aerosol challenge with B. pertussis when 
adminstered parenterally or intranasally (Roberts et al 1992; 1993).
1-4-4 Bordetella resistance to serum killing protein (BrkA)
The autotransporter protein BrkA is expressed as a 103kDa precursor that is processed 
during secretion to yield a 73kDa N-terminal a-domain and a 30kDa C-terminal (3- 
domain. It shows some similarities to PRN, possessing two RGD motifs, an outer 
membrane localisation signal, a proteolytic cleavage site. The RGD sequences, as with 
PRN, have a role in adhesion to epithelial cells and invasion of eukaryotic cells 
(Fernandez and Weiss, 1994). After translocation, the a-domain is tightly associated 
with the bacterial surface and it is not detected in B. pertussis culture supernatants 
whereas the (3-domain is isolated from B. pertussis outer membrane fractions (Passerini 
at a l, 1999; Oliver and Fernandez, 2001). BrkA has been proposed to play a role in 
serum resistance and contribute to the adherence of B. pertussis to target cells in vitro 
and in vivo. The protein also protects against lysis by certain classes of antimicrobial 
peptides. However, it is not required for serum resistance of B. bronchiseptica 
(Rambow et a l,  1998). There is no information on the ability of BrkA to function as a 
protective immunogen and it is not included in any current acellular vaccines. It has 
been shown that a recombinant form of the g-domain of BrkA is able to create channels 
in artificial membranes (Oliver et a l, 2003).
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1-4-4-1 Other autotransporters
On the basis of amino acid similarity, two proteins, Tcf and Vag8 , have been classified 
as autotransporter proteins. Tracheal colonisation factor (Tcf) is a virulence-associated 
factor expressed only in B. pertussis. The protein is encoded by the tc f gene and the 
derived amino acid sequence produces a 6 8 kDa protein which contains a RGD 
sequence and which, after cleavage of a prokaiyotic signal sequence, would give a 
64kDa protein. The C-terminal (30kDa) domain of the protein has 50% identity to the 
C-terminal end of pertactin (Finn and Stevens, 1995). The exact role of Tcf is not clear 
but a mutant lacking Tcf had reduced ability to colonise the mouse trachea compared 
with the paient strain. Hence, Tcf appears to be a unique virulence factor of B. 
pertussis. Finn and Stevens (1995) first described the Vag8 protein. The 95kDa 
autotransporter shows homology with the C-terminal ends of PRN, BrkA and Tcf. This 
protein appears to be involved in type III secretion in B. bronchiseptica (Finn and 
Amsbaugh, 1998).
In addition to Tcf and Vag8 proteins, Bordetella autotransporter C (BapC) is a newly 
identified member of the autotransporter family. The B. pertussis bapC  gene sequence 
was originally submitted to GenBank as a putative autotransporter protein gene 
(accession number AF081494) named bap5 (Blackburn, 2000) and later submitted 
independently as bapC (AJ277634). BapC is predicted to be 79.5kDa. No N-terminal 
signal sequence was detected but the C-terminal domain is chaiacteristic of the 
autotransporter protein family (Blackburn, 2000). Removal of this domain would yield 
a mature passenger protein of 49 kDa and the predicted protein sequence also has a 
RGD motif. It was found to be regulated by the bvg locus (Bokhari, 2002) and is 
predicted to be also encoded by B. parapertussis and B. bronchiseptica (Parkhill et a l,
2003). This protein has properties in common with the other members of the
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autotransporter family, in paiticular with BrkA (Bokliari, 2002). The potential role of 
BapC was identified using a B. pertussis BapC mutant and, like BrkA, it also appears 
to confer serum resistance to B. pertussis and act as an adhesin to host cells. However, 
to date, no information on the protective abilities of BapC have been reported.
1-4-5 Tracheal cytotoxin
Gram-negative bacteria produce a disaccharide tetrapeptide monomer of peptidoglycan. 
However, only B. pertussis and Neisseria gonorrhoeae have been reported to release 
this fragment extracellularly, in the form of muramyl peptides (Cookson et al, 1989). 
Tracheal cytotoxin (TCT) is a muramyl peptide and is the most recently discovered of 
the Bordetella toxins. It is produced by at least 4 species (B. pertussis, B. parapertussis, 
B. bronchesiptica and B. avium) (Goldman et a l, 1988). It is therefore an unusual, low 
moleculai’ weight toxin (Cookson et a l, 1989). The toxin targets the ciliated epithelial 
cells in the respiratory tract, probably by inhibiting DNA synthesis and inducing the 
production of interleukin-1 (IL -la ), which causes an increase in body temperature and 
nitric oxide production in hamster tracheal epithelial (HTE) cells (Heiss et a l,  1993; 
Masure et a l,  1992). It is proposed that, in vivo, the toxin activates host cell nitric oxide 
synthesis and the resulting high levels of nitric oxide diffuse to epithelial ciliated cells 
which are much more susceptible to its damaging effects (Heiss et a l, 1994; Flak and 
Goldman, 1996;). It is involved in initiation of disease and has the ability to cause 
ciliostasis (restriction of the free movement of cilia) and the killing and extrusion of the 
ciliated epithelial cells from the mucosa (Masure, 1992). Such effects could well 
explain some of the pathological events in pertussis infection such as stimulation of 
excessive mucus production in the airways, coughing, the persistence of respiratory 
tract abnormality in pertussis long after elimination of bacteria and tendency to 
secondary bacterial infections (Wardlaw and Parton, 1988). It also has a toxic effect on
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other cells, impairing neutrophil function at low concentrations and causes cytotoxicity 
when present in large quantities (Cundell et a l ,  1994). Other studies indicated that 
endotoxin of B. pertussis plays an important role, in association with TCT, to damage 
the airway epithelium. Endotoxin and TCT were synergistic in induction of IL - la  and 
production of nitric oxide (Flak and Goldman, 1999; Flak et a l,  2000). Moreover, 
although TCT could just be termed a breakdown product of peptidoglycan manufacture, 
it is neverthless considered an integral component in the pathogenesis of pertussis 
infection (Smith et a l ,  2001).
1-4-6 Lipopolysaccharide (LPS) or endotoxin
Different LPS molecules are expressed by different Bordetella spp. which might be a 
factor in the high level of species specificity within this genus (van den Akker, 1998). 
The endotoxin of B. pertussis, like that of some other bacterial pathogens, is generally 
referred to as a lipooligosaccharide (LOS) (Brodeur et a l, 1993). B. pertussis LOS lacks
O-antigen side-chains, and is therefore more similar to rough LPS type, whereas the 
LPS produced by B. bronchiseptica is a smooth type and is similar to that of B. 
parapertussis, as both express temperature-dependent O antigen. They show chemically 
and immunologically identical O-polysaccharide structures, but their core 
oligosaccharide components differed. The core oligosaccharide of B. parapertussis was 
chemically distinct from the core of B. bronchiseptica that appeared to be structurally 
and immunologically similar to a core oligosaccharide of B. pertussis (Di Fabio et a l,
1992).
B.pertussis actually produces two distinct LPS molecules which resolve as two bands 
(A&B) on silver-stained SDS-PAGE (Peppier at al, 1984; Lasfargues et a l, 1993). The 
B band consists of a lipid A molecule linked via a single keto-deoxy-octulosonic acid 
(KDO) residue to a branched oligosaccharide core sructure containing glucose, heptose,
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glutamic acid, glucosamine and galactosaminuronic acid (Caroff et a l ,  1988; 1990). 
Band A consists of band B plus a trisaccharide consisting of N- acetyl-N-methylfucose, 
2,3 di-A-acetyl-mannosaminuronic acid and A-acetyl glucosamine. Several studies have 
reported that the wlb locus, composed of 12 genes {wlbA-wlbV), is required for the 
biosynthesis and assembly of the band A trisaccharide and, from mutational analyses, 
certain functions have been assigned to these genes (Preston et a l,  2002). In B. 
pertussis, deletion of wlb locus leads to the expression only of the B band, indicating 
that these genes are necessary for the addition of the trisaccharide. In B. parapertussis 
and B. bronchiseptica, these mutations result in the loss of both the band A and the O 
antigen (probably due to loss of the core acceptor site), leaving a lipid A-inner core 
molecule (Allen &t a l,  1998; Peterson and MaskelL, 2001).
Both LPS molecules of B. pertussis can activate the alternative complement pathway 
and stimulate cytokine release. However, the role which LPS plays in the pathogenesis 
of Bordetella infection is unclear (Amano et a l,  1990; Watanabe et a l, 1990). It has 
been demonstrated that B. pertussis endotoxin can act synergistically with tracheal 
cytotoxin in the whooping cough syndrome to induce inflammation in the respiratory 
mucosa and damage to ciliated epithelial cells (Flak and Goldman, 1999; Flak et a l,
2000). Also LPS has a role in inducing immunity to pertussis infection. Nevertheless, it 
is probably the main cause of the reactogenicity of the whole-cell pertussis vaccine and 
one of the aims of developing an acellular vaccine was to eliminate this toxin and 
reduce significantly the reactogenic side effects of the vaccine (Cherry et a l,  1988).
1-4-7 Dermonecrotic toxin (DNT)
DNT is a cytoplasmic component and it was one of the first toxins described in B. 
pertussis. DNT toxin is completely inactivated by heating at 56°c for 10 min and for
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this reason it was originally termed heat-labile toxin (HLT) (Livey and Wardlaw, 1984). 
DNT causes necrotic skin lesions, reduced weight gain and spleen atrophy in mice. 
DNT is responsible for mouse lethality when injected intravenously at high doses 
(Endoh et a l, 1986; 1990). The DNTs of three subspecies of Bordetella (B. pertussis, B. 
parapertussis and B. bronchiceptica) are much more highly related genetically and 
biologically than the B. avium  DNT (Walker and Weiss, 1994). It has been reported that 
DNT inhibits the elevation of alkaline phosphatase activity and reduces the expression 
of type-I collagen in an osteoblast-like cell line and was also found to stimulate DNA 
and protein synthesis in these cells without cell division, leading to polynucleation 
(Horiguchi et a l ,  1989). The genes for DNT of B. pertussis and B. bronchiseptica have 
been cloned and sequenced and the ORE of DNT shown to consist of 4395 bp coding 
for 1464 amino acids (aa) with isoelectric point of 6.63 (Pullinger et a l,  1996). 
Kashimoto et al (1999) demonstrated that cysteine in the catalytic domain at position 
1305 is an essential amino acid for the enzymatic activity of dermonecrotic toxin. 
Horiguchi et a l (1997) showed that DNT catalyzes the deamidation of Gln-63 of RhoA 
and converts it into Glu. They concluded that the deamidated RhoA bearing Glu-63 
becomes constitutively active and stimulates the formation of actin stress fibres in DNT- 
treated cells.
The exact role of DNT in whooping cough is still unclear. It seems that the DNT is not 
required for lethal infection in the infant mouse model, also suggesting that DNT does 
not play an important role in virulence for humans (Gueirard and Guiso, 1993). 
However, the production of DNT by B. bronchiseptica strains may play an important 
role in their ability to produce turbinate lesions and pneumonia in neonatal piglets 
(Roop et a l ,  1987).
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1-4-8 Pertussis toxin (PT)
PT is a major colonising factor and a protein exotoxin produced uniquely by B. 
pertussis. It remains cell-bound as well as being released into the extracellular 
environment. It is an AB5 toxin of 106-kDa consisting of an A subunit (SI) and a 
complex B pentamer comprising S2-S5 in a ratio of 1:1:2:1 (Saukkonen et al, 1992). 
Each subunit is synthesised with an N-terminal signal sequence that allows transport of 
the PT subunits into the periplasmic domain via the general export pathway. The five 
structural genes for S1-S5 are followed by nine Ptl (pertussis toxin liberation) genes 
iptlA-ptll) which encode the secretion complex for export from the cell and are co­
transcribed from a single operon, regulated by the Bvg regulatory system (Gross and 
Rappuoli, 1988, Kotob et al., 1995). It has been demonstrated that the A subunit and B 
oligomer have different biological activities in vivo. The enzymatically-active A subunit 
(SI) ADP-ribosylates the alpha subunit of several heterotrimeric G proteins in 
mammalian cells and the B oligomer binds to unidentified glycoconjugate receptors on 
cells (Katada et al, 1983; Alonso et al, 2001). In vitro, the combination of the two 
subunits could induce the toxin activities exhibited by native PT which shows toxicity 
in a CHO cell clustering test and haemagglutination assay (Sheu et a l,  1997). PT is 
involved in a number of activities such as histamine sensitisation, lymphocytosis 
promotion, and insulin secretion in vivo (Weiss et a.l, 1984). Recent reseaich by 
Carbonetti et a l  (2003) shows that the PT acts as colonisation factor and it was found 
that its enzymic activity rather than its cell binding activity was necessary for mouse 
model colonisation. When the SI subunit ADP-ribosylates the G proteins, it prevents 
inhibitory signals to the adenylate cyclase complex, and thus induces intracellular 
cAMP accumulation (Burnette, 1992). PT, like cholera toxin and Escherichia coli heat- 
labile enterotoxin, enters tai'get cells via endocytosis and passes through the Golgi into 
the endoplasmic reticulum (Hazes and Read, 1997). Recent studies have demonstrated
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that the leukocytosis induced by PT is G protein dependent and its effects inhibit the 
increase in intracellular Ca^ "^  levels in CD4^ and CD8  ^cells. It also causes enhancement 
of both T h l and Th2 cytokine production (Loetscher et a l, 1994; Ryan er a l 1998). 
Many studies have shown that PT and FHA are necessary for colonisation of the upper 
respiratory tract by B. pertussis (Tuomanen and Weiss, 1985; Alonso, 2000). PT acts as 
a major virulence factor as it enters the bloodstream, then binds to specific receptors on 
host cells after which it disrupts several functions of cells (Weiss, 1997).
PT has an important contribution to the disease process of B. pertussis and, in 
recognition of that fact, is a component in toxoided foiTn in all acellular pertussis 
vaccines developed and licensed thus far (Hewlett and Cheny, 1997; Castro et a l,
2001). However, the exact role of pertussis toxin in the pathogenesis of whooping 
cough and its main site of action in the host, whether locally in the respiratory tract or 
systemically, remains unclear. The fact that B. parapertussis can also cause whooping 
cough but does not produce PT implies that it may not have a major role in causing the 
typical whooping cough symptoms (Hewlett, 1997; Hoppe, 2000).
1-4-9 Adenylate cyclase toxin (CyaA)
CyaA is one of the major virulence factors of B. pertussis and will be disscused in detail 
in seetion 1-6 .
1-5 Repeat in toxin (RTX) family
RTX (repeat in toxin) toxins, so named because of their amino acid repeat motifs in the 
structural protein, are a family of pore-forming proteins which are produced by a broad 
range of Gram-negative bacteria (Frey and Kuhnert, 2002). They are proteins with 
molecular weights of 102 -177 kDa and have a series of glycine and aspartate-rich 
nonomeric repeats neai' the C-terminal end of the proteins. The number of repeats varies
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between 9-40 in tandem arrays with the sequence UXGGXG (N/D) DX, where U is a 
large hydrophobic amino acid and X is an arbitrary amino acid (Welch, et al, 1992, 
Coote, 1992). RTX toxins lack a cleavable N-teiminal signal peptide and their secretion 
is not sec dependent and they are not exported via the general secretory pathway. The 
extracellular secretion of RTX toxins rather proceeds via the type-1 secretion pathway, 
which allows direct translocation of the toxins across both the inner and outer 
membranes in one step, without any detectable periplasmic intermediate. Inner 
membrane ATPase is one of the three envelope proteins which affect the secretion of 
RTX toxins. The ATP-binding cassette (ABC) protein provides energy for the secretory 
process through hydrolysis of ATP. A membrane fusion protein (MFP), one of the 
transport accessory proteins found mostly in Gram-negative bacteria where they 
function in conjunction with the inner membrane transporters such as ABC proteins 
(Dinh et al., 1994), is also required. The third protein is an outer membrane protein with 
a typical N-temiinal signal sequence. The entire secretion apparatus comprising the 
three proteins is usually designated as an ABC exporter.
All RTX toxins create pores in the cell membrane of target cells leading to eventual cell 
lysis and they appear to require Ca^ "  ^ for cytotoxic activity (Coote, 1992). Based on 
differences in target cell specificity, RTX toxins can be divided into two major groups. 
The first group, comprised of the haemolysin of Escherichia coli (HI y A) and the 
adenylate cyclase toxin of B. pertussis (CyaA), have low specificity and are active on 
many mammalian cell types. The second group includes leukotoxins of Mannheimia 
{Pasteurella) haemolytica (LktA), Actinobacillus actinomycetemcomitans (LtxA) and A. 
pleuropneumoniae which have high specificity and are able to lyse only leukocytes of 
ruminant, primate or porcine origin, respectively (Coote, 1992). It has been shown that 
two RTX toxins, Escherichia coli a-haemolysin and CyaA toxin from B. pertussis, are
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activated by covalent acylation of specific internal lysine residues by a separate gene 
product. Four proteins are actually required for the synthesis, activation and secretion of 
RTX toxins (Coote, 1992) and these are normally encoded by an operon consisting of 
four genes, CABD.
1-5-1 Haemolysin of E. coli
Escherichia coli haemolysin (HlyA) is one of the best-characterised members of the 
RTX toxin family and lyses a wide variety of target cells from many animal species 
(Welch et a l, 1995). HlyA is secreted from E. coli strains causing urinary tract infection 
in humans and animals and these strains are able to produce characteristic zones of 
haemolysis around colonies on blood agar (Cavalier! et a l,  1984). E. coli haemolysin 
(HlyA) is expressed from the hlyCABD  operon, which encodes proteins of 20kDa, 
llOkDa, BOkDa and 55kDa, respectively. HlyA is produced as an inactive protoxin 
(pro-HlyA) which is activated by acylation by HlyC and secreted through a sec- 
independent pathway involving HlyB and HlyD (an inner membrane traffic ATPase and 
inner membrane protein) as well as the genetically-unlinked TolC (Welch et a l, 1995). 
Pro-HlyA is activated intracellular]y by acylation of two internal lysine residues, Lys 
564 and Lys 590. Activation is mediated by the co-synthesized cytoplasmic protein 
HlyC, which acts as an acyltransferase using acylated acyl carrier protein (ACP) as the 
fatty acid donor (Issartel et a l  , 1991; Trent et a l,  1998). It has been demonstrated that 
the a-haemolysin lyses erythrocytes from many species and also shows strong cytotoxie 
and cytolytic activity against a variety of nucleated cells. In addition, HlyA kills 
immune cells involved in first line defence mechanisms, including polymorphonuclear 
(PMN) leukocytes and monocytes (Calvalieri and Snyder, 1982; Bhakdi et a l ,  1989; 
1990). Bauer and Welch (1996) have reported that HlyA impairs the ability of 
macrophages to process antigens.
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1-5-2 Leukotoxins of Mannheimia haemolytica and Actinobacillus 
actinomycetemcomitans
M. haemolytica, the causative agent of bovine pneumonie pasteurellosis, produces a 
104kDa leukotoxin (LktA), a member of the RTX toxin family, that kills only ruminant 
leucocytes (Shewen and Wilkie 1982; Brown et a l,  1997). The genetic organisation of 
the IktA operon (IktCABD) is similar to the E.coli haemolysin (hlyCABD) operon. IktC 
encodes a protein (LktC) that is responsible for activation of leukotoxin (pro-LktA) by 
acylation (Forestier and Welch, 1990). At low concentration, LktA stimulates bovine 
neutrophils to produce reactive oxygen intermediates, degranulate and release 
leukotriene B4 (LTB4). As the LktA concentration is increased, target cells are 
stimulated to undergo apoptosis (Stevens and Czuprynski, 1996). At high 
concentrations of LktA, necrosis occurs, consequent to the membrane damage resulting 
from pore formation, suggesting that the LktA helps the bacteria to evade phagocytes 
and promote bacterial proliferation and survival at the site of infection (Czuprynski et 
a l,  1991; Henricks et a l,  1992; Wang et a l, 1998).
The 116-kDa-protein leukotoxin (LtxA) synthesised by A. actinomycetemcomitans, one 
of the aetiological agents of periodontosis in humans, belongs to the RTX family. 
Structural, genetic organisation and functional domains of LtxA are close to the LktA of 
P. haemolytica. Both LktA and LtxA share a 40-50% amino acid homology with E.coli 
HlyA (Lally et al 1991). LtxA differs from other RTX toxins as it disrupts only human 
and some non-human primate PMNs (Mangan et a l,  1991; Lally et a l,  1999). Again, it 
is presumed that LtxA helps bacteria to evade phagocytes at the site of infection (Lear et 
a l, 1995; Karakelian, 1998). A recent study showed that A. actinomycetemcomitans has 
the potential to secrete abundant leukotoxin, and it is therefore appropriate to consider a 
possible role for leukotoxin secretion in the pathogenesis of the bacterium (Kachlany et 
a l,  2 0 0 0 ).
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1-6 Adenylate cyclase toxin (CyaA)
Adenylate cyclase toxin {CyaA) of Bordetella species is also a member of the RTX 
toxin family (Welch, 1991; Coote, 1992). It is a single protein with a molecular mass of 
177 kDa as calculated from the amino acid sequence, but has an apparent molecular 
weight of 200-216 kDa displayed by SDS-PAGE (Rogel et a l,  1989). It is able to 
release a catalytically-active adenylate cyclase (AC) 45 kDa fragment by proteolysis 
(Bellalou et a l, 1990). The gene for CyaA toxin was cloned and sequenced by Glaser et 
a l, (1988). The 400-residue amino acid N-terminal domain (Figure 1.3) conesponds to 
the calmodulin-activated catalytic moiety (Glaser et a l ,  1988). Calmodulin binds with 
high affinity to the enzyme and stimulates its activity up to 1000-fold. The catalytically- 
active region of CyaA is organised into two domains, an N-terminal domain of 25 kDa 
(T25) which cam es the catalytic site and an 18kDa C-terminal domain (T18) that 
caiTies the calmodulin binding site. T25 is located between amino acid residues 1-224 
and T18 is located between amino acid residues 225-399 (Mock and Ullmann, 1993). 
The haemolysin domain between amino acid residues 400-1706 displays structural 
characteristics that link CyaA to the RTX family (Coote, 1996). It shows 25% similaiity 
with E, coli HlyA and 22% similarity with M. haemolytica LktA and is responsible for 
the haemolytic phenotype of B. pertussis (Glaser, 1988). The haemolysin domain 
mediates the binding and internalisation of the toxin into eukaryotic cells (Ladant and 
Ullman, 1999).
CyaA toxin is initially synthesised as an inactive precursor and activated by CyaC- 
mediated palmitoylation of lysine 983. Acylation facilitates binding to target cells and 
pore formation (Betsou et a l,  1993). The C-terminal haemolytic domain (residues 400-
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Figure 1.3 Structural organization of B. pertussis adenylate cyclase (CyaA) toxin
Numbers represent amino acid residues. The catalytic domain (AC) is enlarged to show 
the T 25 and T 18 subdomains. CBS corresponds to the main calmodulin-binding site, 
and boxes I, II and III represent regions involved in catalysis. A pore forming region 
with four hydrophobic segments, a region of CyaA-dependent palmitoylation, 42 copies 
of Ca^^ binding site and a non-processed carboxy terminal secretion signal is termed the 
haemolytic domain. (Adapted from Ladant and Ullmann 1999).
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1706) is composed of four hydrophobic segments (residues 500-700), the palmitoylation 
region at lysine 983, and 46 characteristic glycine and aspartate rich nona-peptide 
GGXGXDXLX repeats which are located between amino acid residues 1006-1638 that 
represent Ca^^ binding sites. The final C-terminal 106 amino acids residues of the toxin 
contain a signal which is required for secretion by the CyaB, D and E apparatus. As 
described earlier this signal motif is common to the other RTX toxins (Sebo and Ladant,
1993).
A number of Bordetella species such as B. parapertussis and B. bronchiseptica produce 
adenylate cyclase toxin (Preston et a l, 2002). Donato et a l  (2005) have reported that 
B. hinzii produces a full-length CyaA protein in quantities that are comparable to those 
made by B. pertussis. In contrast to B. pertussis CyaA, however, CyaA from B. hinzii is 
less extractable from whole bacteria, non-haemolytic, has a 50-fold reduction in 
adenylate cyclase activity, and is unable to elevate cyclic AMP levels in host 
macrophages (non-toxic). The decrease in enzymatic activity is attributable, at least in 
pai't, to a decreased binding affinity of B. hinzii CyaA for calmodulin, the eukaryotic 
activator of B. pertussis CyaA. In addition, the authors demonstrated that the lack of 
intoxication of tai'get cells by B. hinzii CyaA may be due to the absence of expression of 
cyaC, the gene encoding the accessory protein required for the acylation of CyaA from 
B. pertussis. The inability of purified B. hinzii CyaA to penetrate target cells could 
explain the lack of toxin activity. CyaA is unique among RTX toxins as it has both AC 
and haemolytic activity. The protein has the ability to enter into eukaryotic cells and 
deliver a part of its catalytic domain into the cell (Ladant and Ullman, 1999) where, 
upon activation by endogenous calmodulin, it catalyses formation and production of 
unregulated cAMP levels, CyaA intoxication leads to evident toxic effects on such cells 
as neutrophils and macrophages and prevents phagocytosis and chemotaxis.
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CyaA of B. pertussis penetrates target cells by binding to a specific receptor 
(CD llb/CD18). CyaA displays a selective cytotoxicity towards cells that possess the 
integrin receptor CD llb/CD 18, indicating that its interaction with GDI lb  favours 
translocation of the catalytic domain and the subsequent increase of intracellular cAMP 
concentration and cell death (Guermonprez et a l ,  2001). These authors also noted that 
Ca^^ ions were required for translocation of the catalytic domain into cells suggesting 
that Ca^ '*' binding to CyaA is necessary for interaction of CyaA with GDI lb. A recent 
study demonstrated that the acylation of CyaA is required for interaction of the toxin 
with cells expressing GDI lb . It was shown that pro-CyaA is still able to bind the 
GDI lb  receptor, but this interaction is weak and reduces markedly membrane 
penetration of the pro-toxin. Hence, toxin acylation may be needed to confer a 
conformation on CyaA that is required for cell binding and the transmembrane delivery 
of the catalytic domain to the cell cytosol where it can catalyze the conversion of ATP 
to cAMP (El-Azami-El-Idrissi et al, 2003). However, the catalytic domain is not 
required for binding of toxin to CD 11b because the interaction of toxin with 
GDI lb/CD 18 and with eukaryotic membranes is mediated through the C-teraiinal 
domain of the protein. These studies open new prospects for understanding the 
interaction of B. pertussis with innate and adaptive immune systems (El-azami-El- 
Idrissi et a l,  2003). The reason for this is that immunization of mice with purified CyaA 
or anti-CyaA specific antibodies reduced the time course of respiratory tract 
colonisation by B. pertussis and protected the mice against a lethal intranasal infection 
(Guiso et a l,  1991; Hormozi et a l ,  1999). Other studies have indicated that specific 
antibodies to CyaA were detected in the sera of human infants infected with the bacteria 
(Guiso et a l,  1993).
30
Introduction
In addition to CyaA of B. pertussis, a number of pathogenic bacteria secrete toxins that 
alter the intracellular concentration of cAMP (Ide, 1971; Aseeve, 1987). These toxins 
either disrupt the normal regulation of the host cell's adenylate 
cyclases/phosphodiesterases or they themselves catalyze the synthesis of cAMP in the 
host cell. With regard to the latter activity, three such toxins have been identified: the 
edema factor of Bacillus anthracis, ExoY of Pseudomonas aeruginosa, and the 
adenylate cyclase of Yersinia pestis. These adenylate cyclase toxins enter the eukaryotic 
host cells and is activated by eukaryotic cofactors, like calmodulin, to trigger the 
synthesis of cAMP in these cells and the immune effector cells appear to be the primary 
target of these adenylate cyclase toxins (Ahuja et a l,  2004). Both CyaA and Edema 
factor (EE) are activated in host cells by calmodulin (CaM). CyaA has lOOTold higher 
affinity for CaM than EE. CyaA and Edema factor have about three orders of magnitude 
higher AC aetivity than the AC activity of host cells (Drum et a l ,  2002), and thus the 
entry of EE and CyaA would be expected to raise the cAMP concentration of host cells 
to the supra-physiological. The optimal activation of both toxins by CaM occurs at the 
resting cell intracellular calcium concentration when CaM is not limited (e.g 10 pg/ml 
protein). However, there is a major difference between these two toxins at relatively low 
free CaM concentrations (i.e. 0.1 fxM). Shen et a l  (2002) showed that the apparent 
affinity of EE for CaM is low (> 1 0  pM) at the resting calcium concentration (20-50 
nM) so that EE may be minimally activated. In contrast, CyaA is still optimally 
activated at the resting calcium concentration.
1-6-1 Interaction of CyaA with target ceils
Among bacterial toxins, B. pertussis CyaA has a unique mechanism of entry that 
consists in the direct translocation of its catalytic domain across the plasma membrane 
of target cells. After binding of CyaA to the eukaryotic cell receptor, mediated by the C-
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terminal domain (residues 400-1706), the N-terminal catalytic domain (residues 1-399) 
is directly translocated through the plasma membrane into the cell. The exact 
mechanism of how B. pertussis AC enters targets cells has not been completely 
detennined. However, the penetration through the cell membrane depends on a 
conformational change of CyaA, which is induced by Ca^^ concentrations in the 
millimolar range (Hanski and Coote, 1991).
CyaA has a large number of low affinity {Ko = 0.5-0 .8 mM) Ca^^ binding sites located 
in the Asp-Gly rich repeat region of the toxin. Binding of the toxin to low affinity sites 
induces major structural reaiTangments of CyaA that may be involved in delivery of AC 
domain into target cells (Rose et a l,  1995). On the other hand, binding of calcium to a 
small number of high affinity binding sites might be necessary for haemolytic activity 
of CyaA. The minimal stimulatory concentration of calcium ions ranged from 0.6 to 0.8 
mM, depending on the ionic strength of the aqueous phase. Half-maximal channel 
activity of CyaA was observed at 2-4 mM, and saturation was reached at 10 mM 
calcium concentration, respectively (Knapp et a l,  2003). It has been shown that calcium 
binding to the low affinity sites induces a large conformational change of CyaA, as 
revealed by an important increase in the a-helical structures (Rose et al, 1995). This 
conformation might be directly involved in the Ca^^-dependent translocation of the 
catalytic domain of CyaA through the plasma membrane of target cells. On the other 
hand, addition of Ca^ '*' increases the (3-sheet content of the repeat domain (RD) of CyaA 
indicating that binding of calcium to the repeat motifs stabilizes the secondary structure 
of the protein (Rose et a l,  1995).
It has been noted by Locht and Antonine (1999) that at least three consecutive steps can 
be distinguished in the entry process of CyaA, 1) membrane insertion, 2) translocation, 
and 3) intracellular cleavage. Membrane insertion occurs even at low temperatures.
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whereas translocation only occurs at a temperature above 20°C. In addition, 
translocation requires higher calcium concentrations than membrane insertion. The N- 
terminal fragment of toxin is cleaved in the cell, releasing the enzymatically-active 
45kDa protein of CyaA into the cytosol. Intoxication is a rapid process and an increase 
in cAMP levels in target cells can be detected within seconds of adding CyaA toxin. 
This supports the theory of direct translocation, as entry of toxin through a trafficking 
mechanism or endocytosis would required a much longer exposure time (Rogel and 
Hanski, 1992). Intoxication of target cells by Bordetella pertussis can be blocked by 
monoclonal antibodies against CyaA or C D llb , the receptor for the toxin. It was also 
shown that the increase in cAMP in target cells was not coiTelated with the total number 
of bacteria present in the medium, but depended on the number of bacteria adherent to 
the target cells. Thus attachment of the bacteria was very important for efficient 
delivery of CyaA toxin (Gray et a l ,  2004).
1-6-2 Haemolytic activity of CyaA
CyaA possesses haemolytic activity which is closely associated with the capacity of the 
protein to penetrate target cells (Bellalou et a l, 1990, Rogel et a l, 1991). The 
haemolytic domain of CyaA plays a critical role in the cell binding and entry of CyaA. 
Furthermore, recombinant AC molecules that lack the catalytic domain still exhibit full 
haemolytic activity (Sakamoto et a l, 1992). It is suggested that the main role of the 
haemolytic domain is not to lyse cells but to form channels for translocation of the 
catalytic domain into target cells such as macrophages (Bellalou et a l, 1990). A 
complete C-terminal domain is required for the tight association of AC with membranes 
as well as for its toxic and haemolytic activities (Iwaki et a l,  1995). It was shown that 
the last 217 residues of the C-terminal domain are required for toxicity and the domain 
between residues 624 and 780 is necessary for transfer of the catalytic domain through
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the target cell membrane. The haemolytic functions of CyaA are separable from the 
above function and probably mediated by different domains on the CyaA toxin 
polypeptide (Sebo et a l,  1991; Rogel et a l,  1991). The haemolytic activity of CyaA 
required significantly lower Ca^ "^  concentrations than for membrane binding (Hewlett et 
a l, 1991; Rogel et a l, 1991). It is suggested that the high affinity binding sites of Ca^ "^  
present in CyaA might be required for the binding of the toxin to the membrane and for 
the lysis of red blood cells whereas Ca^ "^  binding to low affinity sites is involved in the 
translocation of the toxin. Translocation of the CyaA domain into the cell probably does 
not proceed through the small transmembrane pore that is formed by the haemolysin 
moiety of CyaA (Rogel and Hanski, 1992; Rose et a l, 1995).
1-6-3 CyaA as a virulence factor
Among the virulence factors produced and secreted by B, pertussis, CyaA toxin and PT 
are able to invade mammalian cells to impair intracellular functions. In addition, 
mutants deficient in both PT or CyaA or both toxins, had a reduced ability to cause 
lethal in infant mice (Weiss et a l ,  1984). It has also been shown that CyaA is an 
essential factor for the initiation of B. pertussis infection (Khelef et a l, 1992). Both PT 
and CyaA may act directly to alter immune cell functions and promote the ability of B. 
pertussis to cause a lethal infection in infant mice (Weiss and Goodwin, 1989; Khelef et 
a l,  1994). It was noted that a CyaA mutant was rapidly cleared from the lungs with no 
viable bacteria remaining at 10 days post-challenge, suggesting that CyaA is an 
important colonization factor required for the bacteria to initiate infection (Goodwin and 
Weiss, 1990). A number of studies have confiiTned that phagocytic cells are a primary 
target of CyaA. The toxin is able to induce apoptosis in mouse alveolar macrophages in 
vitro and in vivo (Khelef et a l ,  1993; Gueirard et a l,  1998).
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Recent studies have suggested that expression of CyaA inhibits uptake and possible 
destruction of B. pertussis by human respiratory epithelial cells and human neutrophils 
(Bassinet et al., 2000; Weingait and Weiss, 2000). Interaction of Bordetella pertussis 
with tracheal epithelial cells results in the secretion of high levels of interleukin-6  (IL-6 ) 
and very low levels of IL-8 , which is dependent on the expression of CyaA by the 
bacterium but not dependent on other toxins or adhesins. This study showed the 
important role of the toxin in the pathogenicity of the bacterium (Bassinet et a l,  2004).
1-7 Immune response to infection
The physiological function of the immune system is defence against microbes, mediated 
by the early reactions of innate immunity and the later responses of adaptive immunity. 
Innate or natural immunity consists of a mechanism that exists before infection, which 
is capable of rapid response to microbes and will react in essentially the same way to 
repeated infections. The components of natural immunity include physical and chemical 
baniers such as the epithelial cell barrier, phagocytic cells (macrophages, neutrophils 
and NK cells) that can bind to microbes, internalise them and then kill them, blood 
proteins such as the complement system and cytokines that regulate and co-ordinate 
many of activities of the cells of innate immunity. The mechanism of innate immunity 
provides the initial defence against infections. However, many microbes have evolved 
numerous mechanism for evading these reactions (Workman, 2003).
Adaptive immunity develops as a specific response to infection and the defining 
characteristics of this immunity are specificity for distinct macromolecules and an 
ability to remember and respond more vigorously to repeated exposure to the same 
microbe. The mechanisms of adaptive immunity develop later in infection and consist 
of activation of lymphocytes and their products (Paul and Seder, 1994). An important
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link between innate and adaptive immunity is that the innate responses participate in 
initiation of the adaptive responses and influence the nature of the responses and, 
secondly, adaptive immune responses use many of the mechanisms of innate immunity 
to eliminate microbes. There are two types of adaptive immune responses, humoral and 
cell-mediated immunity (CMI), which are mediated by different components of the 
immune system and function to eliminate different types of microbes (Paul and Seder,
1994). T lymphocyte and their products, which are important for defence against 
intracellular bacteria mediate CMI, whereas humoral immunity is mediated by B- 
lymphocytes and their products such as antibodies which defend against extracellular 
microrganisms. Both B and T lymhocytes are derived from the bone marrow but T cell 
development proceeds in the thymus. After they leave the bone manow and thymus, 
they enter the circulation and populate the peripheral lymphoid organs (Abbas et al., 
2000).
T cells can also be distinguished by their different antigen receptors. T cell receptors 
(TCRs) divide into two defined types: one type is a heterodimer of two disulphide- 
linked polypeptides, TCR ap, and the other consists of y and 5 polypeptides. These two 
types of TCRs receptors (ap and y5) show quite distinct anatomical locations. 95% of 
apTCRs exist in peripheral T cells, although there is a small proportion of y5 T cells in 
the thymus and lymphoid organs. The ap T cells are subdivided into two different 
forms; one is CD4^ marked and mainly acts as T helper cells which help induce immune 
responses after interaction with other immune cells and recognition of their specific 
antigens related to the MHC class II. The second is CD8  ^ T cells, which recognize 
antigens in association with MHC class I molecules. In addition, two groups o f T helper 
cells (Thl&Th2) develop from the CD4^ lymphocytes, which have different cytokine 
profile production. Thl cells mainly produce IFN-y and IL-2 and are important for 
development of CMI and eliminating intracellular microbes (Murphy et al, 2000), while
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Th2 cells produce IL-4 and IL-10 and are important for developing humoral immune 
responses.
The T hl differentiation pathway is a response to micro-organisms that infect or activate 
macrophages and to those that activate NK (natural killer) cells. Th2 differentiation 
occurs in response to foreign antigen and allergens, which causes chronic T cell 
stimulation, often with little macrophage activation. IFN-y and IL-2 produced by Thl 
cells stimulate phagocytosis, opsonization, and IgG2a production. On the other hand, 
Th2 cells produce IL-4 and IL-10 that stimulates IgG l production and can result in 
IgG l-m ediated allergic reactions in mice. In the majority of cases, an immune response 
elicits both T hl and Th2 activities. Moreover, T h l and Th2 are both able to induce B 
cells to produce immunoglobulin (Ig) (Murphy et al, 2000),
CD8^ T cells can be divided into two subsets, one of which express CD28 molecules 
and produces IL-12 in response to activation signals and the other subset which 
expresses the GDI lb/CD 18 cell receptor molecules. GDI lb/CD 18 or GR3 belongs to 
the a-intergrin family and is expressed on monocytes, PMNs, B and T cells.
B-lymphocytes produce immunoglobulins that are present in biological fluids and are 
also found on the surface of a limited number of cells types of all mammalian cells. One 
of the most important functions of immunoglobulin is to bind antigen, which can result 
in antigen neutralisation.
NK cells are a third population of lymphocytes where receptors are different from those 
of B and T cells. They play an important role in the recognition and killing of certain 
tumour cells. NK cells are also able to kill targets cells coated with IgG antibodies 
(opsonised). Through their receptor for IgG, NK cells can release interferon-a, IL-2 and
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other cytokines when activated, which may be important in the regulation of immune 
responses (Biron et al, 1999).
1-8 Pertussis vaccination
Pertussis (whooping cough) is a ubiquitous, serious infectious disease with 40 million 
cases and nearly 300,000 deaths in children worldwide in 2000. Most cases and deaths 
occur in developing countries (Ivanoff and Robertson, 1997; WHO, 2001). One way to 
reduce these numbers or even to eradicate pertussis is to find more effective vaccines. 
Both curently available WCVs and AC Vs only protect infants from severe pertussis, 
their efficacy is somewhat variable, and they fail to protect the adult population against 
contagious pertussis. It is now thought that the primary reason for the lack of efficacy of 
pertussis vaccines is that they give protection for only a limited period of time (Nennig 
et a l, 1996).
Immunisation against whooping cough was introduced in the UK in 1950s. The 
incidence of whooping cough in England and Wales dropped steadily as the vaccination 
rate rose to around 80% in the 1970s (Pollard, 1983). Unfortunately, after public 
concerns over the safety of the vaccine, the incidence rose again as the vaccination rate 
dropped between 1975 and 1988. This resulted in the 1977-1979 epidemics, when
102,000 children were seriously ill and 32 died. In contrast, in countries such as Fiji, 
where the vaccination programme was not inteiTupted, the disease was practically 
eliminated (Pollard, 1983). In the UK, when vaccination coverage was restored the 
disease incidence declined. Nonetheless, despite the high vaccine coverage levels, the 
disease is still an important cause of morbidity and mortality in England and Wales, 
especially among infants (Crowcroft et ah, 2002). In recent years, several countries 
have reported a resurgence of pertussis, despite maintaining high vaccination coverage. 
According to a survey by the US Health Department, a total of 35,508 cases of pertussis
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were reported to the Center for Disease Control (CDC) through the National Notifiable 
Disease Surveillance System (NNDSS) during 1990-1996. The incidence generally 
decreased over time from 108 cases per 100,000 population in 1990 to 2.9 cases per
100,000 population in 1996, although large outbreaks were reported in Cincinnati and 
Chicago and in Idaho, Massachusetts and Vermont. In 1996, 7796 cases of pertussis 
were reported, the highest number of disease cases reported since 1967 (Guris et a l, 
1999).
Although pertussis vaccination coverage is very high in France, the organism is still 
circulating, affecting the pediatric population, mostly non- or incompletely vaccinated 
infants. The results of Grimprel et a l  (1998) study strongly support the importance of 
adhering to the immunization schedule and suggest introducing booster dose(s) to 
prolong vaccine immunity and reduce the exposure to Bordetella pertussis of infants too 
young to be immunized. In Australia the incidence of disease dramatically increased 
from 2.5 per 100,000 in 1991 to a peak of 30.5 per 100,000 in 1994 (Andrews et a l,  
1997). In the Netherlands, 2771 cases of pertussis were reported to the Inspectorate of 
Health from a population 15 million, compared with 319 cases in 1995. In recent years, 
there has been a dramatic increase in the disease in older children and adults. This is 
attributed to waning immunity over time in vaccinated individuals (Melker et a l, 1995).
1-8-1 Whole cell vaccines (WCY)
Effective killed whole-cell vaccines (WCV) were introduced in the 1950s. They played 
an important role in prevention of pertussis in many countries (Pittman, 1991). WCVs 
against pertussis have now been used in developed countries for approximately 50 years 
and have considerably reduced mortality and morbidity. Vaccines produced by different 
countries differ in potency, immune response and reactogenicity (Edwards et a l,  1999).
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WCV is usually a combination of diphtheria and tetanus toxoids and a suspension of 
killed B. pertussis cells (Department of Health., 1990). In countries with good 
vaccination programmes, DTP is routinely started at two months of age and given as 3 
equal doses at 4-8 week intervals followed by a booster vaccination at 12 to 18 months 
after the first vaccination or before 6  years of age. This schedule should give more than 
90% protection (Preston, 1987). However, the immunisation schedules vary from 
country to country. The efficacy of pertussis WCV has gradually reduced the morbidity 
and mortality of pertussis but, in recent years an increase in incidence of pertussis has 
been reported in USA, Canada, Australia and many of the countries in Europe (see 
section 1-8).
In spite of the efficacy of WCV it may cause local and systemic reactions in children 
such as pain, redness or swelling, mild fever, drowsiness, anorexia, prolonged crying 
and convulsions. More severe reaction such as high fever, permanent brain damage and 
death may occur at an estimated rate of 1 in 100,000 vaccinations (Marcuse and Wentz, 
1990; Gale et al, 1994; Cherry, 1996). Recent research by Ennis et a l  (2005) shows no 
evidence that WCV contributes to allergic asthma, but provides evidence of a 
mechanism whereby WCV vaccination has a protective role against this disease. 
Because of the efficacy and low cost of WCV it will probably be widely used for some 
time to come, particularly in developing countries (Decker and Edwards, 2000). Despite 
this efficacy some countries with high coverage of vaccination have experienced 
increases in pertussis, which may be the result of antigenic differences between the 
WCV strain and circulating strains (Willems and Mooi, 1996). A study in Netherlands 
(1996), showed polymorphisms in the genes coding for B. pertussis virulence factors 
PRN and PT and this was cited as evidence for a vaccine-driven evolution in circulating 
strains that has led to a fall in vaccine efficacy (Mooi et a l,  1998).
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1-8-2 Acellular vaccines (ACV)
Acellular vaccines (ACV) are composed of purified components of B. pertussis (Mahon 
et a l ,  1997, 2000; Murphy et a l,  1997). AC Vs against B. pertussis have been used in 
Japan since 1981 (Sato et a l,  1984). Two types of acellular vaccines B (Biken) and T 
(Takeda) were produced in Japan. The B-type contains an equal amount of toxoided PT 
and FHA, whereas the T (Takeda) type vaccines is a co-purified suspension of PTd, and 
FHA, and also contained pertactin and Fim. It has been reported that both AC Vs were 
able to protect children with similar efficacy and with a low incidence of reaction (Sato, 
1988; Kimura et a l, 1988; Edwards et a l,  1999).
In 1986, AC Vs which contained either PT toxoid alone or FHA and toxoided PT were 
trialled in Sweden. They showed lower efficacy and lower reactogenicity than the WCV 
although they still had some side effects (AD HOC group, 1988; Tuomanen et a l,
1993). A number of other AC Vs were selected for subsequent trials in USA and Europe. 
All included toxoided PT, either alone or with up to 5 components including FHA, 
fimbrial proteins 1 and 2 and pertactin (Storsaeter et a l, 1990). In November 2001 an 
ACV in combination with diphtheria and tetanus vaccines, was introduced in to the UK 
to provide long lasting pertussis immunity into adulthood (Pigott et a l,  2002). 
According to the study of Gustafsson et a l  (1996) the five component ACV (PTd, FHA, 
PRN, Fim2 and3) that they assessed could be recommended for general use, since it had 
a favorable safety profile and confened sustained protection against pertussis whereas a 
two-component ACV and the North American whole-cell vaccine were less efficacious. 
Le et a l  (2004) showed that immunisation of adolescents and adults with an ACV 
induced strong IgG and IgA antibody response against PT, FHA and pertactin, 
suggesting that booster vaccination with AC Vs could help to reduce the incidence of the 
disease in adults. Rappuoli et a l  (1991) produced a third generation of AC Vs with high
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efficacy that contained genetically-toxoided PT, alone or with FHA and pertactin. These 
were clinically tested in 1000  infants that received three doses of the vaccines and it was 
shown that both vaccines were safe and highly immunogenic.
In general, results from various human trials in different countries have shown that all 
of the ACV preparations were effective, with estimates of efficacy against severe 
pertussis ranging from 59-93%. Moreover, the multi-component vaccines (containing 3- 
5 antigens) were better than one and two components (Olin et a l,  1997). Thus, the best 
ACVs have the potential to control the spread of disease. Decker and Edwards (2000) 
noted that the number of components, the quantity of each and the method of 
production, particularly toxoided PT, seems to influence the efficacy of the ACV 
vaccines. Morever, results from animal model studies have been beneficial. A study in 
mice indicated that PT was necessary as a vaccine component for protection against an 
intracerebral challenge with B. pertussis and it appeared that FHA could also play an 
important role, as a vaccine containing a small amount of FHA with a large amount of 
PT (1; 11) was strongly protective in both the aerosol challenge and the intracerebral 
model (Watanabe et a l,  2002). Denoel et a l (2005), in a recent study of immunity in 
the mouse model, compaied immune responses induced by three and five component 
vaccines and their ability to induce clearance of B. pertussis from the lungs of infected 
mice. Their findings also showed that the effect of a bicomponent DTPa vaccine on 
bacterial clearance was lower when compared with tri- or pentavalent DTPa vaccines.
1-9 Immunity to pertussis infection
Acquired immunity against B. pertussis develops after natural infection or immunisation 
with vaccines. Antibodies (Abs) may function either by neutralising bacterial toxins, 
inhibiting extracellular bacteria from binding to cells in mucosal tracts or by enabling 
bacterial uptake and destruction by macrophages and neutrophils (Storsaeter, 1998;
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CheiTy, 1998; Taranger, 2000). There is evidence based on passive immunisation, 
which shows that antibodies (Abs) play an important role in protection against pertussis 
disease. Passive immunisation with mAbs specific for PT, pertactin or LPS were shown 
to protect infant mice from lethal B. pertussis infection (Sato, 1990; Shahin et al., 1990;
1994). IgG and IgA isotypes are involved in host defence against bacterial infection. 
Infection of mice or humans with B. pertussis induced secretory IgA in the respiratory 
tract or nasopharyngeal secretions and also demonstrated IgA in convalescent serum 
which was able to inhibit adherence of B. pertussis to human ciliated epithelial cells 
(Tuomanen et al., 1984; Mills et a l ,  1993). The importance of Abs in immunity to B. 
pertussis was demonstrated using naïve Ig mice where infection by respiratory 
challenge with B. pertussis caused a chronic infection. B cell-deficient mice were 
unable to clear the bacteria from their lungs even after 6  months, whereas the wild-type 
mice could clear infection within 8-10 weeks (Mahon et al, 1997). According to Leef et 
a l  (2000), intranasal immunisation of Ig ''' mice with inactivated B. pertussis resulted in 
partial protection which was restored to full protection after transfer of B. pertussis 
immune B cells. Furthermore, B cells may function in protection against B. pertussis 
independently of antibody production, probably via a role in mucosal immunity or in 
antigen presentation to T cells (Golvokina et a l ,  1999). Moreover, opsonization of B. 
pertussis by antibodies is an important mechanism of host defence required for optimal 
phagocytosis, and phagocytic cells are thought to play an important role in clearance of 
the organism.
Other studies have focused on the induction of CD4^ T cells in immunised or infected 
mice. These findings have reported that respiratory infection or immunisation of mice 
with WCV selectively primes T h l cells. However, ACV immunisation of mice 
generated T cells that produced IL-4, IL-5 and low levels of IFN-y. These results
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generated using spleen or lymph node T cells stimulated in vitro with B. pertussis 
antigens were representative of a more Th2-orientated response (Mills et a l ,  1993; 
1992; Redhead et a l ,  1993; Barnard et a l,  1996). In one report, immunization with 
FHA was found to be the most effective and resulted in complete clearance of the 
bacterial infection from the lungs within 14 days (Cahill et al., 1993). In a recent study, 
FHA induced secretion of IL-10 and IL-6  by macrophages, which might explain the 
suppression of T cell responses in the lungs of mice during infection. IL-10 is a potent 
suppresser of CMI, and reduces T hl immune responses (McGuirk et al, 2000).
It has been demonstrated by Mills et a l  (1998) that the mechanism of immunity against 
B, pertussis might involve both humoral and cellular immune responses. Several studies 
have shown that B. pertussis can persist intracellulary within murine alveolai' and 
human macrophages. Internalisation of the bacteria is immunoglobulin G (IgG) 
dependent, and evidence suggests that survival depends, at least in part, on inhibition of 
phagosome-lysosome fusion (Cheers and Gray, 1996 and Steed et a l,  1991).
Bromberg et a l (1991) indicated that cell-mediated immunity might be a crucial 
component of long teiTU immunity against pertussis as it has been reported that B. 
pertussis can invade and survive within eukaryotic cells including macrophages and 
neutrophils. The extra and intracellular location of B. pertussis is consistent with a role 
for cellular as well as humoral immune mechanisms for bacterial elimination from 
respiratory tract infection (Mills, 2001).
1-9-1 Protection by CyaA
Brezin et a l  (1987) showed that antibodies to CyaA prevented the effects of 
haemorrhagic alveolitis in mice infected by B, pertussis. Protection against pertussis 
infection of mice by CyaA was shown to depend on the post-translational modification 
mediated by the cyaC  gene product (Betsou et a l,  1993; 1995; Hoi*mozi et a l,  1999).
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CyaA has been shown to act as a protective Ag against bacterial colonisation in a 
murine respiratory model where two immunisations with CyaA at a two-week interval 
induced protection against colonisation of B. pertussis (Guiso et a l, 1991; Hormozi et 
a l,  1999). The efficacy of protection by CyaA was reported to be less than the efficacy 
of the WCV. However, it seems that CyaA could be a valuable component of an 
acellular vaccine. The period of bacterial colonisation of the mouse respiratory tract 
could be shortened by both active and passive immunisation with anti-CyaA antibodies 
(Guiso et a l ,  1991). Hoimozi et a l, (1999) showed that purified native CyaA or 
recombinant CyaA produced in E, coli exhibited protective activity in mice against 
intranasal challenge with B. pertussis 18323. It has also been demonstrated that anti- 
CyaA antibodies can be detected in humans after infection with B, pertussis (Arciniega 
et a l,  1991) and such antibodies are also produced after vaccination with WCV. Betsou 
et a l  (1995) located the protective epitopes of CyaA to the 800-residue C-terminal 
repeat portion of CyaA. Weingart and Weiss (2000) demonstrated that CyaA blocks 
phagocytosis by human neutrophils and Weingart et a l  (2000) showed that neutralising 
antibodies to CyaA promoted phagocytosis of B. pertussis through inhibition of the 
activity of CyaA.
In short, the results of these studies demonstrated the potential for CyaA as a protective 
immunogen and that neutralising Ab to CyaA could be helpful in preventing infection 
by B. pertussis, by preventing the action of CyaA on phagocytes. In spite of such 
properties, none of the present acellular pertussis vaccines contains CyaA. As 
recombinant CyaA, expressed in Escherichia coli, is capable of inducing protective 
immune responses in mice, against subsequent challenge with B. pertussis, it is 
therefore a potential candidate for inclusion in ACVs.
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1-9-2 CyaA as an adjuvant
Immune responses against antigens can be potentiated by co-adminstration of adjuvant, 
such as alum or Freund’s complete adjuvant (FCA), CyaA has been shown to enhance 
antibody levels to co-administered ovalbumin (Hoimozi et a t ,  1999). In a recent 
investigation by MacDonald-Fyall et al. (2004), it was shown that CyaA could raise the 
specific IgG responses to PT, FHA and PRN. In addition, it was noted that CyaA*, 
lacking AC enzymic activity, acted as a better adjuvant than CyaA, The adjuvant 
activity of CyaA may reside in its ability to activate cells of the innate immune system 
through increased levels of cAMP or, in the case of CyaA*, it may be more related to 
binding to the receptor CD11/CD18. It has been reported that CyaA can promote 
maturation of monocyte-derived dendritic cell and suppress inflammatory cytokine 
production by human MDDC (Gentile et a l, 1990; Guermonprez et a l, 2001; Bagley et 
a l, 2002). Recent research by Ross et a l  (2004) showed that CyaA may act as an 
adjuvant to enhance specific subsets of CD4^ T cells by promoting activation of DC, 
promoting Th2 and TiT responses, with significant enhancement of antigen-specific IL- 
10-producing T cells. This effect appears to be mediated in part by its ability to activate 
cells of the innate immune system, including DC. However, their data also reveal that 
CyaA can synergize with and modulate TLR4-mediated responses of DC to LPS. The 
adjuvant properties of CyaA* may be more closely linked to the binding of the 
CD 1 lb/CD 18 receptor and subsequent unknown signalling events. A CyaA* derivative 
was shown to have the capacity to deliver its catalytic domain into the cytosol of target 
cells, and to deliver CD8 "^ T-cell epitopes, resulting in intracellular processing and 
presentation of the epitope by MHC class I molecules at the surface of antigen- 
presenting cells (APC) (see below section 1.9.3).
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1-9-3 CyaA as a vaccine delivery vehicle
The main mechanism for elimination of viruses, parasites, and intracellular bacteria that 
reside within cells is by cytolytic T lymphocytes (CTLs), which kill the infected cells. 
Most Ag-specific CTLs are CD8  ^ T cells that recognise cytosolic, usually 
endogenously-processed, foreign antigens in association with class I major 
histocompatibility complex (MHC) molecules on any nucleated cell. Full differentiation 
of CTLs like other lymphocytes requires at least two signals. The first is the presence of 
the antigenic peptide-MHC complex and the second being either cytokines produced by 
CD4^ T cells or costimulators expressed by infected cells. The antimicrobial effects of 
CTLs are mainly concerned with destroying the infected cells before the pathogens are 
reproduced. The mechanisms include activation of nucleases within infected cells that 
degrade microbial DNA and secretion of cytokines with IFNy activity (Abbas et a l,  
2000; Paul, 1999). Exogenous antigens enter the endosomal pathway and are presented 
to CD4^ T cells in association with Class II MHC molecules whereas endogenously 
synthesised Ags, such as viral proteins, ai'e presented to CD8  ^ T cells in association 
with MHC Class I molecules.
Vaccination strategies aimed at generating CTL responses in vivo have been actively 
sought. To date most CTL activation strategies are based on the use of live vectors 
(Fayolle et al 1996). An alternative possibility would be to introduce an antigen into the 
cell cytosol by targeting it via an invasive non-replicative vector. The invasive CyaA of 
B. pertussis is suited for such a purpose as it can deliver its catalytic domain into the 
cytosol of a large number of eukaryotic cells and particularly into antigen-presenting 
cells. It has therefore been used as an appropriate vector to caiTy foreign peptides into 
the cytosolic pathway (Ladant et a l ,  1992). In recent studies, reseai'chers analysed the 
possibility that CTL epitopes delivered to cells by recombinant CyaA toxins could
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associate with MHC class I molecules and induce cytolytic T cell responses in vivo. 
They showed that recombinant CyaA toxin induces strong CTL responses in vivo 
without the requirement for CD4^ T helper cells. High peptide-specific CTL responses 
were also obtained in mice immunised with recombinant CyaA toxin presenting a HIV- 
1 CD8  ^T cell epitope (Guermonprez et al., 1999).
Such an approach would be a potentially efficient tool in inducing protection against 
intracellular microbes and tumours. Using an OVA-expressing tumour mouse model, it 
has also been shown that recombinant CyaA vectors carrying a CDS'*' OVA epitope can 
elicit CTL responses and protect mice against the tumour by causing a regression of 
established tumours in an Ag-specific manner. Therefore CyaA acts as a potentially 
efficient molecule to develop anti-tumour therapeutic immunity. Moreover, CyaA is 
able to deliver more than one CD8 '*' T cell epitope into antigen-presenting cells and 
induce specific cytolytic T lymphocyte responses (CDS'*') in vivo (Fayolle et al, 2001). It 
has been demonstrated that, in vivo, CyaA is efficiently targeted to dendritic cells as a 
result of its interaction with the CD 1 lb/CD 18 intergrin that was previously identified as 
a specific cellular receptor for CyaA (Fayolle et a l ,  2001). The results of Dadaglio et a l  
(2003) showed that tumoral epitopes inserted into CyaA are also efficiently processed 
and presented in association with human MHC molecules. They also suggested that 
CyaA would be capable of activating anti tumoral CTL responses in humans and 
highlighted the potential of CyaA for use in cancer immunotherapy.
Delivery of viral and Mycobacterium tuberculosis epitopes by CyaA* derivative 
generated both CD4'*' and CD8  ^ epitope-specific T cells and the CD4^ T cells were 
characterised as EPNy-producing T hl cells. Thus, induction of these T cell responses 
was via a mechanism other than increased intracellular cAMP production (Schlecht et 
a l,  2004; Wilkinson et a l,  2005; Mascarel et a l ,  2005).
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1-10 Protein-coated microcrystals (PCMCs)
One of the major problems that would be encountered in using recombinant CyaA as a 
vaccine component is the fact that it has to be stored in 8M urea to prevent aggregation 
and to maintain stability of the protein. Urea at high concentrations will have 
detrimental effects on mammalian cells. Thus, a new improved vaccine formulation is 
consequently needed to circumvent this problem. One aim of the proposed research was 
to formulate CyaA by a method that is applicable for large scale manufacture but would 
still retain the immunogenicity of the protein and promote a specific immune response. 
The most attractive feature of PCMCs for pharmaceutical use is their physical 
robustness and resistance to damage caused by high humidity and temperature which 
suggests that PCMCs have great potential in the field of vaccinology (Parker et a l,  
2003). PCMCs were reported by Rreiner et a l  (2001) as a novel system for stabilising 
high-activity biocatalysts for use in organic media in polar and nonpolar solvents. 
Formulation of biomolecules as dry powders is an area of increasing interest because it 
provides stabilisation of bioactivity and serves as a route to new drug and vaccine 
delivery technologies. When dried by conventional routes, such as spray-drying, 
compounds generally contain amorphous excipients and this can limit the range of 
humidity and temperature over which stable powder performance may be obtained. It 
was demonstrated by Kreiner et a l  (2001) that PCMCs with a crystalline core made of 
amino acids such as valine or salt are found to exhibit unchanged powder characteristics 
even when exposed to high humidity and elevated temperature, i.e. there is negligible 
particle agglomeration.
The preparation of PCMCs involves dissolution of the appropriate crystal-forming 
earner together with the given biomolecule in aqueous solution. Quick dehydration of 
the two components is facilitated by the addition of the aqueous solution to a water- 
miscible organic solvent, resulting in the immediate formation of the protein-coated
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microcrystals with the biomolecule immobilised on the surface of the crystalline core 
carrier (Ross et a l ,  2002). The PCMCs are then filter-dried to form a free-flowing 
powder and the morphology, size and biomolecule content can be tuned via appropriate 
choice of dehydration conditions (Ross, A et a l,  2004).
The overall aim of using this process in the present study was to cany out the 
precipitation to yield CyaA-coated valine crystals. The hypothesis was that the urea 
would be lost during the process and consequently would not be present on the PCMCs 
when they were reconstituted in aqueous solution. It was also hoped that any LPS as a 
minor contaminant would also be lost through the process. The different procedures 
used to prepare the PCMCs are detailed in Materials and Methods. A generic method 
for organising biomolecules on microcrystals is shown in Figure 1-4. The figure 
attempts to explain the process of particle formation, but this mechanism remains a 
hypothesis. It is thought that as the aqueous solution contacts the organic solvent, super­
saturation is observed, for both materials, and that due to the high lattice energies of the 
core materials, crystal growth is initiated, the crystal begins to grow and the protein, 
which is intimately associated with the growing crystal, is forced to the surface of the 
particles as reorganisation of the growing crystal takes place. Since the protein is 
insoluble in the solvent, there is nowhere else for the protein to go and it remains bound 
to the surface of the crystal. Two possibilités, regarding the resultant material, can be 
envisaged, a) both the protein and the valine precipitate separately, and the resultant 
precipitate is composed almost entirely of valine crystals and protein particles or b) if 
lattice parameters of the valine allow, the protein could become entrapped within the 
crystal lattice. Lattice paramaters (case b) do not peimit entrapment of particles of 5 nm 
or larger (for protein nanoclusters) within the crystal matrix and scenaiio a) is also not 
commonly observed (M.C. Parker, personal communication).
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Figure 1.4 A generic method for organising biomolecules on microcrystals
The figure attempts to explain the process of particle fomation, but this mechanism 
remains a hypothesis. Two possiblities, regarding the resultant material can be envisaged, 
both the protein and the valine precipitate separately and then reassemble or the protein 
and valine co-precipitae in a 1-step pocess. (Adapted from Dr. M.C.Parker, Chemistry 
Dept, Glasgow University)
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1-11 Aims and objectives
The overall objectives of this study were, first, to produce and purify three forms of 
CyaA from recombinant E. coli by optimised methods and then to characterise the 
properties of these toxins. Following characterisation of toxins, the active and invasive 
CyaA would be used to make protein-coated microcrystals (PCMCs). The purpose of 
this latter part of the research was to use the novel, patented, PCMC technology to 
develop highly stable vaccine formulations and also to remove urea from the toxin. 
Urea is nonnally very important for CyaA stabilisation and it was important to try to 
obtain conditions whereby AC enzymic activity and cell invasiveness of the CyaA 
protein were retained after resolubilisation of CyaA-PCMCs in aqueous buffer. The 
PCMCs prepared with CyaA and reconstituted in aqueous buffer would then be used as 
antigens in the mouse to determine if antigenicity of CyaA was retained.
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Chapter 2
Materials and Methods
2-1 Bacterial strains and plasmids
The strain used for CyaA expression was E. coli BL21/DE3. This strain contains 
chromosomally-located ÀDNA expressing the gene encoding T7 RNA polymerase 
under the control of the inducible lac UV5 promoter. The addition of isopropyl-1-thio- 
p-D-galactoside (IPTG) to a growing culture induces the RNA polymerase that in turn 
transcribes the target DNA in the plasmid from a T7 promoter. E.coli BL21/DE3 lacks 
the Lon protease and outer membrane proteins (OMP) that can degrade some 
recombinant proteins. The enzymatically-active, acylated form of CyaA was produced 
from separate compatible plasmids, pGW44 and pGW54, each under the control of the 
inducible T7 RNA polymerase promoter (Westrop et a l, 1996, 1997). Plasmid pGW44 
expresses the CyaA gene that encodes the CyaA protoxin. Plasmid pGW54 expresses 
the modifying protein, CyaC, which post-translationally acylates the CyaA protoxin. In 
the absence of CyaC, expressed by pGW54, a non-invasive but enzymatically-active 
CyaA pro-toxin is produced. A plasmid pGW44-188 encoding CyaA*, the pro-toxin 
lacking adenylate cyclase activity, was constructed previously in this laboratory by 
replacing a 1.1 kb Nde\IBs,tBl fragment at the 5’ end of the cyaA gene in pGW44 with 
the equivalent fragment from pACM188 (Ladant et a l,  1992). Expression of this 
plasmid produces CyaA pro-toxin with a Leu-Gln peptide insertion between codons 188 
and 189 within the ATP binding site. It was used in the presence of pGW54 to produce 
the enzymatically-inactive, acylated CyaA. The plasmids used in this work are listed in 
Table 2.1.
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Table 2.1 Plasmids used for producing recombinant CyaA proteins
Plasmid (s')____________Relevant phenotype of CvaA________ Antibiotic resistance
pGW44, pGW54 Active AC/ invasive (CyaA) Amp/Chlor
pGW44-188, pGW54 Non-active AC/ invasive (CyaA*) Amp/ Chlor
pGW44 Active AC / non-invasive (CyaA pro-toxin) Amp
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2-2 Growth of E. coli
The E. coli strain was grown overnight at 37°C on Luria Bertani (LB) agar (Appendix 
A T) containing relevant antibiotics (ampicillin or chloramphenicol) for plasmid 
maintenance. The bacterial cells were subcultured into 20 ml LB broth (Appendix A.2) 
and incubated overnight at 37°C with shaking at approximately 200 rpm. 
Chloramphenicol at a final concentration of 12 p.g/ml and ampicillin at a final 
concentration of 50 p,g/ml were used in all cultures of E, coli containing pGW44 or 
pGW44-188 with pGW54, or ampicillin alone at the above concentration for E. coli 
containing pGW44 or pG W l88-54 only.
2-3 Purification of plasmid DNA
Plasmid was extracted using the QIAprep® Mini prep purification system (Qiagen) 
according to the manufacturer’s instructions. A volume of 5ml of E. coli culture, which 
had been incubated overnight, was centrifuged at 10000 x g for lOmin and the bacterial 
pellet resuspended in 250 p,l of P I buffer (includes RNase A). The solution was 
transferred to a microcentrifuge tube and the cells lysed by adding 250 \x\ of buffer P2 
and gently inverting the tube 4-5 times. 350 p,l buffer of N3 were added to the lysate 
and mixed gently before centrifugation at 10000 x g for 10 min. The supernatant was 
applied to the QIA prep column followed by centrifugation at 10000 x g for 1 min, then 
the QIA prep column was washed with 0.5 ml buffer PB followed by centrifugation at 
10000 xg for 1 min. The flow-through was discarded and the column finally washed by 
adding 0.75 ml of buffer PE with further centrifugation for 1 min as described 
previously. The QIAprep column was then placed in a clean 1.5 ml microcentrifuge 
tube, and the DNA was eluted with 50 |Ltl of buffer BB (10 mM Tris. HCl, pH 8.5). This
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was left to stand for 1 min and then centrifuged at 10000 x g for Imin. The flow- 
through was collected and stored at -20‘^ C.
2-4 Preparation of heat shock-competent cells
0.5 ml of an overnight culture of E. coli was inoculated into 50 ml of pre-warmed LB 
and grown with good aeration at 200 rpm at 37°C until an OD^oo nm of 0.4 - 0.5 was 
obtained. The flask was chilled on ice and cells harvested by centrifugation in chilled 
centrifuge tubes at 6000 x g for 15 min at 4°C. The cells were suspended gently on ice 
in a small volume (2 ml) of ice-cold competence solution (Appendix A.3) and then 
made up to 25 ml with ice-cold solution and incubated for 45 min on ice. After 1 min 
centrifugation at 4000 x g the cell pellet was resuspended in 2.5 ml of ice-cold 
competence solution. Finally, ice-cold glycerol (80% v/v) was added to give a final 
concentration of 15% v/v (450 jiil of 80% glycerol to 2.5 ml of ice cold competence 
solution) and then stored at -70°C.
2-5 Heat shock transformation
100 p.1 of the competent cells (stored at -70°C) were thawed on ice and 2 \i\ of plasmid 
DNA were added. The solution was mixed and incubated on ice for 30 min and then the 
tube was heated at 42°C for 90 s. One ml of pre-warmed (37° C) LB was added to the 
cells and incubation continued at 37° C) for 1 h. Finally 100 ftl protions were spread 
onto the LB agar plates containing appropriate antibiotics and the plates were incubated 
at 37°C overnight.
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2-6 Preparation of recombinant CyaA from E.coli
20 ml of an overnight culture of E. coli BL21/DE3 containing the relevant plasmids 
were diluted into 500 ml of LB containing appropriate antibiotics. This was incubated at 
37°C with shaking at 200 rpm until an ODeoonm of between 0.4-0.45 was obtained (~3 
h). At this point, isopropyl-1-thio-p-D-galactoside (IPTG) was added to a final 
concentration of 1 mM and shaking continued at 37°C for 3 h. Finally, cells were 
harvested at 10,000 x g for 25 min and the supernatant discarded. Cells pellets could be 
stored at -20°C if necessary.
2-6-1 Preparation of crude urea extract
The cell pellets were suspended in 10 ml of 20 mM histidine buffer (pH 6.0) (Appendix 
B .l) and were disrupted using a sonicator (Jensons Ltd, UCX-400 Watt) continuously 
for 2 min in ice. The cell lysate was then centrifuged at 15,000 x g for 20 min, the 
supernatant discarded and the pellets containing inclusion bodies of recombinant CyaA 
proteins re-suspended in 10 ml of 1% (v/v) N-octyl P-D glucopyranoside (Sigma) in 20 
mM histidine buffer (pH 6.0). The suspension was centrifuged at 15,000 x g for 20 min 
and the pellet was re-suspended in 2 M urea, 20 mM histidine buffer and, after 
centrifugation, washed again with pyrogen free-water (LAL reagent water, Cambrex 
Company). These washing steps were designed to remove contaminating proteins and 
LPS from the inclusion bodies. The resultant pellets were solubilized in 10 ml of 8 M 
urea, 20 mM histidine buffer (pH 6.0) by stim ng the suspension at 4°C overnight. The 
supernatant, obtained after centrifugation at 15000 x g for 20 min, was stored at -20°C.
2-6-1-1 Q Sepharose column chromatography
A 5 ml volume of packed Q Sepharose fast flow (Amersham) was applied to a glass 
Econo-Column [(1.5 x 30 cm) (Bio-Rad)] and washed with 30 ml of water to remove
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excess ethanol. The column was equilibrated by washing with 30 ml of 8 M urea, 20 
mM histidine buffer pH 6.0 (Appendix B.2). 2 ml of crude urea extract were applied 
directly to the column. After 30 min at room temperature the flow through was applied 
again to the column for 15 min. The column was washed with 2 M urea, 20 mM 
histidine buffer pH 6.0 (Appendix B.3) followed by elution of CyaA protein with 
increasing concentrations of NaCl (0.1-0.4 M) in 8 M urea, 20 mM histidine buffer pH
6.0 (Appendix B.4, A-C). The eluted urea extracts were analysed by SDS-PAGE for the 
presence of CyaA protein, and those containing significant amounts were stored at -  
20°C if necessary.
2-6-1-2 Butyl Sepharose chromatography
The relevant fractions from Q sepharose purification containing CyaA were pooled and 
diluted 1 in 5 with 4 M (NH4) 2 SO4 in 20 mM histidine pH 6.0 (Appendix B.5) to give a 
final concentration of 0.8 M (NH4) 2 SO4. A 2ml volume of packed Butyl Sepharose 
(Amersham) was applied to an Econo-column [(1.5 x 30 cm) (BioRad)] and washed
with 30 ml of water to remove excess ethanol. The diluted CyaA sample was applied to 
the column after it had been equilibrated with 30 ml of 8 M urea, 20 mM histidine, and 
0.8 M (NH4) 2 SO4, 0.3 M NaCl, pH 6,0 (Appendix B.6 , D) for 30 min. The column was 
washed with 2M urea, 0.8 M (NH4) 2 SO4 in 20 mM histidine buffer, pH 6.0 followed 
by washing with 8 M urea, 20 mM histidine 0.8 M (NH4) 2 S04, 0.2 M NaCl, pH 6.0 
(Appendix B.7, E). Once again the column was washed with 8 M urea, 20 mM 
histidine, 0.6 M (NH4) 2 SO4 (Appendix B .8 , F). Finally the CyaA protein was eluted 
with 8 M urea, 20 mM histidine, 0.32 M (NH4) 2 SO4, 0.08 M NaCl, pH 6.0 (Appendix
B.9) and fractions containing CyaA protein pooled and stored at -70°C.
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2-6-2-3 Dialysis of purified CyaA
For use in protein-coated microcrystals (PCMCs) (see section 2-15) CyaA preparations 
were sometimes dialysed against 8 M urea, 20 mM histidine pH 6.0 to remove (NH4) 2 
SO4 and NaCl. 5 ml of purified CyaA were dialysed twice against the above solution 
(200 ml of 8 M urea, 20 mM histidine, pH 6.0) using a 3ml capacity slide dialysis 
cassette (SnakeSkin® Dialysing Tubing 10000 Pierce). First, it was dialysed for 4 h at 
4°C and then the dialysis solution was changed with a fresh one, and dialysis continued 
at 4°C overnight. The resultant preparation was used to make CyaA-PCMCs.
2-7 SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
SDS-PAGE was done according to the method of Laemmli (1970) in a vertical gel 
electrophoresis tank. Gel plates were assembled following the manufacturer’s 
instructions. The separating gel, containing 7.5% (Appendix C .l) or 15% acrylamide 
(Appendix C.2), was poured between the plates to approximately 4.5 cm below the top 
of the plates and absolute ethanol was used as a eover. The gel was placed at room 
temperature for 45 min until the gel set. The stacking gel, containing 4.5% acrylamide 
in buffer (Appendix C.3) was poured directly onto the polymerised sepai'ating gel after 
washing the top of the gel with distilled water to remove traces of ethanol and drying 
with filter paper. Combs were placed into the gel and the gel was incubated at room 
temperature for 30 min. The combs were removed after the gel had set, A 10 \x\ aliquot 
of sample was added to 10 jul of solubilising buffer (Appendix C.4) and kept at 100°C 
for 5 min. The heated samples were loaded into wells of the gel and current applied at 
120 mA until the tracking dye moved to the bottom of the separation gel. At this point 
the power was switched off and the gel removed. The gel was stained with coomassie
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blue (Appendix C.5) for 30 min and then de-stained with de-stain solution (Appendix
C.6 ) for several changes until protein bands were visible against a clear background.
2-8 Silver stain for lipopolysaccharide
This was done according to the method of Tsai and Frasch (1982). SDS-PAGE (15% 
acrylamide) was done according to the method described previously (section 2-7). A 10 
p,l volume of LPS control (25 [Ag/ml from E. coli BL21/DE3) and samples were added 
to 10 111 of solubilising buffer and boiled for 5 min. The heated samples were loaded 
into the gel and electrophoresis done at 120  mA until the tracking dye moved to the 
bottom of separation gel. The gel was removed into fixing solution (Appendix D .l) in a 
clean dish (20 x 20 x 5 cm) and left overnight with shaking at room temperature. The 
fixing solution was then replaced with oxidising solution (200 ml of 0.7% periodic acid 
in 40% ethanol-5 % acetic acid) and left for 5 min. The gel was washed with 500-1000 
ml of distilled water for 15 min, three times. The gel was placed in the staining reagent 
(Appendix D.2) and agitated vigorously (70 ipm) for 10 min. The gel was then placed in 
developing solution (Appendix D.3). LPS in the gel was stained dark brown in 2-5 min. 
Development was terminated when the stain reached the desired intensity or when the 
clear gel background showed the first signs of discolouration. The process was stopped 
with 10% (v/v) acetic acid solution and after washing for 30 s, with water three times, 
the gel was stored in water.
2-9 Estimation of protein concentration
This was done according to the method of Bradford (1976). Bovine serum albumin 
(BSA, Sigma) was used as standard with serial dilutions (1 in 2 to 1 in 128) in distilled 
water (500 to 7.8 jLig/ml). Each dilution of standard and samples (25 p.1) were transferred 
to duplicate wells in flat bottom microtitre plates followed by addition of 20 0  p,l of 
protein assay reagent (Bio-Rad reagent, Coomassie brilliant blue G-250). The OD was
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measured with a plate reader at 630 nm in the presence of blank (diluent) and protein 
concentrations determined from a standard curve derived from the OD of the BSA 
dilutions.
2-10 Western blotting
This was earned out according to the method of Towbin et ah (1979). The proteins 
were separated in 7.5% SDS-PAGE and the gel then soaked in transfer buffer 
(Appendix E .l) for 20 min. Nitrocellulose membrane (Hybond-C Amersham) and 
absorbent paper (Whatman 3 MM) were cut to the size of the gel and soaked in transfer 
buffer for 1 min. The gel was then placed between the membrane and absorbent paper 
with one Scotch Brite pad on each side and rolled over to make a good contact. The 
complete blot was placed in a tank of transfer buffer (Appendix E .l)  and subjected to a 
voltage of 100 volts for 1 h. The membrane was then removed and washed with BSA 
containing Tween 20 (PBST) (Appendix E.2) and then the membrane was incubated 
with blocking buffer (Appendix E.3) with shaking at room temperature for 
approximately 1 h to prevent non-specific adsorption of the immunological reagents. A 
rabbit anti-CyaA serum used as primary antibody (kindly supplied by R. Parton) was 
diluted 1 in 1000 in blocking buffer and incubated with the blot with shaking at 4°C 
overnight. The membrane was washed with PBST twice for 15 min. The secondary 
antibody, goat-anti rabbit IgG conjugate (HRP, Scottish Antibody Production Unit), was 
diluted 1 in 1000  in blocking buffer and incubated with the membrane at room 
temperature with shaking for one hour. The membrane was then washed twice with 
PBST and developed with freshly prepared 3,3-diaminobenzidine (DAB) solution 
(Appendix F.4) for 2-10 min after which it was washed in distilled water several times 
to stop the reaction and the membrane was stored at room temperature in the dark.
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2-11 LAL (Limulus amoebocyte lysate) assay
Limulus amoebocyte lysate is an aqueous extract of blood cells (amoebocytes) from the 
horseshoe crab, Limulus polyphemus. The test is refened to as a chromogenic assay and 
empolys a synthetic chromogenic substrate that, in the presence of LAL and endotoxin, 
produces a yellow color that is linearly related to the endotoxin concentrati on .The 
standard endotoxin reagent is a lyophilised product that comes with a certificate of 
analysis which states how much water should be added to the standard to give a final 
concentration of 50 lU/ml. This standard, once reconstituted, is suitable for use for up to 
a month if stored at 4°C. The diluted standards are usable within a day, otherwise they 
should be thrown away. Use of endotoxin-free water during the assays is very 
important. The Limulus amoebocyte lysate is also lyophilised and once reconstituted 
should be stored at -20°C where it is stable for two weeks. It is very important to use the 
standard endotoxin and LAL reagent as a matched standard pair. An appropriate volume 
of water was added to standard endotoxin and vortexed for 15 min. It also needs to be 
vortexed for 4-5 min prior to use again to ensure the endotoxin is not clumped. 
Reconstituted standard, vortexed as described above, was then used as a stock to derive 
a standard curve. Using endotoxin-free tubes (Sigma), 10-fold dilutions of the standard 
were made by mixing 900 \x\ of water with 100 pi of stock, mixing for 1 min between 
each dilution. For the standard, 5 dilutions were made from 50 lU/ml to 0.005 lU/ml. 
Samples were diluted 1 in 100 and 1 in 1000 as described and vortexed for 1 min. To a 
96-well flat bottom microplate (Promega, Cat No: 3590), 100 pi of diluted standard and 
100  pi of lysate was added in duplicate wells and 100  pi of diluted samples and lysate 
were added as duplicate test samples. The plate was incubated at 37°C for 15 min. It is 
important to add the lysate after warming. The plate was read at 405 nm, over a period 
of 90 min. The amount of LPS was calculated for 1 ml of sample. To calculate the
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actual amount of LPS in 1 mg of CyaA, the reading was multiplied by 3.33. This is 
because the concentration of both CyaA and CyaA* were adjusted to 300 pg protein/ml.
2-12 Macrophage cell culture
The mouse-macrophage-like cell line (J774.2, EC AC), rat basophilic leukemia (RBL- 
2H3) cells (ATCC), sheep bone maiTow mast cells (Dr John Huntley; Mordun Research 
Institute, Edinburgh), African green monkey kidney cells (Vero, ECAC) and U937, 
human monoblastic cells (ATCC) were used when determining cytotoxicity, apoptosis 
and DNA fragmentation. Each culture was passaged weekly in RPMI 1640 medium 
(J774.2 and U937 cells) or Dulbecco’s modified eagle’s medium (DMEM, Gibco) 
(Vero, RBL-2H3 and mast cells) containing 10% (v/v) foetal calf serum, 1% (w/v) L- 
glutamine 1% (w/v), amphotericin B and 1% (w/v), penicillin-streptomycin (Gibco). 
Cells were prepared in a sterile filter unit (Gelaire) and incubated at 37°C with 5% CO2.
2-13 Characterisation of recombinant CyaA
2-13-1 Adenylate cyclase enzymic activity
AC enzymic activity was evaluated by measuring the change in conductance using an 
enzymometer (conductimetry assay) which was developed by Lawrence et al. (1998). 
The device consists of 8 glass cells (tubes) each containing platinum electrodes, which 
have been fused to the bottom of the tube. The sampling period is one second per cell, 
cycling through from one to eight glass cells. The apparatus is linked to computer 
software which processes the conductimetric readings and uses software to create curve 
slopes and total changes, and the export of standard fonnat data files. Buffer (Appendix 
E .l) containing lOmM bicine, 1.5 mM magnesium acetate pH 8.0 was degassed by 
heating for 1-2 min >90 °C and placed under the vacuum pressure for 30 sec. After 
allowing the buffer to cool to room temperature, ATP was added to a final concentration
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of 0.5 mM. A volume of 2 ml of buffer, 1 \x\ of calmodulin (1.8 mg/ml, kindly provided 
by Dr. A. Lawrence, Glasgow University) and 1 |il pyrophosphatase (0.5 lU, Sigma) 
were added to each cell. Balancing of the cells to the same base line was allowed to 
occur before addition of CyaA samples. The reaction was started by addition of 2 jjtl of 
CyaA sample. Curve slopes and total changes in conductance were measured on screen 
whilst reactions were proceeding. One especially important feature is the ability to 
subtract the reading of one cell from all of the others so that test samples can be 
standardized to a blank loading. There is no change in conductance unless the (PPi 
Mg)^’ product is cleaved, freeing the Mg^’^  ion from chelation. It is the release of the
independently mobile ions, 2Pi^‘ and Mg that produce the change in conductance that 
is measured by the assay. pyrophosphatase
(ATP. Mg) + Bicine ' cAMP" + (BicineH) + (PPi Mg)^' -> 2Pi^ +
CyaA-CaM
Finally the total conductance changes were measured by taking the gradient of the 
conductance curves using the equation: initial rate = y/x
jamol/min/ml for a substrate concentration of 1 mM giving a total change of x units and 
an initial slope of y units/min.
2-13-2 MTT Dye reduction assay (Cytotoxicity assay)
Cytotoxic activity was determined by the MTT assay as described originally by 
Mosmann (1983) using the CellTiter 96 ™ assay kit (Promega). This assay is based on 
the reduction of a yellow tétrazolium dye ] 3-(4,5-dimethylthiazol~2-3yl) -2-5-diphenyl 
tetrazoliumbromide, MTT) \ into insoluble purple formazan by dehydrogenases active in 
mitochondria of living cells. The activity of toxin on cells inhibits this reaction. J774.2 
mouse macrophage-derived cells and other cell lines were prepared in appropriate 
medium (Section 2-12) to a concentration of 5 x 10  ^cells/ml. A 50 |il volume of cells
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was diluted in 10 |il trypan blue 0.25% and 40 \x\ water and transfeiTed to a Neubauer 
chamber (haemocytometer). This was placed on a horizontal surface to allow the cells 
to settle for 1 min. Under the X 10 objective of a light microscope, the average number 
of cells in four squares were counted and then multiplied by two as a factor of dilution 
to give total cell number. Uptake of trypan blue reflects the lack of integrity of the 
plasma membrane and cells were examined to ensure >90% live cells. Aliquots of 50 p.1 
of cells in duplicate were transfeiTed to wells of a 96-well microtiter plate (Corning) and 
incubated at 37°C for 1 hour. A CyaA sample was diluted in cell culture medium in 
serial 2-fold dilutions starting at a protein concentration of 5 fig/ml. Then, volumes of 
50 jil of each dilution were added in duplicate to wells of 96-well plate. The plate was 
incubated at 37°C for 2 hours in a humidified 5% CO2 atmosphere before the addition 
of 15 |L tl of MTT dye (Promega) to each well and incubation continued as above for 4 h. 
The stop (solubilization) solution (100 p,l/well, Promega) was added and incubation 
continued at 37°C overnight. The ODg^onm of the wells was measured using an ELISA 
reader (Life Science Int, Uk) against a positive (cells + 1% Triton X-100) and a 
negative (Cell + medium) control. 100% killing was taken as the mean absorbance 
value for the positive control. The percentage killing of cells was calculated using the 
following formula:
Percentage killing = 1-
test sample -  positive control
X 100
negative control -  positive control J  
2-13-3 ATP cytotoxicity assay
Cytotoxicity of CyaA for macrophges was further investigated using a bioluminescent 
cell viability assay (CellTiter-Glo assay, Promega). This assay determines the number 
of viable cells based on the quantification of light output as a measure of ATP present in 
the cells. ATP was measured using a bioluminescence method based on the luciferin-
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luciferase reaction (Higashi et a l ,  1985). The reaction, which results in the generation 
of measurable light, is given below:
LuciferaseATP + Luciferin + O2 ______ ^  Oxyluciferin + AMP + PPi + CO2 + light
J774.2 mouse macrophages, RBL and mast cells were cultured as described in section 
2-12 and maintained at 37°C in 5% CO2 and then diluted to 5 x 10  ^ cells/ml after 
counting cells in the haemocytometer. A volume of 50 |il of each cell suspension was 
added to the wells of a 96-well flat bottom plate (Costai*) and then incubated for 1 h at 
37°C, 5% CO2. CyaA samples were prepared at different concentrations in the growth 
medium used for cell culture. 50 |il of each concentration were added to the cells in 
duplicate. The plate was incubated for 6 h followed by addition of 100 jiil of Cell Titer- 
Glo Reagent (Promega) to lyse the cells and release ATP for the luciferase reaction. 
Cytotoxicity was evaluated after 10 min by measuring the luminescent signal in a 
luminometer and comparing the relative light output to that of a negative control with 
no toxin added and a positive control with Triton X-100 added to a final concentration 
of 1% (v/v). The percentage killing of cells was calculated using the equation given in 
section 2.13.3.
2-13-4 Apoptosis assay
The homogeneous caspase 3/7 assay (Promega) provides a fluorescent substrate with 
an optimized bifunctional cell lysis/activity buffer for caspase 3/7 (DEVDase) activity 
as an indicator of apoptosis. Various types of mammalian cells were prepared to a cell 
concentration of 5 x 10  ^ per ml (See section 2-12) and treated with diluted CyaA 
preparations as described in section 2-13-2. A volume of 50 \x\ of each cell dilution was 
added in duplicate to a 96-well flat bottom microti ter plate (Opaque) and the plate was 
incubated at 37°C in 5% CO2 for 6 h. After the incubation time, 100 p,l of homogenous
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caspase 3/7 Reagent (Apo-ONE and caspase substrate Z-DEVD-Rhodamine 110 
Promega) were added. These reagents were prepared by thawing the lOOx substrate and 
buffer at room temperature, mixing by inversion or vortexing, then the substrate 
solution was diluted 1 in 100 with the buffer to obtain the desired volume of reagent. 
The microtitre plate was shaken at 200 rpm for 30 min at room temperature. Caspase 
activity was measured by using a fluorescence spectrometer (Perkin Elmer instrument 
LS 55) at an excitation wavelength of 485 ± 2.5nm and an emission wavelength of 530 
± 2.5nm. Activity was measured over a range of toxin concentrations from 2.5 to 0.010 
pg/ml. The amount of fluorescent product generated is proportional to the amount of 
caspase 3/7 cleavage activity present in the sample.
2-13-5 DNA fragmentation as a measure of apoptosis
The J774 mouse macrophage-like cells, RBL-2H3 cells, sheep bone maiTow mast cell 
and Vero cells were grown in 25 ml flasks as described in section 2-12 and maintained 
in a 5% CO2 atmosphere at 37°C overnight. The same cells grown in appropriate media 
minus foetal calf serum (ECS) were included as a positive control. Urea buffer at a 
concentration equivalent to that used for each CyaA concentration tested was incubated 
as a negative control. The cells were treated with CyaA samples at the final 
concentration of 0.039 jug/ml. After 12 h, the cells were removed and DNA purified 
using a Wizard Genomic DNA purification kit (Promega) following the manufacturer’s 
instructions. Samples (10 pi) were subjected to electrophoresis in 1% agai'ose in TEB 
buffer solution (Appendix A.4) at 100 V for 120 min and visualised by staining with 
ethidum bromide.
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2-14 Phagocytosis procedure
The phagotest Kit (OPREGEN Pharma; BD Biosciences, Oxford, UK) allows the 
quantitative determination of leukocyte phagocytosis. It contains fluorescently (FITC- 
fluorescein isothiocyanate) labelled, opsonized bacteria {E.coli-FITC) and measures the 
overall percentage of macrophages and granulocytes showing phagocytosis in general 
(ingestion of one or more bacteria per cell) and the individual cellular' phagocytic 
activity (number of bacteria per cell).
The investigation of phagocytosis can be performed either by flow cytometry or by 
fluorescence microscopy. Because of the quantitative analysis, very accurate work is 
important, especially when day to day comparisons are required. The detailed 
instructions result from specific experience and precise validation assays.
The ingestion activity of peripheral human granulocyte cells in whole blood, J774.2 and 
U937 cell lines was evaluated in the presence and absence of recombinant CyaA protein 
using the flow-cytometry based Phagotest kit according to the manufacturer's 
instructions for conjugated E, coli. Briefly, 100 jil of whole blood or a volume of 0.4 x 
10*^  of J774.2 mouse macrophages or human monoblastic U937 cells were added at the 
bottom of a 5 ml Falcon tube. Samples were incubated (120 minutes, 37°C, 5% CO2) 
with either CyaA or CyaA* diluted in 8 M urea, 20mM histidine (0.05, 0.1 or 0.2 
jag/ml) or PBS, then incubated for another 20 minutes at 3T C  in 5% CO2 with 
opsonized E. coli-VIYC cells (6 cells per leukocyte). A sample with PBS and no 
Bioparticle and another sample with PBS (120 min) and opsonized FITC-labeled E. coli 
cells (20 min) remained on ice for the whole period of experiment, these acted as 
negative controls.
At the end of the incubation time all samples were placed on ice in order to stop 
phagocytosis. A volume of 100 fxl of ice-cold quenching solution was added and mixed
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gently. Then 2ml of washing solution was added to each tube after which the tubes were 
centrifuged at 4°C for 5 min at 250 x g. The cell samples were incubated in washing 
solution containing 1% paraformaldehyde for 10 min, washed again and centrifuged as 
described. Finally, 200 |il of DNA staining solution were added to each tube, mixed and 
incubated for 10 min on ice. Cells were analysed by flow cytometry (FACSCalibur, BD 
Biosciences) and 5000 granulocyte events acquired to obtain the percentage and number 
of cells ingesting bioparticles, as well as their mean fluorescence intensity (MFI) using 
Cellquest Pro software (BD Biosciences). The nucleated cells were discriminated by a 
setting in the red fluorescence channel (DNA staining FL2-H, Fig 2.1 A), detecting those 
events which have the DNA content of a human diploid cell (to exclude bacterial 
aggregates). The nucleated events were then discriminated; into lymphocytes, 
monocytes and polymorphonuclear cells by combined measurements of the forward 
angle light scatter (FSC) and side angle light scatter (SSC). The granulocyte cluster was 
then gated in the analysis program in the scatter diagram (FSC vs SSC) (Fig 2. IB), and 
its green fluorescence histogram (FLl) was analysed (Fig 2. ID and E). The SSC vs FL- 
1 diagram also was also set to make sure that the appropriate cell population data was 
collected (Fig 2.1 C).
2-15 Oxidative burst procedure
The oxidative burst component of the phagocytic process was measured in whole blood 
peripheral polymorphonuclear cells with the commercial flow cytometric-based 
BurstTest kit (OPREGEN Pharma; BD Biosciences) according to the manufacturer’s 
instruction for E.coli bioparticles. This assay allows the quantitative determination of 
leukocyte activity without prior purification. The BurstTest assay relies on unlabelled 
opsonized E.coli bacteria as the paiticulate stimulus and dihydrorhodamine (DHR) 123
69
M aterials and M ethods
as a fluorogenic substrate of oxidative activity. Briefly, either heparinised whole blood, 
or J774.2 mouse macrophages and U937 human monocytes were incubated (120 
minutes, 37°C, 5% CO2) with either recombinant CyaA or CyaA* in 8 M urea, 20mM 
histidine diluted to 0.05, 0.1 or 0.2 \xg protein/ml or with PBS, then incubated for 
another 15 minutes at 3T C  in 5% CO2 with opsonized E. coli cells (6 cells per 
leukocyte).
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Fig 2.1 Data acquisition and analysis of the Phagotest and the Phago Burst by flow 
cytometry.
A-Gating for nucleated cells (DNA Staining), the peak shows the maximum fluorescence 
B-Gating nucleated cells, based on SSC and FSC, the cells in the circle area are viable 
granulocytes which are used for evaluation of phagocytosis 
C-Fluorescent intensity and SSC (number of events containing fluorescence) 
D-Histogram of fluorescent intensity of granulocytes
E-Statistical analysis of fluorescent intensity of cells. In this study, the mean of total was 
used which showed on part D as M2 with the highest peak of fluorescent.
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A sample without stimulus served as negative background control. DHR 123 was then 
added and the cells incubated (10 minutes, 37°C, 5% CO2). The reaction was stopped 
by the addition of lysing buffer, which partially fixes leukocytes and lyses erythrocytes. 
Finally, a DNA staining solution was used, as described for the Phagotest. Cells were 
analysed by flow cytometry (FACS Calibur, BD Biosciences) and 5000 granulocyte 
events acquired to obtain the percentage and number of cells having produced reactive 
oxygen radicals, as well as their mean fluorescence intensity (oxidative activity) using 
the Cellquest Pro software (BD Biosciences). Similar to PhagoTest, nucleated cells 
were discriminated by setting in the red fluorescence channel (DNA staining FL2-H, 
Fig 2.1 A), for those events which have DNA content as for the human diploid cell. The 
granulocyte cluster was then gated in the analysis program in the scatter diagram (FSC- 
H) vs SSC-H) (Fig 2 .IB), and its green fluorescence histogram (FLl-H) was analysed 
(Fig 2.1 D and E). In general, in this experiment the mean total (M2) was used in 
statistical calculation as shown in part E.
Suspensions of J774.2 and granulocytes cells (0.5 x 10^, 10pi) were placed on 
immunofluorescence slides and dried. After fixing the coverslip with fluorescent 
mounting medium (Citifluor, London, UK) and sealing with nail varnish, samples were 
viewed under a fluorescence microscope (Nikon Microphot-SA) and where necessary, 
images were collected with a confocal microscope (Zeiss LSM 510, Germany).
2-16 CyaA protein-coated microcrystals (PCMCs)
The procedure used to prepare PCMCs is simple, rapid and relatively inexpensive. It is 
a newly developed and patented process, which yields micron-sized particles in a dry 
foimulation suitable for drug delivery to, for example, the lungs (Kreiner et a l,  2001). 
In these experiments, the crystal-forming coprecipitant (excipient) used was DL-valine. 
The water miscible organic solvent used was ethanol and in addition propan-2-ol was
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tested on a few samples. A variety of PCMCs were prepared under different conditions. 
Although the mechanism of the PCMC formation process is unknown, the driving force 
for the organisation of the protein molecules on the surface of the excipient (DL- valine) 
is thought to be the high crystal lattice conformation of the core material. Essentially, 
the protein molecules behave as impurities in the crystallisation process and, since they 
are insoluble in the sunounding solvent, they remain confined to the crystal surface. 
Figure 2.2 shows how PCMCs were made.
2-16-1 PCMC preparation from crude CyaA in 8M nrea
1 ml of crude urea extract of CyaA containing 3.4 mg protein//ml in 8 M urea, 20 mM 
histidine, pH 6.0 was added to 1 ml of saturated DL-valine solution (60 mg/ml in 
distilled H2O) and mixed for approximately 30 s. The aqueous protein solution was then 
added dropwise, with rapid mixing or stimng, to 40 ml of absolute ethanol saturated 
with DL-valine. Stim ng (1500 rpm) was continued for a set time (15-20 mins). Crystals 
became visible gradually. The resulting crystals were filtered onto filter paper 
(Millipore Ltd., UK, 0.45 pm HV) and washed with 40 ml of absolute ethanol. The 
filter paper was placed in a petri dish, and covered with parafilm; the parafilm was 
pierced to allow air to circulate in the dish and the PCMCs were left to dry overnight at 
room temperature.
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Figure 2.2 Preparation of CyaA-protein-coated microcrystals (PCMC)
The procedure used to prepare CyaA-coated microcrysyals.
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2-16-2 PCMC preparation from crude CyaA in 2M urea
A volume of 0.5 ml of crude urea extract of CyaA containing 3.4 mg protein/ml was 
added to 1.5 ml of sodium phosphate buffer (Appendix B.IO) to give a CyaA solution in 
2M urea. The protein solution was added to 2ml of saturated DL-valine (60 mg/ml) in 
dH20 and vortexed for 30 s. The solution was added dropwise to 80 ml absolute ethanol 
saturated with DL-valine then stirred (1500 rpm) for 15-20 min to make crystals. The 
solution was filtered immediately and washed with 80 ml of absolute ethanol. The filter 
paper was placed in a petri dish, and covered with paiafilm. The PCMCs were left to 
dry overnight at room temprature. It should be noted that some samples were made by 
shaking and some were made by stirring.
2-16-3 PCMC preparation from purified CyaA 
2-16-3-1 Method 1: CyaA-PCMCs
A volume of 6 ml of purified CyaA in 8 M urea, 20 mM histidine , 0.32 M (NH4)2S0 4 , 
0.08 M NaCl (pH. 6.0) containing 290 pg/ml of protein was added to 2ml of saturated 
DL-valine (60 mg/ml) and vortexed for 30 sec. The solution was added dropwise to 80 
ml of absolute ethanol saturated with DL-valine then stirred (1500 ipm) for 15-20 mins 
to make crystals as described above (section 2-16-2).
2-16-3-2 Method 2: CyaA-BSA-PCMCs
A volume of 1 ml of purified CyaA (290 pg protein/ml) was added to 3 ml of sodium 
phosphate buffer pH 6.0 containing 870 pg of bovine serum albumin (CyaA: BSA 1: 10 
molar ratio). The protein solution was added to 2 ml of saturated DL-valine (60 mg/ml 
in dH20) and vortexed for 30 s. All other steps were done as described in method 1.
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2-16-3-3 Method 3: CyaA-CaM-PCMCs
A volume of 1 ml of purified CyaA (290 pg/ml) and 46 pi of calmodulin (1.8 mg/ml in 
dHzO) were mixed to give a ratio of 1:3 molar and the mixture was added to 2 ml of 
saturated DL-valine (60 mg/ml in dHgO) and vortexed for 30 s. All other steps were 
done as described in method 1.
2-16-3-4 Method 4: CyaA-CaM-BSA-PCMCs
A volume of 4 ml of purified CyaA (290 pg protein/ml), 200 pi of calmodulin (1.8 
mg/ml) and 12 ml of sodium phosphate buffer containing 3480 pg of BSA was added to 
2 ml of saturated DL-valine (60 mg/ml dH20) to give a molar ratio of 1: 3 and vortexed 
for 30 s. All other steps were done as described in method 1.
2-16-3-5 Method 5: CyaA-CaM-BSA-CaClz-PCMCs
A volume of 4 ml of purified CyaA (290 pg protein/ml), 200 pi of calmodulin (1.8 
mg/ml), 20 pi 1 M CaCL and 12 ml of sodium phosphate buffer containing 3480 pg of 
BSA was added to 2 ml of saturated DL-valine (60 mg/ml in dH20) and vortexed for 30 
s. All other steps were done as described in method 1.
2-16-3-6 Method 6; CyaA-BSA-CaM-ATP-PCMCs
A volume of 4 ml of purified CyaA (290 pg protein/ml), 200 pi of 100 mM adenosine 
triphosphate (ATP) and 12 ml sodium phosphate buffer containing 3480 pg BSA, 200 
pi of CaM (1.8 mg/ml) was added to 2ml of saturated DL-valine (60 mg/m! in dH20) 
and vortexed for 30 s. All other steps were done as described in method 1.
2-17 Determination of urea concentration of PCMCs
10 mg of PCMCs were dissolved in 10 ml of distilled water. A volume of 0.5 ml of 1 
mg/ml urease (Sigma) was added to 9.5 ml of PCMC sample solution and incubated for
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10 min. The urease converts one mole of urea to two moles of ammoina. The incubated 
solution was poured into a 10 ml cuvette. 4 di'ops of the first reagent (code HI 93715A) 
were added followed by 4 drops of the second reagent (code HI 93715B) and incubated 
for 3 min at room temperature. The amount of urea was monitored using an ammonia 
meter (Hana Instmments, Ion Specific Ammonia Meter, HI 93715) which measures the 
UV absoiption of the ammonia-containing solution. The instrument directly displays 
concentration in mg/L of ammonia nitrogen. To convert the reading to mg/litre of urea, 
the display is multiplied by a factor of 1.214.
2-18 Scanning electron microscopy (SEM)
SEM was used to characterise PCMC size and morphology. The SEM is designed for 
direct study of the surfaces of solid objects. By scanning with an electron beam that has 
been generated and focused by the operation of the microscope, an image is formed in 
much the same way as a TV (Figure 2.3). The SEM allows a greater depth of focus than 
the optical microscope. For this reason the SEM can produce an image that is a good 
representation of the three-dimensional sample. Biological samples require coating with 
a metal, such as gold, prior to imaging. Each sample was loaded onto a metal stub for 
SEM analysis. Before the dry powder samples could be applied to the stub, the stubs 
had to be covered with double-sided sticky copper tape. The dry powder samples were 
then sprinkled lightly onto the stubs where they stuck to the copper tape. Only a fine 
coating of powder is required for SEM analysis and any excess powder on the stub was 
removed by lightly blowing over the stub surface. A thin coating of gold was then 
evaporated onto the stubs which were then examined using a Phillips 500 SEM over a 
magnification range of X800 and X1600 and images were recoverd by Imageslave 
Windows Software.
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Figure 2.3 Scanning electron microscopy (SEM)
SEM was used to characterise PCMC size and morphology. The Scanning Electron 
Microscope creates the magnified images by using electrons instead of light waves. 
A representation of the SEM instrument is shown opposite.
M aterials and M ethods
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2-19 In vivo assay 
2-19-1 Mice
Female BABL/c mice (Harlan, UK), aged 4 to 5 weeks, were maintained in quarantine 
for a week and housed in boxes of five animals each.
2-19-2 Immunisation
CyaA-CaM-BSA-PCMCs prepared as in method 4 were suspended in sterile PBS. One 
group of five mice was injected subcutaneously on days 0 and 28 with 0.2 ml of CyaA- 
CaM-BSA-PCMC solution containing 15|ig of CyaA (from a preparation containing 
290pg protein/ml), 67.5 |ig of BSA and 5 jiig of CaM per dose. A control group of 5 
mice was injected with a solution containing the same amount of BSA and CaM in PBS. 
Mice were bled at 14 days after the second injection and serum was separated and 
pooled for each group and stored at -20°C.
2-19-3 Enzyme-linked immunosorbent assay (ELISA)
Antibody responses to the PCMC compounds were measured by 96-well ELISA. The 
ELISA plates (high bonding capacity, Greiner) were coated with 50 jil per well of 
antigen (purified CyaA, BSA or CaM) at final concentrations of Ipg/ml in coating 
buffer (Appendix G .l) and incubated overnight at 4°C. The plates were then washed 
with washing buffer (Appendix G.2) containing 0.05 % Tween in PBS and dried by 
repeated blotting on to paper towels. The plates were then blocked with 200 |xl per well 
of 0.01% gelatin in PBS (Appendix G.3) for 1 h at 37°C. Plates were washed as before 
for 3 times and dried. A volume of 50 pi of PBS was added into each well from rows B 
to H. 100 pi of serum sample (diluted 1 in 100) were added to row A and 50 pi of the 
serum from row A were transfeiTed to row B etc to make a doubling dilution series 
down the plate. The last 50 pi from row H were discarded and the plates were incubated
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for 1 h at 37°C. The plates were washed 3 times as above and 50 pi of anti-mouse IgG 
peroxidase conjugate (Sigma) at 1 in 20,000 dilution were added per well and incubated 
for 1 h at 37°C. Before adding the OPD-FAST substrate (Appendix G.4) the plates 
were washed 3 times with washing buffer. After 30 min the reaction was stopped by 
addition of 50 pi of 3M HCl per well and the CD 492nm was measured in an ELISA plate 
reader (Life Science Int, UK).
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Chapter 3 
Results
3-1 Production of recombinant CyaA toxin from E. coli
CyaA was produced in different recombinant forms and E. coli BL21/DE3 was used as 
the host strain for production of these recombinant proteins (section 2.1). The CyaA 
pro-toxin, which has AC enzymic activity and the CyaC protein required for 
posttranslational activation of cytotoxic activity, were expressed from two separate 
compatible plasmids, pGW44 and pGW54 respectively. Co-expression of cyaA and 
cyaC  in the presence of ImM  IPTG in E. coli BL21/DE3 containing both plasmids 
(pGW44 and pGW54) resulted in production of biologically-active (with enzymic and 
invasive activity) CyaA. Expression of CyaA in the absence of CyaC from E. coli 
harbouring only pGW44 resulted in production of enzymatically-active, non-invasive 
(non-acylated) pro-CyaA. A plasmid pGW44-188 encoding CyaA pro-toxin lacking 
adenylate cyclase enzymic activity, was co-expressed with pGW54 to create 
catalytically-inactive, invasive CyaA (CyaA*). Both active and non-active foi-ms of 
CyaA were extracted as inclusion bodies that were solubilized in 8 M urea from induced 
E. coli cultures. These extracts contained 200 kDa proteins that reacted with anti-CyaA 
polyclonal antibody in Western blots (Section 3.2.4). The results of cultural conditions 
on the yield of CyaA preparations from E. coli BL21/DE3 (pGW44) or E. coli 
BL21/DE3 (pGW44, pGW54) are shown in Figure 3.1.1.
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Figure 3.1.1 SDS-PAGE analysis of crude CyaA preparations from 
E.coli BL21/DE3
Crude urea extracts of CyaA from E. coli BL21/DE3 (pGW44, pGW54) or CyaA* 
(pGW44/188, pGW54), before and after inducing by IPTG, were subjected to 
electrophoresis on a 7.5% polyacrylamide gel and stained with 1% coomassie blue 
solution (Section 2.7). Arrows shows the position of the molecular weight markers.
M: Molecular weight markers
Lanes 1,4: E.coli whole cells without IPTG induction.
Lanes 2, 5: E.coli whole cells after induction with 1 mM IPTG for 3 h.
Lanes 3,6: Crude urea extracts of CyaA preparations CyaA and CyaA*
Lines 1-3 Samples from E. coli BL21/DE3 (pGW44, pGW54)
Lines 4-6 Samples from E. coli BL21/DE3 (pGW44-188, pGW54)
The large arrow shows the position of CyaA
Results
M
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3-2 Purification of CyaA from whole-cell urea extracts.
Crude urea extracts from E. coli BL21/DE3 were firstly purified by Q Sepharose 
column chromatography and step-wise elution with increasing concentrations of NaCl 
and then by Butyl Sepharose and different washing steps (section 6.1). Q Sepharose 
column chromatography was most effective in removing contaminating proteins and 
EPS. Figure 3.2.1 shows that the majority of contaminating proteins were removed in 
the first steps. Figure 3.2.2 shows the results of Butyl Sepharose column 
chromatography purification of CyaA from recombinant E, coli BL21/DE3. Figure 
3.2.3 shows the SDS-PAGE profile after silver staining, where EPS is visualised, 
indicating that the crude urea extract contained a large amount of EPS, compaiable to 
that in the control EPS sample from E. coli BL21/DE3. Only faint bands coiTesponding 
to this EPS band are seen in fractions 8 and 9 after Q Sepharose chromatography, 
indicating that most of the EPS was removed by the washing steps. Figure 3.2.4 shows 
the Western blotting result of the final purified CyaA preparations with anti-CyaA 
antibody, a rabbit polyclonal antiserum raised against the 200 kDa CyaA protein. It was 
clear that the combination of these two chromatographies (Q Sepharose and Butyl 
Sepharose) was a more suitable method for CyaA purification.
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Figure 3.2.1 SDS-PAGE of crude CyaA after Q Sepharose purification
Crude urea extract of CyaA was purified by Q Sepharose. After washing and elution with 
different concentrations of NaCl, samples were subjected to 7.5% SDS-PAGE and 
staining with 1% Coomassie blue.
M: Molecular weight markers
C: Crude urea extract
Lanes 1, 2: Wash with 2 M urea, 20 niM histidine
Lanes 3 ,4 : Eluted with 0.1 M NaCl in 8 M urea, 20 mM histidine
Lanes 5, 6: Eluted with 0.2 M NaCl in 8 M urea, 20 mM histidine
Lanes 7, 8 Eluted with 0.25 M NaCl in 8 M urea, 20 mM histidine
Lanes 9, 10; Eluted with 0.3 M NaCl in 8 M urea, 20 mM histidine
Lanes 11, 12: Eluted with 0.4 M NaCl in 8 M urea, 20 mM histidine
The large arrow shows the position of CyaA
Results
M C 1 2 3 4 5 7 8 9 10 11 12
250 ^
zuu^
1 0 0 ^
75
50 —>
40
20
84
Figure 3.2.2 SDS-PAGE of CyaA after Butyl Sepharose purification
The pooled CyaA fractions from Q Sepharose were further purified by Butyl Sepharose. 
After washing and elution with decreasing concentrations of ammonium sulphate, 
fractions were subjected to 7.5% SDS-PAGE and staining with 1% coomassie blue.
M: Molecular weight markers
Lane 1 : Wash with 2 M urea, 20 mM histidine, 0,8 M ammonium sulphate
Lane 2 : Wash with 8 M urea, 20 mM histidine, 0.2 M NaCl, 0.8 M ammonium
sulphate
Lane 3 : Eluted with 8 M urea, 20 mM histidine, 0.6 M ammonium sulphate
Lanes 4-7 : Eluted with 8 M urea, 20 mM histidine, 0.08 M NaCl, 0.32 M ammonium 
sulphate
An'ow shows the position of CyaA
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Figure: 3.2.3 LPS analysis of CyaA fractions from Q Separose purification, by 
silver staining
Crude urea extract of CyaA was purified by Q Sepharose. After washing and elution with 
different concentration of NaCl, fractions were subjected to 15 % SDS-PAGE and LPS 
was visualised by silver staining.
M Molecular weight markers
Co LPS control (from E. coli BL21/DE3)
Cr Crude urea extract of CyaA from E. coli BL21/DE3
Lanes 1, 2: Wash with 2 M urea, 20 mM histidine
Lanes 3, 4: Eluted with 0.1 M NaCl in 8 M urea, 20 mM histidine
Lanes 5 ,6 : Eluted with 0.2 M  NaCl in 8 M urea, 20 mM histidine
Lanes 7, 8 : Eluted with 0.25 M NaCl in 8 M urea, 20 mM histidine
Lanes 9, 10: Eluted with 0.3 M NaCl in 8 M urea, 20 mM histidine
Lanes 11, 12: Eluted with 0.4 M NaCl in 8 M urea, 20 mM histidine
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Figure 3.2.4 Western blot analysis of purified CyaA preparations using anti-CyaA 
polyclonal antibody
Different types of purified adenylate cyclase toxin were subjected to 7.5% SDS-PAGE, 
transferred to nitrocellulose membrane, and probed with primary and secondary 
antibodies.
Lane M: Broad range molecular weight markers
Lane 1: Purified pro-CyaA (pGW 44)
Lane 2: Purified CyaA* (pGW44-188/pGW 54)
Lane 3: Purified CyaA (pGW 44/ pGW54)
The large arrow shows the position of CyaA
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3-3 Summary of SDS-PAGE analysis of CyaA preparations
The major band in the CyaA preparations migrated on a 7.5% polyacrylamide gel at 
around 200 kDa (Figure 3.1.1). This is the expected apparent mol. wt of CyaA (Rogel et 
aL, 1990) although the actual predicted mol. wt of the toxin is 177 kDa. Crude urea 
extracts of the CyaA preparation displayed many additional bands, which indicated the 
presence of contaminating proteins. The majority of these proteins were removed by Q 
Sepharose column chromatography (Figure 3.2.1). Further purification was obtained by 
Butyl Sepharose chromatography (Figure 3.2.2). All purified CyaA forms (CyaA, 
CyaA* and pro-toxin CyaA) showed very similar bands on Western blot analysis. 
Purified CyaA preparations probed with anti-CyaA polyclonal antibody produced a 
profile with a clear band at approximately 200 kDa (Figure 3.2.4). This shows that the 
antiserum cross-reacted with the band at a 200 kDa, the expected size of CyaA, and the 
same size as the band induced after IPTG treatment of E. coli BL21/DE3 (Figure 3.1.1).
3-4 Endotoxin estimation of purified CyaA preparations
The levels of LPS in the purified CyaA preparations were visualised by silver staining 
(Fig 3.2.3) and also measured by LAL assay (section 2.11). The Limulus amoebocyte 
lysate test (LAL assay) is commonly used for the detection and quantification of LPS. 
The test depends on the ability of minute amounts of LPS to cause gelation of a lysate 
of the amoebocytes from the horseshoe crab, Limulus polyphemus. The purification 
methods were successful in reducing the endotoxin level in each preparation. The levels 
of LPS were 128 and 67 lU/mg protein for CyaA and CyaA*, respectively, which is low 
(recommended dose <5 lU  per dose for vaccine antigens, where the dose might be in the 
region of 10-25 jiig protein). The endotoxin content of each preparation is given in Table 
3.1.1 The level of LPS contamination was much lower than values reported by Mac 
Donald-Fyall (2002) and MacDonald-Fyall et a l  (2004).
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Table 3.1.1 Characterisation of purified CyaA preparations
Three different purified forms of CyaA were prepared and purified by Q and Butyl 
Sepharose chromatography. The AC enzymic and cytotoxicity activities for J774.2 
macrophage-like cells were determined by conductimetry and MTT assays, 
respectively. LAL assay was used to measure the LPS levels.
Sample Total volume 
ml
Protein
p,g/ml
LPS levels 
lU/mg 
protein
Cytotoxicity 
(50% killing of  
macrophages) 
pg protein/ml
AC enzymic 
activity 
pmol cAMP/mg 
protein/min
CyaA 35 290 128 0.025 + 0.01 674 + 9.19
Pro-CyaA 6.5 168 Not done >2.5 815 + 13.4
CyaA* 14 330 67 >2.5 5.5 + 0.63
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3-5 Characterisation of purified CyaA preparations
3-5-1 Adenylate cyclase assay
AC enzymic activity of purified CyaA preparations from E, coli BL21/DE3 [(pGW44), 
(pGW44, pGW54) and (pGW44-188, pGW54)] were determined by conductimetric 
assay (section 2. 13.1). CyaA, and pro-CyaA showed high enzymatic activity, but no 
significant activity was detected with CyaA* (Table 3.1.1; Figure 3.5.1.1). This is 
because CyaA* has a dipeptide insertion within the ATP binding site which results in a 
lack of AC enzymic activity. In order to calculate the AC enzymic activity in 
international units (lU) per mg protein, the total conductance change should be known. 
Total conductance changes in arbitrary units for a substrate concentration of 1 mM of 
ATP was 2200 and this value was used for determination of AC enzymic activity 
(Lawrence et aL, 1998). The same concentration of both CyaA, pro-CyaA and CyaA* 
proteins were made for use in the conductimetry assay. The conductance of CyaA 
preparations and level of enzymic activity of the two enzymatically-active toxins (CyaA 
and pro-CyaA) preparations were routinely in the range of 660-880 p,mol cAMP/mg 
protein/min respectively.
In order to calculate the AC enzymic activity in units per mg of protein the stock 
preparation of CyaA (300 |ig protein/ml) was used at 1 in 5 dilution and 2 |Lil were 
added to a final volume of 2  ml buffer.
Initial reaction rate = tangent of reaction (y) containing 0.06 |4g protein/ml (units/min)/ 
total change value (x) (arbitary units).
For example: 86 (y)/ 2200 (x) = 0.039 pmoles/ml/min 
To convert |imoles/ml/min to p,moles/min/|Xg protein
= 0.039 jimoles/ml/min/ 0.06 p,g protein/ml= 0.65 jLimoles/min/jLig protein or 650 
[xmoles/min/mg protein.
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Figure 3.5.1.1 AC enzymic activity of purified preparations of three forms of
CyaA
Three different purified forms of CyaA were diluted in 8M urea, 20mM histidine pH 6.0 
to the same toxin concentration (60 p,g/ml protein) . The AC enzymic activity was 
determined using a conductimetry assay in the presence of Bicine buffer and Ifil of 
inorganic pyrophosphatase, l|xl of Calmodulin and 2 p,l of each sample in each cell. AC 
enzymic activity is indicated by the gradient of the conductance curve.The figure shows 
the on-screen appearance of the conductance change for each sample. Cell 1 was a blank 
control consisting of buffer and reagents. Cell 2 was the positive control containing a 
CyaA standard with defined protein, LPS and AC enzymic activity. Cell 3 was purified 
CyaA from a new purification. Cell 4 was purified pro-CyaA and cell 5 contained 
purified CyaA*.
Results
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3-5-2 Cytotoxic effect of purified CyaA preparations
The effect of CyaA preparations on cell killing of mouse macrophage-derived (J774.2) 
cells grown in RPM I 1640 medium was determined by the MTT dye reaction assay 
using the CellTiter 96™ assay kit (Promega). This assay is based on the inhibition of 
the ability of active mitochondria in living cells to reduce tétrazolium dye solution. Pro- 
CyaA is non-acylated and only a very low cell killing effect was detected at the highest 
concentrations of toxin (Table 3.1.1 and Figure 3.5.2.1). CyaA demonstrated a high 
level of killing effect that is in line with its enzymic and invasive activities. Some 
cytotoxicity effect was detected with CyaA* at the higher concentrations of toxin, 
similar to that seen with pro-CyaA (Figure 3.5.2.1). As all preparations were prepared 
and solubilized in the same amount of urea buffer (starting at 8 M) it is possibile that 
this low level of cytotoxicity may have been due to an effect of urea at the higher 
concentrations of toxin (7.19, 21.2 and 5.5 pg/well for CyaA, pro-CyaA and CyaA*, 
respectively) (Table 3.1.1, Figure 3.5.2.1). It should be noted that all CyaA dilutions 
were made in RPM I 1640 medium without urea, which means that lower concentrations 
of toxin contained lower concentrations of urea. The results with the different CyaA 
preparations against J774.2 mouse macrophage cells using the MTT assay showed the 
importance of both the AC enzymic activity and the acylation of CyaA for cytotoxicity.
Similar experiments were performed on different mammalian cells, including 
undifferentiated U937 human monoblastic cells and U937 cells differentiated by 
treatment with phorbol myristate acetate (PMA) and IFNy as a stimulator. However, 
whereas J774.2 cells were killed by CyaA at low concentrations of toxin (e.g 50% 
killing at 0.025 p,g protein/ml), RBL-2H3 (rat basophil leukemia) cells, Vero (African 
green monkey kidney) cells, and mast cells (sheep bone marrow) showed less than 50% 
killing at all toxin concentrations tested (Figure 3.5.2.2) even though these cells were
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Figure 3.5.2.1 Cytotoxic activity of CyaA preparations on J774.2 mouse 
macrophage cells
Cytotoxicity activity of different purified CyaA preparations was determined on the 
J774.2 mouse macrophage cell line by the MTT dye reduction method. The percentage of 
cell killing at various toxin concentrations, relative to that in RPM I 1640 medium alone 
was determined using the CellTitre 96^"" assay (Promega) kit plate. The results represent 
the mean of two values (± S.D).
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Figure 3.S.2.2 Cytotoxicity of purified CyaA on different types of mammalian cells
The cytotoxic activity of purified CyaA on J774.2, RB-2H3L, sheep bone marrow mast 
cells and Vero cells were determined by the MTT dye reduction method (CellTitre 96^™ 
assay (Promega) kit plate). The results represent the mean of two values (± S.D)
Results
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cultured in DMEM medium which contain 5 mM of CaCla. Similarly, a maximum 30% 
killing was seen in undifferentiated U937 cells grown in RPMI 1640 medium but up to 
60% cytotoxicity was seen with CyaA at much lower levels by differentiating the cells 
by adding IFNy (500 units/ml) or 0.020 p,g/ml PMA final concentration (Figure 3.5.2.3). 
It should be noted that U937 is an immature human monoblastic cell line. To 
differentiate these cells to monocytic, macrophage-like cells, they needed to be 
stimulated by adding PMA or JPNy. Such cells are known to have a greater capacity to 
generate superoxide and express higher levels of CD 11b, the receptor for CyaA 
(Kikuchi et al., 1996).
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Figure 3.5.2.3 Cytotoxicity of CyaA on U937 human monocytes with and without 
activator
The effect of CyaA on undifferentiated and differentiated U937 human monocytes was 
determined by the MTT dye reduction (CellTitre 96^*” assay (Promega) kit) after 
incubation with IFNy (500 units/ml) or inceasing concentrations of PMA (0.01, 0.02 and 
0,05}xg/ml final concentrations). The results represent the means of two values (± S.D).
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3-5-3 The effect of added of calcium on CyaA and CyaA^ cytotoxicity
The cytotoxic and haemolytic activities of the CyaA are absolutely calcium-dependent. 
CyaA hai'bours two classes of calcium binding sites of different affinities (Rose et ah, 
1995). Binding of calcium to high affinity binding sites is thought to be required for 
haemolytic activity and induces major structural rearrangment of CyaA that may be 
involved in delivery of the AC domain into target cells. On the other hand, there are 40- 
45 low-affinity calcium-binding sites located in the repeat region of CyaA toxin. 
Binding of Ca to these sites might be necessary for both the membrane binding 
capability and the hemolytic activity of the toxin and each site could bind one calcium 
ion. In order to test whether Ca^^ added to the RPM I 1640 medium could influence the 
cytotoxicity of CyaA and CyaA*, various concentration of Ca^^ (CaCh) were used. 
RPM I 1640 medium contains approximately 0.423 mM CaNOs. The cytotoxic effect of 
the two forms of CyaA was assayed in the presence of added Ca^ "  ^ (CaCl2) from ImM
to 5mM. CyaAs were diluted to concentration of 5 pg protein/ml and then CaC^ was 
added. Cytotoxicity was assayed by the CellTiter 96 ™ assay kit (Promega) as described 
the Materials and Methods (section 2.13.2). The results indicated that the cytotoxic 
activity of CyaA* increased with increasing calcium concentration. However, even at 
highest concentration of CaCh tested (5 mM), the cytotoxic activity of CyaA* was still 
<1/10 of that of CyaA preparation. No obvious effect of added Ca^^ on cytotoxicity 
was seen with CyaA toxin (Table 3.5.3.1),
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Table 3.5.3.1 Effect of added Ca^^ on the cytotoxic activity of CyaA preparations in 
RPM I medium.
J774.2 mouse macrophage-like cells in RPM I medium were treated with CyaA 
preparations in the presence of added CaC^. Cytotoxicity (% cell killing) was measured 
by MTT dye reduction using the CellTiter 96 ™ assay kit (Promega). Results are the 
means of 2 determinations (± S.D).
CaCl2 added Concentration of CyaA 
(pg protein /ml) giving 50% 
cell killing
Concentration of CyaA* 
(pg protein /ml) giving 50% 
cell killing
0 0.030 + 0.02 > 3
ImM Not done 2.4
2mM 0.042 ± 0.05 1.75 ±0.07
3mM 0.044 ± 0.01 1 .2±0.14
4mM 0.075 ± 0.045 1.1 ± 0.21
5mM 0.050 ± 0.03 0.75 ±0.12
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3-5-4 ATP cytotoxicity assay
The adenosine triphosphate (ATP) assay is an alternative assay for measuring 
cytotoxicity as it determines the number of viable cells in a culture based on 
quantitation of ATP, by a bioluminescence method, which signals the presence of 
metabolically-active cells. The amount of ATP is directly related to cell numbers. 
J774.2 (grown in RPM I 1640 medium), RBL-2H3 and sheep bone marrow mast cells 
(grown in DMEM medium) were treated with different concentrations of CyaA or 
CyaA* for 2 h at 37°C. The CellTiter-Glo™ reagent (section 2.13.3) was added to each 
sample and bioluminescence output was compared to that of a negative control 
(untreated) (0% cytotoxicity) preparation. As Figure 3.5.4.1 shows, according to this 
method 50% cytotoxicity for J774.2 cells was caused by CyaA around 0.02 pg 
protein/ml but was not achieved by CyaA* up to 1.25 pg protein/ml. Little cell death 
(<15%) was detected with CyaA* below 0.02 pg/ml. The results are similar to those 
recorded in the cytotoxicity (MTT) assay (Table 3.1.1 and Figure 3.5.2.1). The effect of 
CyaA on sheep bone maiTow mast cells and RBL-2H3 cell line was also detennined. 
CyaA was less toxic for RBL-2H3 and mast cells than J774.2 cells (Figures 3.5.4.2, 
3.5.4.3) but 50 % killing was achieved at 0.2 pg/ml for mast cells and 1.0 pg/ml for 
RBL-2H3 cells. Thus, CyaA showed greater cytotoxicity using this assay than with the 
MTT assay for these cell types (see figure 3.5.2.2). There was only slight cytotoxicity 
by CyaA* on RBL-2H3 and sheep bone maiTOw mast cells, even at the highest 
concentrations. This effect was similar to that seen in both RBL-2H3 and mast cells by 
the MTT assay (Figure. 3.5.2.2). It was not determined whether addition of Ca^^ could 
enhance cytotoxicity using this assay, but DMEM medium contains 5 mM CaClg.
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Figure 3.5.4.1 ATP assay for determining cytotoxicity of CyaA and CyaA* on 
J774.2 mouse macrophage-like cells.
Intracellular ATP was measured using the CellTiter-Glo assay kit (Promega). The graph 
shows the effect of CyaA and CyaA* at different protein concentrations on cell viability 
of J774.2 cells after 2 incubation. Each bar represents the mean of the three values (± 
S.D).
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Figure 3.S.4.2 ATP assay for determining cytotoxicity of CyaA and CyaA* on
sheep bone marrow mast cells
The effect of CyaA preparations at different protein concentrations on cell survival on 
sheep bone marrow mast cells was determined after incubation for 2 h. Each bar 
represents the mean of the three values (± S.D).
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Figure 3.S.4.3 ATP assay for determining cytotoxicity of CyaA and CyaA* on
RBL-2H3 cells
The effect of CyaA preparations at different protein concentrations on cell survival in 
RBL cells was determined after incubation of 2 h. Each bar represents the mean of the 
three values (± S.D).
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3-5-5 Caspase (apoptosis) assay
One of the main characteristics of apoptosis is the activity of caspases 3 and 7, cysteinyl 
aspartate-specific proteinases with key effector roles in apoptosis (Nicholoson and 
Thombeny, 1997). Caspases 3/7 can be used as indicators of apoptosis in macrophages 
and are detected by their ability to cleave a pro-fluorescent substrate to produce a 
fluorescent signal. The amount of fluorescent product generated is proportional to the 
amount of caspase 3/7 cleavage activity present in the sample and therefore reflects 
apoptotic activity. Figure 3.5.5.1 shows the change in caspase activity in J774.2 mouse 
macrophage-like cells six hours after addition of two different CyaA preparations in the 
presence of urea buffer. Caspase 3/7 activities were measured over a range of toxin 
concentrations. At these concentrations, neither urea buffer alone nor CyaA* induced 
any significant increase in caspase 3/7 activity from J774.2 cells. It should be noted that 
there was a peak of caspase 3/7 activity at 0.039 fxg protein/ml with CyaA but this 
declined at higher toxin concentrations, possibly due to increased necrosis rather than 
apoptosis.
In addition, other mammalian cells were treated with CyaA under the same conditions 
(Fig 3.5.5.2). Measurement of caspase 3/7 activity indicated that the greatest effect of 
CyaA was on RBL-2H3 cells, where increasing concentration of CyaA gave increasing 
caspase activity. With sheep bone mairow mast cells, there was a small peak of caspase 
activity at 0.039 p.g protein/ml, a result similar to that obtained with J774.2 cells (Figure 
3.5.5.1). With Vero cells, there was no appaient effect or dose response. The same 
experiment was carried out with CyaA* on sheep bone marrow mast cells and RBL- 
2H3 cells within the same range of toxin concentrations (Figure 3.5.5.3). There was no 
obvious effect on mast cells even at the highest concentrations, although RBL-2H3 cells 
showed some response at the highest concentration of CyaA* tested (2.5 pg protein/ml).
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Figure 3.5.5.1 Induction of apoptosis (caspase 3/7 activity) by CyaA, CyaA* and
urea buffer in J774.2 mouse macrophages
The cells were incubated with toxin preparations or with urea at the same concentration 
as used in the toxin preparations, for 6  h, after which caspase 3/7 activity was determined 
by the Caspase-Glo™ 3/7 Assay (Promega) kit. Results are expressed as relative 
fluorescent light units (RFLU) and represent the mean of two values (± S.D).
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Figure 3.5.S.2 Induction of apoptosis (caspase 3/7 activity) by CyaA in sheep bone
marrow mast cells, RBL-2H3 cells and Vero cells.
Sheep bone marrow mast cells, RBL-2H3 cells and Vero cells were incubated with 
increasing doses of CyaA for 6  h. The caspase 3/7 activity was determined by the 
Caspase-Glo™ 3/7 Assay (Promega) kit. Results are expressed as relative fluorescent 
light units (RFLU) and represent the mean of two values (± S.D).
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Figure 3.5.S.3 Induction of apoptosis (caspase 3/7 activity) by CyaA* in sheep 
bone marrow mast ceils and RBL-2H3 cells
The change in caspase activity in sheep bone marrow mast cells, RBL-2H3 cells after 
incubation with increasing doses of CyaA* for 6  h. The caspase 3/7 activity was 
determined by the Caspase-Glo™ 3/7 Assay (Promega) kit and results are expressed as 
relative fluorescent light units (RFLU) and represent the mean of two values (± S.D).
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3-5.6 DNA fragmentation (apoptosis) assay
Fragmentation of genomic DNA into multimers of approximately 200 base pairs, a 
characteristic of apoptosis, was measured in J774.2 mouse macrophages-like cells and 
other mammalian cells (sheep bone marrow mast cells, RBL-2H3 and Vero cells). The 
cells were treated with either CyaA or CyaA* at 0.039 pg protein/ml final concentration 
for 12 h. This was chosen as the concentration that gave maximum induction of caspase 
3/7 activity by CyaA in J774.2 mouse macrophage-like cells (Figure 3.5.5.1) and in 
mast cells by CyaA* (Figure 3.5.5.2) after incubation at 37°C with 5% CO2 for 6  h. For 
DNA fragmentation, all cells were treated with the same concentration of urea as was 
present in the toxin samples as a negative control. As a positive control, cells were 
grown without foetal calf serum (FCS) for 24 h, a condition known to induce apoptosis. 
DNA fragmentation was evaluated by electrophoresis on a 1% agarose gel stained with 
ethidium bromide. Although, DNA fragmentation is not a quantitative assay, as shown 
in Figure 3.5.6.1, after 12 h of incubation, CyaA promoted the DNA fragmentation in 
mast cells and RBL 2H3 cells and showed a clear laddering of DNA fragments, a 
pattern characteristic of apoptosis. It should be noted that DNA from J774.2 cells 
treated with CyaA showed a necrotic smear possibly because of the onset of necrosis 
after 12 h. There was no effect seen on the DNA banding pattern from Vero cells with 
CyaA. Urea, at the concentration used for the toxin had no effect on DNA. The positive 
control, RBL cells incubated without FCS, showed a clear laddering effect. This was 
not apparent, however, with Vero cells incubated in the absence of FCS. As shown in 
Figure 3.5.6 .2, the CyaA* preparation was unable to induce DNA fragmentation. Cells 
incubated with urea again showed no laddering pattern but RBL and J774.2 cells grown 
in RPM I minus FCS, showed a pronounced laddering pattern (Figure 3.5.6.2). The 
results indicated that AC enzymic activity is necessary for the induction of apoptosis 
and invasive capability alone was shown to be insufficient to cause apoptosis although
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slight activity was detected with CyaA* at high concentrations after incubation with 
RBL-2H3 cells (Figure 3.5.5.3) but this was not apparent in the DNA fragmentation 
experiment (figure 3.5.6 .2). The results show that there are some differences between 
induction of caspase 3/7 activity and DNA fragmentation among these cells. In spite of 
the remarkable effect of CyaA on J774.2 cells, other mammalian cells showed very low 
response to CyaA with the exception of RBL-2H3 cells. However, CyaA showed an 
obvious laddering pattern with sheep bone marrow mast cells and RBL-2H3 cells but 
Vero cells did not. The reason for these differences are unknown but the incubation 
time of treatment of toxin (6  h and 12 h for caspase 3/7 activity and DNA 
fragmentation, respectively) may play an important role in this matter.
108
Figure 3.5.6.1 Agarose gel electrophoresis of genomic DNA from different
mammalian cells after incubation with CyaA
DNA fragmentation of J774.2, sheep bone marrow mast cells, RBL-2H3 cells and Vero 
cells treated with CyaA, was determined after incubation for 12 h. DNAs were extracted, 
separated by electrophoresis in a 1% agarose gel and stained with ethidium bromide 
(section 2.5).
Line M: Marker (Ikb DNA ladder)
Lane 1: DNA from i l l 4.2 cells + CyaA
Lane 2: DNA from mast cells + CyaA
Lane 3: DNA from RBL-2H3 cells + CyaA
Lane 4: DNA from Vero cells + CyaA
Lane 5: DNA from J774.2 cells + urea (as negative control)
Lane 6 : DNA from mast cells + urea (as negative control)
Lane 7 : DNA from RBL-2H3 cells + urea (as negative control)
Lane 8 ; DNA from RBL-2H3 cells without FCS (as positive control)
Lane 9: DNA from Vero cells + urea (as negative control)
Lane 10: DNA from Vero cells without FCS (as positive control)
Results
M 1 2 3 4 5 6 7 8 9  10
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Figure 3.S.6.2 Agarose gel electrophoresis of genomic DNA from different
mammalian cells after incubation with CyaA*
DNA fragmentation of J774.2, sheep bone marrow mast cells, RBL-2H3 and Vero cells 
treated with CyaA* after incubation for 12 h. DNAs were extracted, separated by 
electrophoresis in a 1% agarose gel and stained with ethidium bromide (section 2.5).
Line M:
Lane 1:
Lane 2 :
Lane 3:
Lane 4:
Lane 5:
Lane 6 :
Lane 7:
Lane 8 :
Lane 9:
Lane 10 :
Lane 1 1 :
Lane 1 2 :
Marker (Ikb DNA ladder)
DNA from J774.2 cels + urea (as control negative)
DNA from mast cells + urea (as control negative)
DNA from RBL-2H3 cells + urea (as control negative)
DNA from Vero cells + urea (as control negative)
DNA from J774.2 cells + CyaA*
DNA from mast cells + CyaA*
DNA from RBL-2H3 cells + CyaA*
DNA from Vero cells + CyaA*
DNA from RBL-2H3 cells without PCS (as positive control) 
DNA from J774.2 mast cells without PCS (as positive control) 
DNA from Vero cells without PCS (as positive control)
DNA from J774.2 without PCS (as positive control)
Results
10 11 12
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3-6 Summary of characterisation of CyaA preparations
The purified CyaA toxins were chaiacterised by several assays. The conductimetry 
assay was used as a novel, rapid and easy method to evaluate the level of AC enzymic 
activity. The results indicated that the purified forms of both CyaA and pro-CyaA were 
enzymatically active, whereas CyaA* was shown to have very low activity.
The MTT dye reduction cytotoxicity (CellTiter 96™ assay kit) assay with J774.2 cells 
showed that CyaA caused considerable cell death after incubation for 2 h at 37°C in 5% 
CO2 whereas CyaA* and pro-CyaA showed more than 100-fold less activity. However, 
CyaA* activity was shown to be more dependent on the concentration of Ca^ "*" than 
CyaA. In addition, the viability of these macrophage-like cells treated with different 
concentrations of CyaA and CyaA* was assayed by the ATP assay using CellTiter-Glo 
assay, Promega. The MTT and ATP assays were compared to assess their ability to 
measure cytotoxicity in 1774.2 cells due to CyaA toxins. The assays gave comparable 
results, although it was cleai- that the MTT assay was slightly less sensitive than the 
ATP assay, showing 50 % killing at 0.025 pg protein /ml compared to 0.02 pg 
protein/ml respectively.
Induction of apoptosis was evaluated by caspase 3/7-activity determination and DNA 
fragmentation assays. For the caspase assay, different mammalian cell lines were treated 
with two-fold serial dilutions of CyaA and CyaA* for six hours at 37°C and in 5% CO2 . 
The results with J774.2 cells, sheep bone maiTow mast cells and RBL-2H3 cells 
indicated that the AC enzymic activity of CyaA was important for the induction of 
caspase activity or DNA fragmentation. This is presumably because CyaA is able to 
penetrate the host cell, bind calmodulin, and then incease the intracellular cyclic AMP 
concentration that can lead to apoptosis. Measurement of caspase 3/7 activity indicated
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that CyaA had the greatest effect on J774.2 cells and RBL-2H3 cells, the least on Vero 
cells and sheep bone maiTow mast cells. Interestingly, the decline in caspase activity 
seen with J774.2 cells at concentration higher than 0.05 pg/ml did not occur with RBL 
cells in which a more steady increase in caspase activity was seen with increasing 
concentration of CyaA.
In the DNA fragmentation assay, the greatest effect of CyaA was seen with mast cells 
and RBL2H3 cells. The reason for the lack of DNA laddering in J774.2 cells was not 
clear, but may have reflected the fact that apoptosis induction was poor above 0.039 
pg/ml, as indicated by caspase activity, and the longer incubation time for DNA 
fragmentation (12  h) rather than 6  h for caspase activity may have resulted in a loss of 
DNA fragmentation due to the onset of necrosis rather than apoptosis. The onset of 
necrosis in J774.2 cells at CyaA concentrations above 0.039 pg/ml would explain the 
decline in caspase activity, in agreement with the sharp rise in cytotoxic activity of 
CyaA at 0.02-0.05 pg/ml (Figures 3.5.2.1 and 3.5.5.1).
3-7 Effect of CyaA preparations on phagocytosis
Using flow cytometry, the phagocytic ingestion of E, coli by human peripheral blood 
cells from healthy donors, 1774.2 mouse macrophages and U937 human monoblastic 
cells was determined after exposure to different concentrations of CyaA and CyaA*. 
This technique was developed for the evaluation of phagocytosis activity in human 
peripheral blood (neutrophils and monocytes) and other cells. Ingestion activity was 
measured as the mean fluorescence intensity (MFI) produced after 20 minutes of 
incubation with FITC-conjugated E, coli. All tubes were read by flow cytometry at a 
wavelength of 488 nm after quenching and DNA staining (see section 2.14).
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Exposure of granulocytes or J774.2 cells to different concentration of CyaA and CyaA* 
(0.05, 0.1, 0.2 pg/ml final concentrations) resulted in significantly lower mean 
neutrophil ingestion in the presence of CyaA compared to CyaA* at the same 
concentrations, and the unexposed controls cells (Table 3.7.1 and Figure 3.7.1). The 
results also showed that phagocytosis was significantly impaired by increases in CyaA 
concentrations for granulocytes and J774.2 cells compared to cells treated with PBS or 
CyaA*. With 0.2 pg protein/ml of CyaA there was almost complete (92%) inhibition of 
phagocytosis by J774.2 cells and 63% inhibition of phagocyotosis by human 
granulocyte cells. CyaA* had no obvious affect on phagocytosis except at the highest 
concentration of toxin used (0 .2  pg/ml) where 10 % inhibition with granulocytes was 
seen but this was not significant. The flow cytometry histograms that represents the 
amount of ingested E. coli, also indicated the dose-dependent inhibitory effect of CyaA 
on J774.2 and granulocytes (Fig 3.7.1, images 2 and 4), while there was lack of 
inhibitory effect of CyaA* on 1774.2 and granulocytes (Fig 3.7.1, images 1 and 3). In 
similar experiments, undifferentiated and differentiated U937 human monocytes were 
treated with CyaA only at O.lpg/ml. As Table 3.7.1 shows, only differentiated cells 
were affected by CyaA, showing 42% inhibition of phagocytosis. Overall the results of 
this assay would imply that inhibition of phagocytosis by CyaA was due mainly to the 
AC enzymic activity of the protein.
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Table 3.7.1 Suppression of phagocytosis activity of granulocytes, J774.2 and U937 
cells by CyaA prepai'ations
Toxin cone 
(pg/ml)
% Inhibition 
of 1774.2 
cells 
(mouse 
macrophages)
% Inhibition of 
granulocytes 
(Human 
peripheral blood)
% Inhibition of 
U937 cells
(human monocytes) 
(without PMA)
% Inhibition of 
U937 cells
(human 
monocytes) 
(with PMA)
CyaA (0.05) 26 28 Not done Not done
CyaA (0.1) 79 58 0 42
CyaA (0.2) 92 63 Not done Not done
CyaA* (0.05) 0 0
CyaA* (0.1) 0 0
CyaA* (0.2) 0 10
PBS 0 0
The statistical analysis of data by t test was as follows:
CyaA (0.0 5pg/ml) vs PBS, P < 0.044,, ; CyaA ( 0.1, pg/ml) PBS, P < 0.004,
CyaA (0.2 pg/ml) vs PBS, p  < 0.005,
CyaA* (0.2 pg/ml) PBS, /? < 0.19,
CyaA* (0.2 pg/ml) vj CyaA, p  < 0.001
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Figure 3.7.1 The effect of CyaA and CyaA* on phagocytosis of E. coli by J774.2
mouse macrophage-like cells and human granulocyte cells
Phagocytosis was measured in fresh human granulocyte cells and J774.2 cells by flow 
cytometry with the commercial BurstTEST™ assay (OPREGEN Pharma; BD 
Biosciences). Normalised fluorescence intensity (FL-Hl) represents the number of 
ingested FITC-conjugated E. coli. The histograms show a dose-dependent reduction in 
phagocytosis of granulocytes treated with various concentration (0.05, 0.1, 0.2 pg/ml) of 
CyaA, compared with untreated cells (PBS).
Image 1 : CyaA* + J774.2 cells at different concentrations
Image 2: CyaA + J774.2 cells at different concentrations
Image 3: CyaA* + human granulocyte cells at different concentrations
Image 4; CyaA 4- human granulocyte cells at different concentrations
Results
Image 1 Image 2
Image 3 Image 4
Negative
PBS
CyaA or CyaA* 0.05 ng/ml 
CyaA or CyaA* 0.1 p.g/ml 
CyaA or CyaA* 0.2 |lg/ml
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3-8 Effect of CyaA preparations on the oxidative burst
Flow cytometry assays for the measurement of the oxidative burst are based on the 
conversion of a non-fluorescent molecule to the fluorescent form under the influence of 
intracellular reactive oxygen intermediates. This conversion reflects the amount of 
oxidative burst induced by various stimuli. The substrate used was dihydrorhodamin- 
123 (DHR-123), which enters the cells as a freely permeable dye and is converted to 
rhodamine 123. It was used as an indicator of oxidative burst and has been found to be 
more sensitive than other substrates (Rothe et aL, 1988). The cells (human granolocytes, 
J774.2 and U937) were treated with either CyaA or CyaA* (0.5, 0.1 and 0.2 |Lig 
protein/ml final concentration) for two hours and then incubated with opsonised E, coli 
for 15 min. In addition, some of the cells were incubated with PBS instead of CyaA, as 
controls. Cells were washed and then read by flow cytometry at a wavelength of 488 nm.
Induction of the oxidative burst was significantly reduced in the presence of CyaA 
compared with control cells (treated with PBS). With 0.2 p.g protein/ml of CyaA there 
was almost complete (80%) inhibition of phagocytosis by J774.2 cells and 70% 
inhibition of phagocotosis by human granulocyte cells. The results (Table 3.8.1 and 
Figure 3.8.1) showed that production of the oxidative burst was significantly impaired 
by increasing concentrations of CyaA compared to cells treated with PBS. CyaA* had 
no obvious affect on inhibition of the oxidative burst except at the highest concentration 
of toxin used (0.2 jug/ml protein). The statistically significant results obtained with 
CyaA were substantiated by the flow cytometric histograms (Figure 3.8.1 images 2 and 
4). Images 1 and 3 showed that CyaA* had little effect on J774.2 and or granulocytes 
only at the highest concentration. Similar experiments were earned out with 
undifferentiated and differentiated U937 human monoblast treated with CyaA at 0.1 
fxg/ml. As Table 3.8.1 shows, only differentiated cells were affected by CyaA.
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Tables.8.1 Inhibition of oxidative burst activity of human granolocytes, J774.2 and 
U937 cells by CyaA preparations
Toxin cone 
(pg/ml)
% Inhibition 
of oxidative 
burst in 
1774.2 cells
(mouse
macrophages)
% Inhibition of 
oxidative burst 
in granulocytes 
(Human 
peripheral blood)
% Inhibition of 
oxidative burst 
in U937 cells
(human monocytes) 
(without PMA)
% Inhibition of 
oxidative burst 
in U937 cells 
(human 
monocytes) 
(with PMA)
CyaA (0.05) 18 35 Not done Not done
CyaA (0.1) 38 55 0 40
CyaA (0.2) 80 70 Not done Not done
CyaA* (0.05) 0 0
CyaA* (0.1) 0 0
CyaA* (0.2) 0 21
PBS 0 0
The statistical analysis of data by t test was as follows:
CyaA (0.0 5 Rg/ml) vs PBS, P < 0.003 ; CyaA (0.1 pg/mi) PBS, P < 0.024, 
CyaA (0.2 pg/ml) vs PBS, p < 0.002,
CyaA* (0.2 pg/ml) V5 PBS, p  < 0.01 
CyaA* (0.2 pg/ml) vs CyaA, p  < 0.01
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Figure 3.8,1 The effect of CyaA and CyaA* on inhibition of oxidative burst in
J774.2 mouse macrophage-like cells and human granulocyte cells
The oxidative burst was measured in fresh human granulocyte cells and J774.2 cells by 
flow cytometry with the commercial BurstTEST^^ assay (OPREGEN Pharma; BD 
Biosciences), Normalised fluorescence intensity (FL-Hl) represents the amount of the 
fluorogenic product, rhodamine 123, produced via reactive oxygen intermediates from 
the non-fiuorogenic substrate, dihydrorhodamine (DHR) 123, and therefore is a measure 
of reactive oxidants.
Image I: CyaA* + J774.2 at different concentrations
Image 2: CyaA + J774.2 at different concentrations
Image 3: CyaA* 4- human granulocyte cells at different concentrations
Image 4: CyaA + human granulocyte cells at different concentrations
Results
Image 1 Image 2
S - i
FL1-H
Image 3 Image 4
Negative
PBS
CyaA or CyaA* 0.05 pg/ml 
CyaA or CyaA* 0.1 lag/ml 
CyaA or CyaA* 0.2 |lg/ml
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3-9 Confocal laser scanning microscopy of ingestion activity of J774.2 
macrophages and human granulocytes in the presence of CyaA 
preparations
In this part of the study, confocal microscopy (see section 2-15) was used to determine 
how CyaA inhibits phagocytosis of bacteria by J774.2 cells and granulocytes. Ingestion 
of FITC-conjugated E. coli was evaluated in the presence of 0.05 pg/ml of CyaA or 
BSA for J774.2 cells (Fig 3.9.1) and 0.05, 0.1 and 0.2 |Xg/ml CyaA or BSA for 
granulocytes (Figs 3.9.2- 3.9.4). The green fluorescent particles representing ingested 
bacteria were clearly seen within the J774.2 cells in the control sample. In the presence 
of CyaA (0.05 p,g/ml) there were possibly fewer intracellular particles and the majority 
were seen to be more contained to the periphery of the cells, possibly on the outside 
(Fig 3.9.1 and 3.9.2). With increased concentrations of CyaA, 0,1 pg/ml and 0.2 pig/ml 
(Fig 3.9.3), fewer fluorescent bacteria were associated with the human neutrophils 
compared to the control cells. The confocal laser microscopy results indicated that 
CyaA interfered with uptake of bacteria in support of the data obtained by flow 
cytometry (section. 3.7).
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Figure 3.9.1 Morphological analysis of uptake of FITC-E. coli by J774.2 cells in 
the presence of CyaA by Confocal microscopy
Ingestion of FITC-conjugated E. coli was evaluated with J774.2 cells in the presence of 
0.05 pg of CyaA toxin or in cell treated with PBS only. Arrowheads show intracellular 
bacteria.
Results
A: J774.2 + PBS (magnifîcation of 250x) Al: magnification of lOOOx
B: J774.2 + CyaA (magnification of 250x) B1 : magnification of 4000x
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Figure 3.9.2 Morphological analysis of uptake of FITC-E. coli in human 
granulocyte cells in presence of CyaA by Confocal microscopy
Ingestion of FITC-conjugated E. coli was evaluated in the presence of 0.05 pg of CyaA 
toxin or in cells treated with PBS only in human granulocyte cells. Arrowheads show 
intracellular bacteria.
Results
A: Granolocytes + PBS (magnifîcation of 250x) A l: magnification of lOOOx
\
B: Granolocytes + CyaA (magnifîcation of 205x) Bl: magnification of lOOOx
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Figure 3.9.3 Morphological analysis of uptake of FITC-E. coli in human 
granulocyte cells in presence of CyaA by Confocal microscopy
Ingestion of FITC-conjiigated E.coli was evaluated in the presence of 0.1 pg (C) and 0.2 
pg (D) of CyaA toxin in human granulocyte cells . Arrowheads show intracellular 
bacteria.
Results
C: Granolocytes + CyaA (magnifîcation 250x) Cl: magnifîcation of lOOOx
D: Granolocytes + CyaA (magnifîcation of 250x) D l: magnifîcation of lOOOx
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3-10 Protein-coated microcrystals (PCMCs)
3-10-1 Experiments with crude CyaA
The recombinant CyaA preparations were routinely solubilized in 8M urea and such 
preparations would not be suitable for use as vaccine components. In consequence, it 
was decided to remove urea and try to create a formulation that was stable and could be 
solubilized in its absence whilst retaining the enzymic and cytotoxic properties of the 
toxin. For this purpose, the use of protein-coated microcrystals (PCMCs) was proposed. 
Two forms of CyaA (crude and purified) were used to make the PCMCs (section 
2.13.8).
As a preliminary test, to ensure that the crystallisation process did not interfere with the 
structural integrity of the CyaA protein, three crude CyaA preparations (batches A, B 
and C) with various protein concentrations were used to make CyaA-PCMCs under the 
same conditions but on different occasions. To further examine the properties of 
PCMCs, CyaA-PCMCs were made by shaking or by stirring. After the PCMCs had 
been made, the next step was to determine the concentration of protein present on the 
PCMCs which was measured by the Bradford assay (see section 2.9). For this, 10 mg of 
each batch of CyaA-PCMCs were dissolved in 1 ml of 8 M  urea, 20 mM histidine (pH
6.0). The AC enzymic and cytotoxicity activities of CyaA-PCMCs were determined on 
these urea-solubilised fractions by conductimetry and by the MTT dye reduction assay, 
respectively (sections 2.13.1 and 2.13.2). The results of these experiments aie shown in 
Table 3.10.1.1.
Both AC enzymic and cytotoxic activities were somewhat diminished by PCMC 
foimulation, but CyaA-PCMCs made by stim ng displayed greater activities than those 
made by shaking. Indeed, a greater PCMC protein concentration was obtained by 
making the PCMCs using a magnetic stirrer bar then when they were made by shaking.
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Table 3.10.1.1 Characterisation of CyaA-PCMCs from crude CyaA (batches A, B, C)
CyaA
Sample
Buffer used to 
dissolve crystals
Protein
concentration
pg/ml
AC enzymic 
activity 
pmol/mg 
protein/min
Cytotoxicity 
50% killing of 
J774.2 cells 
pg/ml protein
LPS content 
visualized on 
gel by silver 
stain
Crude urea 
extract A*
8 M urea, 20 
mM histidine 
pH 6.0
2000 375 0.033 ++
CyaA-
PCMCs
A l#
8 M urea,
20 mM histidine 
pH 6.0
76 159 0.069 -
CyaA-
PCMCs
A 2 f
8 M urea,
20 mM histidine 
pH 6.0
97 240 0.035 -
Crude urea 
extract B*
8 M urea,
20 mM histidine 
pH 6.0
3400 379 0.049 ++
CyaA-
PCMCs
B l#
8 M urea,
20 mM histidine 
pH 6.0
320 180 0.1 -
CyaA-
PCMCs
B2+
8 M urea,
20 mM histidine 
pH 6.0
374 219 0. 034 -
Crude
urea
extract C*
8 M urea,
20 mM histidine 
pH 6.0
4000 395 0.02 ++
CyaA-
PCMCs
C l#
8 M urea,
20 mM histidine 
pH 6.0
180 195 0.15 -
CyaA-
PCMCs
C24
8 M urea,
20 mM histidine 
pH 6.0
210 216 0.05 -
* A, B, C refer to original crude CyaA preps used for PCMCs.
# A l, B l, C l refer to PCMCs made by shaking (see section 2.16.1)
♦ A2, B2, C2 refer to PCMCs made by stirring (see section 2.16.2)
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Using a magnetic stiiTer bar, the PCMCs also formed a lot quicker compared to when 
they were made by shaking. A possible reason for this is that when the precipitation is 
earned out, the water content of solvent increases as the protein and excipient are 
added. This is because the excipient (DL-valine) is prepared in deionized water. 
Therefore, it is possible that the longer the PCMCs are left in the reaction vessel, as in 
the case of shaking, there is a possibility that some crystals may re-dissolve. If this was 
the case then the re-dissolved PCMC would be washed through the filtration stage and 
lead to loss in PCMCs yield and protein concentration.
A CyaA band was observed from three different batches of PCMCs (A, B and C) when 
they were dissolved in 8 M urea (Figures 3.10.1.1 and 3.10.1.2). To complement these 
assays, PCMCs prepared by shaking or stirring (batch C), were dissolved in histidine 
buffer alone or histidine buffer with increasing concentrations of urea, and visualised on 
SDS-PAGE. Results (Figure 3.10.1.3) showed that no protein band equivalent in size to 
CyaA was visible in urea up to 0.5 M but was present at higher concentrations. LPS is a 
major contaminant of crude CyaA and it was of interest to determine if it would be 
washed through the process. In this experiment, the LPS was visualised on SDS-PAGE 
gels by silver stain and showed clear evidence of LPS in the original crude CyaA but 
not in PCMCs dissolved in increasing concentration of urea (Fig 3.10.1.4 and Table
3.10.1.1).
Following the SDS-PAGE results another experiment was carried out with crude CyaA- 
PCMCs (batch C). 10 mg of each preparation (made by shaking or stimng) were 
dissolved in histidine buffer alone or histidine buffer with increasing concentration of 
urea. The AC enzymic and cytotoxicity properties were determined by conductimetry 
and cytotoxicity (MTT) assays. The results indicated that AC enzymic and cytotoxicity 
activities were only detected when CyaA-PCMCs were dissolved in at least 1 M urea
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Figure 3.10.1.1 SDS-PAGE analysis of crude CyaA-PCMCs (batch A)
Crude CyaA-PCMCs were made from crude CyaA batch A by either shaking (A l) or 
stirring (A2), were dissolved in 8M urea, 20mM histidine buffer pH 6.0. Samples were 
subjected to electrophoresis on a 7.5% polyacrylamide gel and stained with 1% 
coomassie blue solution.
M: Molecular mass standard
Lane 1 : Crude urea extract A (original)
Lane 2: Crude CyaA-PCMCs from CyaA batch A (A l)
Lane 3: Crude CyaA-PCMCs from CyaA batch A (A2)
A it o w  shows the position of CyaA
Results
kDa M M
2 5 0 ^
200^
100- +
75->
50-
126
Figure 3.10.1.2 SDS-PAGE analysis of crude CyaA-PCMCs (batches B & C)
Crude CyaA-PCMCs, made from crude CyaA B and C, were dissolved in 8M urea, 
20mM histidine buffer pH 6.0. All samples were subjected to electrophoresis on a 7.5% 
polyacrylamide gel and stained with 1% coomassie blue solution.
M: Molecular mass standard
Lane 1: Crude urea extract batch C (original)
Lane 2 : CyaA-PCMCs from crude C by shaking (C l)
Lane 3 : CyaA-PCMCs from crude C by stirring (C2)
Lane 4 : CyaA-PCMCs from crude B (B1)
Arrow shows the position of CyaA
Results
KDa M
250->  
200- +
100- »
75->
5 0 ^
^ W , :  - ’
4 - m
' " f"
, g@@gaJ/rif ‘^ ^ - t  <sWi!y-,^Si;
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Figure 3.10.1.3 SDS-PAGE analysis of crude CyaA-PCMCs dissolved in different
concentrations of urea (batch C)
Crude CyaA-PCMCs made from crude CyaA batch C by either shaking (A l-G l) or 
stirring (A2-G2) were dissolved in histidine alone buffer or increasing concentration of 
urea in histidine buffer (pH 6.0). All samples were centrifuged and samples of 
supernatant were subjected to electrophoresis on a 7.5% polyacrylamide gel and stained 
with 1% coomassie blue solution.
M; Molecular mass standard
Lanes A1 & A2; CyaA-PCMCs dissolved in 20mM histidine alone buffer pH 6.0
Lanes B1 & B2 : CyaA-PCMCs dissolved in 0.1 M urea, 20 mM histidine pH 6.0
Lanes C l & C2 : CyaA-PCMCs dissolved in 0.2 M urea, 20 mM histidine pH 6.0
Lanes D1 & D2 : CyaA-PCMCs dissolved in 0.5 M urea, 20 mM histidine pH 6.0
Lanes E l & E2 : CyaA-PCMCs dissolved in 1 M urea, 20 mM histidine pH 6.0
Lanes F I & F2 : CyaA-PCMCs dissolved in 2 M urea, 20 mM histidine pH 6.0
Lanes G1 & G2 : CyaA-PCMCs dissolved in 5 M urea, 20 mM histidine pH 6.0
Bold arrow shows the position of the CyaA band
Results
kDa M A1 B1 C l D1 E l F I G1 G2 A2 B2 C2 D2 E2 F2
2 5 0 - 4
2 0 0 ^
7 5 - 4
5 0 ^
37-^
2 5 - 4
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Figure 3.10.1.4 Silver stain for analysis of LPS content of crude CyaA-PCMCs
dissolved in different concentrations of urea (batch C)
Crude CyaA-PCMCs were made from crude batch C and were dissolved in histidine 
alone buffer or increasing concentration of urea in histidine buffer (pH 6.0). All samples 
were centrifuged and samples subjected to electrophoresis on a 15% polyacrylamide gel 
and stained with silver stain to visualize the LPS.
M ; Molecular weight markers
Co : LPS control
Cr: Crude urea extract batch C
Lane 1 : CyaA-PCMCs dissolved in histidine alone buffer pH 6.0
Lane 2: CyaA-PCMCs dissolved in 0.1 M urea, 20 mM histidine pH 6.0
Lane 3: CyaA-PCMCs dissolved in 0.2 M urea, 20 mM histidine pH 6.0
Lane 4: CyaA-PCMCs dissolved in 0.5 M urea, 20 mM histidine pH 6.0
Lane 5: CyaA-PCMCs dissolved in 1 M urea, 20 mM histidine pH 6.0
Lane 6 : CyaA-PCMCs dissolved in 2 M urea, 20 mM histidine pH 6.0
Lane 7: CyaA-PCMCs dissolved in 5 M urea, 20 mM histidine pH 6.0
Results
kDa
2 5 0 -4
1 0 0 -4
7 5 ->
5 0 -4
3 7 -4
2 5 ->  
1 0 -4
M Co Cr 1 6 7
-il2
f e j ^ _
IE’S?-?
rm> f-
m m m ' ' ^ - ' ^
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(Tables 3.10.1.2 and 3.10.1.3). In comparison, histidine buffer alone and urea 
concentrations up to 0.5 M did not yield any activity. It was interesting to note that, 
although a CyaA protein band was visible after dissolving the PCMCd in 0.5 M urea, no 
enzymic or cytotoxic activities were detected with this sample. Even with 1 M urea, the 
enzymic and cytotoxic activity was lower than with 2 M and 5 M urea. The results of 
this part of study show that CyaA-PCMCs have good activities only when redissolved 
in buffer containing a high concentration of urea. It can be concluded that in general 
PCMCs have enzymic and cytoxicity activities approximately 2-fold lower than the 
original crude urea extract. The process of preparing PCMCs did not therefore greatly 
perturb the conformation of CyaA required for its enzymic and cell-invasive properties.
3.10.2 Urea concentration in CyaA-PCMCs
The removal of urea was a major aim in this project. The urea content of CyaA-PCMCs 
was determined by the urease assay (section 2.17), and was found to be 0.00005lg/100 
ml, a ratio of 1:1,000,000. The concentration of urea in the CyaA stock material in 8 M 
was 48 g/100ml therefore, the ratio of urea after and before PCMCs is 0.000001. The 
result shows that during the process the majority (> 99.99%) of urea has been removed.
Sample Meter reading 
Ammonium 
concentration 
(mg/L)
Urea concentration 
(mg/L)
% Urea 
(mg/1 0 0  ml)
PCMC 0.42 0.51 0.051
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Table 3.10.1.2 Characterisation of CyaA-PCMCs prepared from crude CyaA (batch C 
with shaking) dissolved in increasing concentrations of urea buffer
CyaA-PCMCs prepared from crude sample batch C were dissolved in 20mM histidine 
(A l) or in histidine buffer with increasing concentrations of urea buffer (B l-G l). The 
AC enzymic and cytotoxicity activities were determined by conductimetry and MTT 
assay on samples of supernatant after centrifugation. LPS was visualised by silver stain.
PCMCs prepared 
from crude CyaA 
batch C
Protein cone 
pg/ml
AC enzymic 
activity 
pmol/min/mg 
protein
Cytotoxicity 
%50 killing of 
J774.2 cells 
pg/ml protein
LPS 
visualized 
on gel by 
silver stain
Ai-Dissolved in 
20 mM histidine 
pH 6.0
No protein 
detected
No activity 
detected
No cytotoxicity 
detected -
Bi-Dissolved in 
20 mM histidine, 
0.1 M urea pH 6.0
No protein 
detected
No activity 
detected
No cytotoxicity 
detected -
Cl-Dissolved in 
20 mM histidine, 
0.2 M urea 
pH 6.0
No protein 
detected
No activity 
detected
No cytotoxicity 
detected -
Di-Dissolved in 
20 mM histidine, 
0.5 M urea 
pH 6.0
No protein 
detected
No activity 
detected
No cytotoxicity 
detected -
El-Dissolved in 
20 mM histidine, 
1 M urea pH 6.0
120 131 0.15 -
El-Dissolved in 
20 mM histidine,
2 M urea pH 6.0
180 195 0.07 -
Gi- Dissolved in 
20 mM histidine,
5 M urea pH 6.0
228 275 0.05 -
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Table 3.11.1.3 Characterisation of CyaA-PCMCs prepared from crude CyaA (batch 
C with stirring) dissolved in increasing concentrations of urea buffer
CyaA-PCMCs from crude sample batch C and were dissolved in 20mM histidine (A2) 
or in histidine buffer with increasing concentrations of urea buffer (B2-G2). The AC 
enzymic and cytotoxicity activities were determined by conductimetry and MTT assay 
on samples of supernatant after centrifugation. LPS was visualised by silver stain.
PCMCs prepared 
from crude CyaA 
batch C
Protein
conconcentration
lag/ml
AC enzymic 
activity 
pmol/min/mg 
protein
Cytotoxicity 
50% killing of 
1774.2 cells fxg/ml 
protein
LPS
visualized 
on gel by 
silver stain
A2-Dissolved in 
20 mM histidine 
pH 6.0
No protein 
detected
No activity 
detected
No cytotoxicity 
directed -
B2-Dissolved in 
20 mM hihtidine, 
0.1 M urea pH 6.0
No protein 
detected
No activity 
detected
No cytotoxicity 
detected -
C2-Dissolved in 
20 mM histidine, 
0.2 M urea 
pH 6.0
No protein 
detected
No activity 
detected
No cytotoxicity 
detected -
D2-Dissolved in 
20 mM histidine, 
0.5 M urea 
pH 6.0
No protein 
detected
No activity 
detected
No cytotoxicity 
detected -
E2-Dissolved in 
20 mM histidine, 
1 M urea pH 6.0
165 119 0 .6 -
F2-Dissolved in 
20 mM histidine,
2 M urea pH 6.0
210 216 0.15 -
G2"Dissolved in 
20 mM histidine,
5 M urea pH 6.0
295 281 0.05 -
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3-10-3 Experiments with purified CyaA-PCMCs 
3-10-3-1 Stability of AC enzymic activity of CyaA-PCMCs
Based on previous experiments where CyaA-PCMCs were made with crude CyaA 
preparations, CyaA-PCMCs were prepared with purified CyaA for further investigation 
(section 2.16.1 and 2.16.2). Prepared crystals were kept in different conditions for two 
weeks (i.e. 37, 20, 4, -20° C). 10 mg of each of two preparations (prepared from CyaA 
in the presence of 2 M or 8 M urea) were dissolved in 1 ml of 8 M urea, 20 mM 
histidine, (pH 6.0) and AC enzymic activity determined. In parallel, 100 pi of original 
CyaA in 8 M urea were stored at the above conditions for two weeks (Table 3.10.3.1.1). 
As Table 3.10.3.1.2 shows, the PCMCs prepared from CyaA in 8 M urea (batch A) 
displayed more stablity and higher activity than those that made from CyaA in 2 M urea 
(batch B) at a temperature of 4° C and above. Stability was similar at -20° C. The 
results from the original CyaA preparation in 8 M urea stored for 2 weeks at different 
temperatures showed that AC enzymic activity was retained well even at room 
temperature but, at 37° C, only 13.5 % of the original activity was retained (Table
3.10.3.1). It can be concluded that CyaA-PCMCs prepared from CyaA in 8 M urea pH 
6.0 retained AC enzymic activity at approximately 90 % even at 37° C which is in 
contrast to original CyaA kept in 8 M urea at 37 ° C when 80-90 % of activity was lost. 
PCMCs have the potential, therefore, to be stored at ambient temperature and still retain 
enzymic activity.
3-10-3-2 The effect of different detergents on recovery of AC enzymic activity 
from CyaA-PCMCs
As mentioned previously, reasons for preparing CyaA-PCMCs was to remove the urea 
and possibly the LPS. The problem so far encountered was that the CyaA activities were 
not recoverd when CyaA-PCMCs were dissolved in histidine buffer alone. However, it
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Table 3.10.3,1.1 Stability of purified original CyaA
Purified CyaA in 8M urea was examined for stability of toxin activity. 200 jil of sample 
were stored in different conditions (37, 20, 4 ,-20°C) for two weeks. The enzymic 
activity was determined by conductimetry assay. Results are the mean values ± standard 
deviation of 2  determinations.
Samples
AC enzymic activity 
(|umol/min/mg protein)
CyaA at 37 °C 109 ± 14
(13.5 %)
CyaA at room temp 600 ± 19
(84<%)
CyaA at 4 °C 750 ± 16
(92 %)
CyaA at -20  °C 812+ 11
(1 0 0  %)
134
__________________________________________________________________________________________Results
Table 3.10.3.1.1 Stability of purified CyaA-PCMCs
CyaA-PCMCs were prepared from purified CyaA in two different concentrations of 
urea (2 M and 8 M) to examine stability of the toxin in the PCMCs format. 10 mg of 
each sample were dissolved in 1 ml of 8 M urea, 20mM histidine (pH 6.0) after storage 
at different temperatures (37, 20, 4 ,-20°C) for two weeks. The enzymic activity was 
determined by conductimetry assay. Sample A (CyaA-PCMCs) prepared from purified 
CyaA in 8 M urea and sample B (CyaA-PCMCs) prepared from purified CyaA in 2 M 
urea. Results are the mean values ± standard deviation of 2 determinations.
Assay -4 AC enzymic activity pimol/min/mg protein
Before
storage
After storage two weeks
Sample i
-20°C 4°C 20°C 3 T C
CyaA-PCMCs 
(A) in 8 M urea 480 ±13 
(100  %)
480 ±13 
(1 0 0  %)
440 ±15 
(92<%)
403 ± 4  
(84 %)
402 ± 12 
(84<%)
CyaA-PCMCs 
(B) in 2 M urea 392 ± 16 410 ± 45 272 ± 17 269 ±17 231 ±14
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may be possible that addition of other reagents would help to recover the CyaA 
activities. To this end, a number of detergents (Hampton Research Reagent) (Appendix 
H) were tested. 5 mg of CyaA-PCMCs from CyaA-PCMCs batches A and B were 
dissolved in 100 jil of 2 % of above detergents. After Ih at room temperature the AC 
enzymic activity of both CyaA-PCMCs preparations was determined, and compared 
with that of the two preparations dissolved in 8 M urea, 20 mM histidine pH 6.0. As 
tables 3.10.3.2.1 and 2.10.3.2.2 showed none of the above reagents allowed good 
recovery of the AC enzymic activity of toxin.
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Table 3.10.3. 2.1 AC enzymic activity of CyaA-PCMCs dissolved in different 
detergents (1-12 from Hampton Research)
CyaA-PCMCs prepared from purified CyaA (batches A and B) were dissolved in 
different detergents in an attempt to identify whether any detergent had an effect on the 
recovery of CyaA enzymic activity from CyaA-PCMCs. The AC activity was 
determined by conductimetry assay after 1 h at room temperature.
Sample AC enzymic activity (|amol/min/mg protein) of PCMCs dissolved in different detergents
Detergent
CyaA-
PCMCs
8 M urea, 
20 mM 
histidine
1 2 3 4 5 6 7 8 9 10 11 12
CyaA- 
PCMCs 
A in 8 M 
urea
480+13 9.5 8 4 7 11.3 15.5 6.3 9.2 8 0 4 0
CyaA-
PCMCs
B i n 2 M
urea
392 ±16 0 0 2 0 0 1 0 0 4 0 4 1
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Table 3.10.3.2.2 AC activity of CyaA-PCMCs dissolved in different detergents (13- 
24 from Hampton Research)
CyaA-PCMCs prepared from purified CyaA (batches A and B) were dissolved in 
different detergents in an attempt to identify whether any detergent had an effect on the 
recovery of CyaA enzymic activity from CyaA-PCMCs. The AC activity was 
determined by conductimetry assay after 1 h at room temperature.
Sample
AC enzymic activity (jamol/min/mg protein) of PCMCs 
dissolved in different detergents
Detergent
CyaA-
PCMCs
8 M urea, 
20 mM 
histidine
13 14 15 16 17 18 19 20 21 22 23 24
CyaA- 
PCMCs 
A from 
8 M urea
480 ±13 1 1 1 2 0 0 1 1 0 0 0 0
CyaA- 
PCMCs 
B from 
2 M urea
392 ±16 0 0 1 0 0 1 0 0 0 0 0 1
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3-10-3-3 AC enzymic and cytotoxic properties of CyaA-PCMCs made with 
different components
As detergents appeared not to help with recovery of CyaA activity, it was decided to 
make different batches of CyaA-PCMCs which included a number of other components 
(e.g. CaM, BSA, ATP and CaCl2) in an attempt to identify any extra component that 
might have an effect on CyaA-PCMCs properties (section 2.16). It is known that folding 
of protein in the bacterial cell is dependent on the assistance of chaperone proteins such 
as GroEL (Singler et ah, 1998) so it was thought that addition of other protein 
components with CyaA during PCMC formulation may aid solubility. As little AC 
activity was detected when CyaA-PCMCs were dissolved in histidine buffer, the CyaA 
may have formed aggregates on the crystal surface or aggregated when reconstituted in 
aqueous buffer. The toxin is known to be prone to aggregation in aqueous solution due 
to its hydrophobic nature and is the reason why CyaA preparations are stored in 8 M 
urea. Thus, introducing other biomolecules into the PCMC procedure may help to 
separate CyaA molecules and prevent aggregation.
CyaA-CaM-PCMCs and CyaA-CaM-BSA-PCMCs (batch number 1) were made of 
CyaA plus CaM and BSA in molar ratio of 1: 3 and 1: 10, respectively. 10 mg of each 
PCMC sample were dissolved in 1 ml of 8 M urea, 20 mM histidine (pH 6.0) to 
measure the total protein concentration (Bradford assay) in order to calculate the 
amount of protein incorporated into the PCMCs. In addition, the weight of PCMCs was 
obtained and this provided the theoretical amount of protein in the PCMCs by dividing 
the total protein added to make the PCMCs by the total weight of the PCMCs. The 
measured protein content of the PCMCs would allow calculation of the actual total 
protein in the PCMCs. In order to calculate the CyaA content of the different PCMCs, 
an assumption was made that each protein would coat the valine crystals equally, by 
weight (Table 3.10.3.3.1 and 3.10.3.3.2).
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Table 3.10.3.3. 1 Properties of three types of PCMCs (batch 1)
CyaA-PCMCs were made with 2 ml of CyaA (260 /tg/ml) in 8 M urea and 2 ml of DL- 
Valine (60 mg/ml). CyaA-CaM-PCMCs were prepared by mixing 3ml of purified CyaA 
(260 /t,g/ml) with 99 (i\ of CaM (1.8 mg/ml). CyaA-CaM-BSA-PCMCs were prepared 
by mixing 4ml of purified CyaA (260 jttg/ml) with 173jLtl of CaM (1.8 mg/ml) and 3120 
jag of BSA. 10 mg of each type of PCMCs were dissolved in 8 M urea, 20 mM histidine 
(pH 6.0) to determine the protein concentration.
PCMCs
type
Amount 
of protein 
to make 
PCMCs 
(Mg)
Weight
of
PCMCs
(mg)
Theoretical
protein/mg
PCMCs
Actual total 
protein 
(Mg/mg, 
PCMCs 
(Bradford)
CyaA
content*
Pg
protein/mg
PCMCs
Total
CyaA
recovered
(Mg)from
PCMCs
%
CyaA
recovery
CyaA-
PCMCs
520
58 8.9 6 .12 6 .1 2 355 68
CyaA-
CaM-
PCMCs
780
178 78 11.9 8.9 6 .86 537.5 68.9
CyaA-
CaM-
BSA
PCMCs
1040
312
3120
110 44 48 6.52 717 69.9
'^assuming proteins coated equally onto PCMCs)
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Table 3.10.3.3. 2 AC enzymic and cytotoxicity activities of different PCMC 
formulations dissolved in buffers at various pHs
CyaA-PCMCs, CyaA-CaM-PCMCs and CyaA-CaM-BS A-PCMCs were prepared 
according to Table 3.10.3.3.1 and lOmg of each were dissolved in Bicine buffer of three 
different pH values. AC enzymic and cytotoxicity activities were compared with those 
obtained with CyaA-PCMCs dissolved in 8 M  urea, 20 mM histidine (pH 6.0) as a 
positive control. Results are the means of 2 deteiminations (± S.D).
Sample AC enzymic activity 
p.mol/min/mg protein 
and % activity
Cytotoxicity 
50%  killing of J774.2 
macrophages (|4g 
protein/ml)
CyaA-PCMCs 670 ± 14 0 .1 2  + 0.021
in 8 M urea, 20 mM 
histidine pH6.0
(1 0 0 ) (100)
CyaA-CaM-PCMCs 174 + 6 0.51 ±0.028
in Bicine pH 7.7 (26) (23)
CyaA-CaM-PCMCs 159 ± 5 0.38 ± 0.035
in Bicine pH 8.1 (24) (31)
CyaA-CaM-PCMCs 151 + 9 >1
in Bicine pH 8.5 (2 2 )
CyaA-CaM-BSA-PCMCs 781 + 12 >1
in Bicine pH 7.7 (116)
CyaA-CaM-BSA-PCMCs in 6 10± 11 >1
Bicine pH 8.1 (91)
CyaA-CaM-BSA-PCMC 595 + 10 >2
in Bicine pH 8.0 + CaCla* (89)
CyaA-CaM-BSA-PCMCs in 720 ± 30 0.51± 0.042
Bicine pH 8.5 (107) (23)
CyaA-CaM-BSA-ATP- 490 >2
PCMCs in Bicine pH 8.0 (73)
* CaC12 added to Bicine not to crystals
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Table 3.10.3.3.3 AC enzymic activity of 3 types of PCMCs dissolved in different 
buffers
PCMCs were prepared according to tabe 3.10.3.3.1. AC enzymic activities of the 
different types of crystals were compared with the original CyaA preparation in 8 M 
urea. Results are the means of 2 determinations (± S.D).
Sample AC enzymic activity 
(jumol/min/mg protein)
CyaA (original) preparation in 8 M 
urea, 20 mM histidine pH 6.0 734 ± 26 (1 0 0  %)
CyaA-PCMCs in 8 M urea, 20 mM 
histidine pH 6.0 676 ± 8  (92 %)
CyaA-CaM-BSA-PCMCs in 8 M 
urea, 20 mM histidine, pH6.0 692 ± 25 (94 %)
CyaA-CaM-BSA-PCMCs 720 ± 30
in 100 mM Bicine pH 8.0 (98 %)
CyaA-CaM-PCMCs in 8 M urea. 660 ± 23
20 mM histidine pH 6.0 (90 %)
CyaA-CaM-PCMCs in 100 mM 
Bicine pH 8.0
185 ± 12 
(25 %)
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10 mg of each type of crystal were dissolved in 1 ml of either 8 M urea, 20 mM 
histidine pH 6.0 or in 100 mM Bicine buffer alone at various pHs (Bicine buffer 10 mM 
pH 8.0 is the normal diluent for the conductimetry assay). AC enzymic and cytotoxicity 
activities of these samples were assayed and compared to that of CyaA-PCMCs 
dissolved in 8 M urea in 20 mM histidine pH 6.0.
The results for CyaA-CaM-PCMCs showed AC enzymic and cytotoxic activities at ~ 
25% of that found in 8 M  urea at pH 7,7 (Table 3.10.3.3.2). Cytotoxicity improved at 
pH.8.1 but AC enzymic was worse at pH 8.5. In-corporation of BSA with CaM, CyaA 
allowed almost full recovery of AC activity at all pH values but only low recovery of 
cytotoxicity which was best at pH 8.5. Some of the CyaA-PCMCs from batch number 1 
were dissolved in 100 mM Bicine (pH.8.0) in presence of 200 /xl of 5 mM CaClz and 
then assayed. The results indicated that in the presence of CaClz, most of the AC activity 
was retained but the cytotoxicity was decreased (Table 3.10.3.3.2). Likewise, 
incorporation of ATP into CyaA-CaM-BSA-PCMCs had little effect on enzymic or 
cytotoxic activities. In another experiment, AC enzymic activities of different types of 
crystals were compared in 8 M urea, 20 mM histidine (pH.6.0) and 100 mM Bicine (pH
8.0) and compared with the original CyaA preparation (Table 3.10.3.3.3). The most 
significant finding here is that full enzymatic activity was recovered from CyaA-CaM- 
BSA-PCMCs dissolved in either buffer. Again, the highest level of activity was seen in 
CyaA-PCMCS prepared in cooperation with CaM and BSA.
Further work involved preparation of another set of PCMCs (batch number 2). These 
were made using the same conditions as for batch 1 but with different concentrations of 
CyaA and other components (Table 3.10.3.3.4). For AC enzymic activity of these 
PCMCs, 10 mg of each type was dissolved in 8 M urea, 20 mM histidine pH 6.0 or 20 
mM histidine buffer pH 6.0 alone. These dissolved samples were left at room
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Table 3.10.3.3.4 Properties of three types of PCMCs (batch 2)
CyaA-PCMCs were made by using 2 ml of CyaA (290 jag/ml) in 8 M  urea and 2 ml of 
DL-valine (60 mg/ml). CyaA-CaM-PCMCs were prepared by mixing 2 ml of purified 
CyaA (290 /tg/ml) with 870 /tg of BSA. CyaA-CaM-BSA-PCMCs were prepared by 
mixing 4ml of purified CyaA (290 fJig/wl)  with 200 of CaM (1.8 mg/ml) and 3480 f i g  
of BSA. 10 mg of each type of PCMCs were dissolved in 8 M urea, 20 mM histidine 
(pH 6.0) to determine the protein concentration
PCMC
type
Amount 
of 
protein 
to make 
crystals
(Pg)
Weight of 
PCMCs 
(mg)
Actual
total
protein
PCMCs
Mg/mg
(Bradford)
CyaA
content*
(Mg/mg
protein)
PCMCs
Total
CyaA
recovered
Pg
from
PCMCs
% CyaA 
recovery
CyaA-
PCMCs
580
82.4 6 6 494.4 85
CyaA-
BSA-
PCMCs
290
870 109.4 8.1 2.025 221.5 76.3
CyaA-
BSA-
CaM-
PCMCs
1160
3480
360
115.5 27.6 6.4 739.2 63.7
* Assuming all protein coated equally onto PCMCs
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temperature and enzymic activity measured at intervals for up to one week. As shown in 
Table 3.10.3.3.5, the AC enzymic activities derived from all the PCMCs types were 
retained at high level for two days in 8 M urea and then decreased noticeably. In 
histidine buffer alone, 20-30% of the AC activity recoved in urea was detected for both 
CyaA-BSA and CyaA-BSA-CaM crystals, but not for CyaA-PCMCs. This level of 
activity was retained up to day 7 for the CyaA-BSA crystals and up to day 3 for the 
CyaA-BSA-CaM-PCMCs.
Some of the CyaA-PCMCs from batch number 2 were also dissolved in histidine, 
HEPES or Bicine buffer at different pH values. As Table 3.10.3.3.6 shows, the highest 
activity, comparable to that in urea, was obtained at pH 8.0 with CyaA-CaM-BSA- 
PCMCs in 100 mM Bicine buffer. As was found for histidine buffer, no AC activity of 
CyaA-PCMCs was detected when they were dissolved in HEPES buffer whereas, in the 
presence of CaM or CaM, BSA some activity was seen. It can be concluded that no 
detectable AC activity was found when CyaA-PCMCs were dissolved in histidine or 
HEPES buffer whereas, with CyaA-CaM-PCMCs, 20-30% activity can be recovered in 
histidine buffer alone and with CyaA-CaM-BSA-PCMCs nearly complete activity is 
recovered (62 %). Therefore, addition of BSA or CaM during manufacture of PCMCs 
seemed to prevent subsequent aggregation of CyaA on removal of urea and exposure to 
aqueous medium. There was some indication that CyaA activity of CyaA-CaM-PCMCs 
and CyaA-CaM-BSA-PCMCs dissolved in histidine buffer alone was very stable at 
room temperature. Even greater CyaA activity was recovered when CyaA-CaM-BSA- 
PCMCs were dissolved in lOOmM Bicine at pH.8 .
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Table 3.10.3.3.5 AC enzymic activity of three types PCMCs (batch 2) dissolved 
in different buffers and assayed over a period of seven days.
10 mg of each type of PCMCs (see Table 3.10.3.3.4) were dissolved in 200 jal of either 
8 M urea, 20 mM histidine (pH 6.0) or 20 mM histidine (pH 6.0) alone. These samples 
were left at room temperature and enzymic activity measured at intervals for up to one 
week.
Sample AC activities (p-mol/min/mg protein) after 7 days
1 h 3h 6 h 24 h 30 h 48 h 142 h
CyaA- 
PCMCs in 
8M urea
432 401 424 477 379 128 76
CyaA- 
PCMCs in 
histidine
N/D N/D N/D N/D N/D N/D N/D
CyaA-BSA- 
PCMCs in 
8M urea
522 522 500 545 547 375 295
CyaA-BSA- 
PCMCs in 
histidine
113 102 136 129 113 129 136
CyaA-BSA- 
CaM- 
PCMCs in 
8M urea
951 781 563 980 660 N/D 21
CyaA-BSA- 
CaM- 
PCMCs in 
histidine
234 227 312 255 241 213 N/D
N/D = No detectable activity
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Table 3.10.3.3.6 AC enzymic activity of 3 types of PCMCs (batch 2) dissolved in 
histidine, HEPES or Bicine buffer at different pH values
10 mg of each type of crystals were dissolved in 200 pi of histidine, HEPES or Bicine 
buffers at various pHs to assay AC enzymic activity. Results are the means of 2 
determinations (± S.D).
Sample AC enzymic activity 
(pmol/min/mg protein) 
(% activity)
CyaA-PCMCs in 8 M urea, 20 mM 500 ± 29
histidine (pH 6.0) (100 )
CyaA-PCMCs in histidine (pH 6.0) N/D
CyaA-PCMCs in HEPES N/D
(pH 7.0)
CyaA-BSA-PCMCs in 20mM 34 ± 4
histidine pH 6.0) (7 )
CyaA- BSA-PCMCs in HEPES 45 ± 7
(pH 7.0) (9 )
CyaA- BSA-PCMCs in Bicine 81 ± 5
(pH 8.0) (16)
CyaA-BSA-CaM-PCMCs in 312 + 9
histidine (62)
H 6 .0 )
CyaA-BSA-CaM-PCMCs in 241 ± 6
HEPES (pH 7.0) (48)
CyaA-BSA-CaM-PCMCs in Bicine 674 ± 19
(pH 8.0) (134)
N/D= No detected activity
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3-10-3-4 Properties of three types of CyaA-PCMCs in the presence of different 
concentrations of CaM
Previous data (Table 3.10.3.3.2) had indicated that addition of CaM to CyaA (in the 
molar ratio of 3:1) resulted in improved recovery of cytotoxicity when CyaA-CaM- 
PCMCs were dissolved in Bicine buffer at pH 8.0. It was decided to increase the 
concentration of CaM in the PCMCs to see if this further improved cytotoxicity. 
Different molar ratios (3:1, 10:1, 30:1) of CaM: CyaA were used to make CyaA-CaM 
crystals (Table 3.10.3.4.1). The assay results indicated that, in comparison to the CyaA- 
CaM-PCMCs in the original formulation there was an increase in both AC enzymic and 
cytotoxic activities with increasing amounts of CaM incorporated into the PCMCs 
(Table 3.10.3.4.2).
3-10-4- 4 AC enzymic activity of purified CyaA before and after dialysis
Purified CyaA, after the final Butyl-Sepharose purification, was contained in 0.32 M 
ammonium sulphate, 0.08 M sodium chloride in 20 mM histidine buffer, 8 M urea pH 
6.0 (section 2.6.1.2). In order to investigate the importance of these salts to the 
formulation and yield of PCMCs, a sample of purified CyaA was dialysed against 100 
ml of 8 M urea, 20 mM histidine buffer pH 6.0 for 4 h at 4° C and then against fresh 
buffer overnight, to remove most of the ammonium sulphate and sodium chloride. The 
dialysed CyaA and original toxin preparation were then used to make PCMCs under the 
same condition. The results indicated that, in the absence of ammonium sulphate and 
sodium chloride, only a small amount of crystals formed which were very amorphous 
and difficult to manipulate, for example, for weighing out. However, the AC enzymic 
activities of both samples were assayed after they were dissolved in 8 M urea, 20 mM 
histidine, pH 6.0. There was little difference in AC activity between the two types of
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PCMCs when reconstituted (699 and 536 |imol/min/mg protein for non-dialysed and 
dialysed preparations, respectively).
1 4 9
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Table 3.10.3.4.1 Properties of CyaA-PCMCs prepared in the presence of different 
concentrations of CaM (batch 3)
CyaA“CaM“PCMCs were made by using 3 ml of CyaA (260 jttg/ml) in 8 M urea and 2 
ml of DL-valine (60 mg/ml). CyaA-CaM-PCMCs was prepared by mixing 3 ml of 
purified CyaA (260 jttg/ml) with increasing amounts of CaM. 10 mg of each type of 
PCMCs were dissolved in 8 M urea, 20 mM histidine (pH 6.0) to determine the protein 
concentration
PCMCs
type
Amount of 
protein to 
make 
PCMCs
M
Weight
of
PCMCs
(mg)
Theoretical 
fJLg total 
protein/mg 
PCMCs
Actual total 
protein 
(Mg/mg 
PCMCs 
(Bradford)
CyaA
content*
protein/mg
crystal)
Total
CyaA
recovered
(Mg)
CyaA- 
CaM 3x 
PCMCs
780
248 95 10.82 4.7 3.6 339
CyaA-
CaM-lOx
PCMCs
780
827 71.2 2 2 .6 6.42 3.15 224
CyaA-
CaM-30x
PCMCs
780
2481 158.3 2 0 .6 5.12 1.23 194.5
* Assuming all proteins coated equally onto PCMCs
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Table 3.10.3.4.2 AC enzymic and cytotoxic activities of three types of CyaA- 
CaM-PCMCs in the presence of different concentrations of CaM (batch 3)
The AC enzymic and cytotoxic activities of three types of CyaA-CaM-PCMCs in 100 
mM Bicine were compared to those of CyaA-CaM 3x-PCMCs dissolved in 8 M urea 
buffer.
Sample AC enzymic activity 
p,mol/min/mg protein 
(% activity)
Cytotoxicity 
50% killing of J774.2 cells 
pg protein/ml 
(% activity)
CyaA-CaM3x-PCMCs in 770 ± 14 0.12 ±0.04
8 M urea, 20 mM histidine (100 ) (100)
pH 8.0
CyaA-CaM 3x-PCMCs in 86  ± 9 2.2 ±0.014
100 mM Bicine pH 8.0 (11) (5 )
CyaA-CaM lOx-PCMCs 160 ± 8 1.7 ± 0 . 021
in 100 mM Bicine pH 8.0 (2 1 ) (7 )
CyaA-CaM 30x-PCMCs 422 ± 23 1.47 ±0.11
in 100 mM Bicine pH 8.0 (5 5 ) (8 )
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3-10-3-5 AC enzymic and cytotoxicity activities of CyaA in the presence of 
components used to prepare PCMCs
Experiments had indicated that, to achieve good AC and cytotoxicity activities from 
CyaA-PCMCs when they were redissolved in aqueous solutions, CyaA needed to be co­
crystallised not only with valine, which was part of the normal procedure, but also with 
CaM or BSA or both. In order to investigate whether valine, CaM or BSA had any 
effect on the properties of CyaA in the absence of PCMC formulation, all of the above 
substances were included with CyaA in AC enzymic and cytotoxicity assays. The 
results of the assays indicated that these additions had little effect on AC activity but 
that CaM interfered with cytotoxic activity when added with CyaA. However, this 
apparent inhibition was overcome if BSA and valine were added in addition to CaM 
(Table 3.10.3.5.1).
In a similar experiment, CyaA-BSA-CaM-PCMCs (batch 2) were dissolved in PBS at 
pH 7.3 and the AC enzymic and cytotoxic activities of the solution were determined. 
Interestingly, the results showed almost complete recovery of enzymic activity and 
reasonable cytotoxic activity (559 ± 29 pmol/min/mg protein and 50 % killing at 0.4 pg 
protein/ml, respectively).
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Table 3.10.3.5.1 AC enzymic and cytotoxicity activities of CyaA in the presence 
of components used to prepare PCMCs
The activities of the original form of CyaA alone in 8 M urea, 20 mM histidine pH 6.0 
or when mixed with components of PCMCs were determined by conductimetry and 
cytotoxicity assays and then compared. Valine was used at 60 mg/ml final 
concentration, CaM and BSA was used at molar ratio 3:1 and 10:1 respectively. Results 
are the mean values ± standard deviation of 2  determination
Sample AC enzymic activity 
pmol/min/mg protein 
(% activity)
Cytotoxicity 
pg/ml protein requred 
for 50 % killing of 
J774.2 cells 
(% activity)
CyaA alone 880 ±3.5 0 .0 2 1 ± 0 .001
(100) (100)
CyaA+Valine 770 ±2.82 0.024 ± 0.003
(87) (87)
CyaA+CaM 976 ± 4.24 0.062 ± 0.01
(111) (34)
CyaA+BS A+CaM+V aline 928 ± 3.5 0.03 ± 0.009
(105) (70)
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3-11 Scanning electron microscopy (SEM) images
The SEM is designed for directly studying the surfaces of solid objects. By scanning 
with an electron beam that has been generated and focused by the operation of the 
microscope, an image is formed in much the same way as a TV. The SEM allows a 
greater depth of focus than the optical microscope. For this reason the SEM can produce 
an image that is a good representation of the three-dimensional sample.
SEM gave a good indication of particle size and morphology of the valine crystals and 
PCMC powders. It was seen that by slightly changing the experimental parameters, 
SEM images showed an enonnous change in the size and morphology of the resulting 
PCMCs. SEM was earned out on 10 different samples. Some of these samples were 
with DL-valine alone; DL-valine BSA plus urea buffer without CyaA (images 1-4) and 
others were CyaA-PCMCs with CaM, or BSA-PCMCs (images 5-10).
From the images 1-3 it can be concluded that the DL-valine crystals are relatively large 
and regular but of various sizes (approximately 3-lOpm). However, sample 4 has more 
regular crystals of similar morphology with approximate size of 4-15 jam. Note that in 
the images 2 and 3 some salts were seen and the crystals were more irregular. It is quite 
difficult to pinpoint an accurate size of each crystal type, as there seemed to be a variety 
of different sized crystals in all samples. Crystals in image 1 has a fairly regular 
rectangular shape, which is typical of valine crystals (Dr. M. C. Parker, personal 
comunication).
The crystals in sample 5 made from cmde CyaA are large and rectangular with average 
size 20-40 jam in diameter and some salts were seen on the crystals. It is of interest to 
compare the morphology of these crystals with those of image 2  prepared from the 
buffer in which crude CyaA was solubilized (8  M urea, 20 mM histidine). The presence
1 5 4
Figure 3.11.1 Scanning electron microscopy 
1: Valine crystals
These were made with DL-valine precipitated with saturated ethanol in the absence of 
any protein. 60 mg of DL-valine was dissolved in 2 ml deionised water then used to make 
crystals as in the PCMC process.
2: Valine-urea buffer 1 crystals
These were made with the buffer used in final Butyl Sepharose purification. 8 M urea, 
0.32 M ammonium sulphate, 0.08 M sodium chloride in 20 mM histidine (pH 6.0) were 
precipitated with saturated ethanol.
A= Salt
Results
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of CyaA has created rectangular, regular crystals. Similarly, crystals samples 6  to 10 
made with purified CyaA have a well-defined shape, but are smaller than CyaA-PCMC 
crystals. The samples however, have an approximately 1-5 jam diameter size, smaller 
than those prepared from crude CyaA (image 5). The shape and size of crystals derived 
from CyaA-BSA-CaM-ATP (image 10) seem to be different. They are comprised of 
small and large particles of different morphology, some pyramid!al, fused rods and flat 
plates. Small, regular in size crystals remain attached to the large crystals.
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3: Valine-urea buffer 2 crystals
These were made with DL-valine in 8 M urea, 20 mM histidine. 60 mg of valine was 
dissolved in 2 ml of de-ionised water and 2 ml of 8 M urea in 20 mM histidine (pH 6.0) 
and precipitated with saturated ethanol.
A= Salts
4: Valine-BSA-PCMCs
These were made with DL-valine and BSA. 60 mg of valine was dissolved in 2 ml of de­
ionised water together with 1150 pg of BSA and precipitated with saturated ethanol to 
make val ine-B S A-PCMCs
Results
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5: CyaA-PCMCs from crude CyaA
These were made with crude urea extract of CyaA and DL-valine. 60 mg of valine was 
dissolved in 2 mi of deionised water and then 2 ml of CyaA was added and precipitated 
with saturated ethanol to make crude CyaA-PCMCs 
A= Salts
6: CyaA-PCMCs from crude CyaA
These were made with purified CyaA and DL-valine. 60 mg of valine was dissolved in 2 
ml of deionised water and then 2 ml of purified CyaA was added and precipitated with 
saturated ethanol to make a purified CyaA-PCMCs
A= Flat plates
Results
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7: CyaA-CaM- PCMCs from purified CyaA
These were made with purified CyaA, CaM, and DL-valine. 60 mg of valine was 
dissolved in 2 ml of deionised water, then 2 ml of purified CyaA and 0.2ml CaM (1.8 
mg/ml) was added and then precipitated with saturated ethanol to make purified CyaA- 
PCMCs
Image 8: CyaA-BSA-PCMCs from puriBed CyaA
These were made with purified CyaA, BSA and DL-valine. 60 mg of valine was 
dissolved in 2 ml of deionised water, then 2 ml of purified CyaA and BSA(1150 jag) were 
added and then precipitated with saturated ethanol to make a purified CyaA-BSA- 
PCMCs
Results
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Image 9: CyaA-BSA-CaM-PCMCs from purified CyaA
These were made with purified CyaA, CaM, BSA and DL-valine. 60 mg of valine was 
dissolved in 2 ml of deionised water, then 2 ml of purified CyaA and 0.2ml CaM (1.8 
mg/ml) and BSA (1150pg) was added and then precipitated with saturated ethanol to 
make purified CyaA-M- PCMCs
A= Flat plates
B= All small particles thought to be salts
Image 10: CyaA-BSA-CaM-ATP-PCMCs from purified CyaA
These were made with purified CyaA, BSA and DL-valine. 60 mg of valine was 
dissolved in 2 ml of deionised water, and then 2 ml of purified CyaA, CaM (1.8 mg/ml) 
and BSA (1150jag) and ATP (lOOmM) were added and then precipitated with saturated 
ethanol to make a purified CyaA-CaM-BSA-ATP-PCMCs 
A= Pyramidal 
B= Flat plates 
C= Fused rods 
D= Small and regular in size
Results
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3-12 Humoral response to CyaA-BSA-CaM-PCMCs
To investigate whether CyaA was still immunogenic after formulation as PCMCs, 
BALB/c mice were immunised with CyaA-CaM-BSA-PCMCs that had been dissolved 
in PBS pH 7.3. As a control, BSA and CaM were dissolved in PBS at the same 
concentration as used in the CyaA-BSA-CaM-PCMCs and also used to immunised 
mice. The mice received two (0.2 ml) doses of CyaA-CaM-BSA-PCMCs (containing 15 
pg of CyaA, 67.5 jag BSA and 5 |ag CaM per dose) or BSA plus CaM at days 0 and 28 
(section 2.18.3). Heart bleeds were taken at 2 weeks after the second dose and sera were 
pooled for each group. ELISA was used to determine the humoral responses to CyaA, 
BSA and CaM. Anti-CyaA IgG levels were compared with those of a mouse anti-CyaA 
hyperimmune serum. This was supplied by Dr. R. Parton.
Figure 3.12.1 shows the results of the ELISA with CyaA as the coating antigen. It can 
be seen that there was a different dose response for each sample. CyaA-CaM-BSA- 
PCMC generated a good anti-CyaA IgG response in mice whereas BSA plus CaM 
which was used as a negative control did not. The highest anti-CyaA IgG response was 
seen in the control hyperimmune serum.
When BSA was used as the coating antigen for ELISA there were good responses to 
sera from mice which had received BSA as immunogen (Figure 3.12.2). There was no 
obvious response seen against CyaA hyperimmune serum.
Little antibody response was seen when mouse anti-CyaA-CaM-BSA-PCMC or anti- 
BSA-CaM sera were tested against CaM as coating antigen (Figure 3.12.3).
It can be concluded that CyaA-CaM-BSA-PCMCs were able to raise CyaA-specific 
antibodies when used as an immunogen, indicating that important epitopes were 
conserved on CyaA in the PCMCs.
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Figure 3.12.1 ELISA responses to CyaA in mice immunised with CyaA-CaM-
BSA-PCMCs or BSA-CaM
Anti-CyaA IgG levels in sera from mice immunized either with two doses of CyaA-BSA- 
CaM-PCMCs or BSA plus CaM at days 0 and 28. Terminal bleeds were taken at two 
weeks after the second immunization. CyaA was use of as the coating antigen for ELISA. 
The results are the means of two values at each serum dilution (± S.D).
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Figure 3.12.2 ELISA responses to BSA in mice immunised with CyaA-CaM-BSA-
PCMCs or BSA-CaM
Anti-BSA IgG levels in sera from mice immunized either with two doses of CyaA-BSA- 
CaM-PCMCs or BSA plus CaM at days 0 and 28. Terminal bleeds were taken at two 
weeks after the second immunization. BSA was use of as the coating antigen for ELISA. 
The results are the means of two values at each serum dilution (± S.D).
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Figure 3.12.3 Anti-CaM responses in mice immunised CyaA-CaM-BSA-PCMCs
or BSA-CaM
Anti-CaM IgG levels in sera from mice immunized either with two doses of CyaA-BSA- 
CaM-PCMCs or BSA plus CaM at days 0 and 28. Terminal bleeds were taken at two 
weeks after the second immunization. CaM was use of as the coating antigen for ELISA. 
The results are the means of two values at each serum dilution (± S.D).
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______________________________________________ Results
3-13 Effect of mouse anti-CyaA-BSA-CaM-PCMC sera on the AC 
enzymic and cytotoxic activities of CyaA
The serum samples described in section 3-12 were diluted in PBS or RPMI to 
investigate any neutralisation effect on AC enzymic and cytotoxicity activities, 
respectively. A preparation of purified CyaA toxin was diluted in PBS to a final 
concentration of 60 p,g protein/ml. A volume of 50 pi of CyaA and an equal volume of 
doubling dilutions of sera, 1/4 down to 1/128, were mixed and incubated at 37°C for 1 
h. The AC enzymic activity of these samples was then determined by conductimetry 
assay. The same dilutions of sera and CyaA at concentration of 0,16 pg protein per well 
(previously shown to kill 85% of J774.2 cells in 2 h as measured by MTT assay) were 
prepared and incubated as above. A volume of 50 pi of each of these samples was added 
to 50 pi of J774.2 macrophage-like cell suspension (25000 cells per well) in 96-well 
plate in duplicate. Cytotoxicity was then evaluated by the MTT dye reduction assay 
(section 2.13.2) and compared to that of CyaA toxin alone.
The results of the conductimetry assay showed that the serum from mice immunised 
with CyaA-BSA-CaM-PCMCs, paiticulaiiy at lower dilutions, was able to inhibit the 
enzymic activity (Table 3.12.1). The MTT assay on these samples indicated that no 
cells were killed at lower dilutions (1 in 8 ), but when CyaA was incubated with sera at 
higher dilutions, cell killing gradually increased (Table 3.12.2). The results showed that 
the antibody produced from mice immunised with CyaA-CaM-BSA-PCMCs, was able 
to neutralise both the AC enzymic and cytotoxic activities of CyaA in vitro.
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Table 3.12.1 AC enzymic activity of CyaA alone or CyaA with different dilutions 
of serum from mice immunised with CyaA-BSA-CaM-PCMCs
Sample AC enzymic activity of serum concentrations (pmol/min/mg
protein)
Serum dilution
Control
no
serum
1/2 1/4 1/8 1/16 1/32 1/64
CyaA plus 
Control serum 
from mice 
immunised with 
BSA plus CaM
567 N/D N/D N/D N/D N/D
CyaA plus serum 
from mice 
immunised with 
CyaA-BSA- 
CaM-PCMC
618 N/D 32 45 68 90 136
N/D; not done
Table 3.12.2 Cytotoxicity of CyaA alone or CyaA with different dilutions of sera 
from mice immunised with CyaA-BSA-CaM-PCMCs
Sample
Percentage of killing of J774.2 cells
Serum dilutions
Control 
no serum 1/8 1/16 1/32 1/64 1/128
CyaA plus serum 
from mice 
immunised with 
CyaA-BSA- 
CaM-PCMC
85 0 14 18 21 28
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CHAPTER 4
Discussion
4-1 Production of CyaA from recombinant E. coli strains
A 200kDa form of CyaA was produced from urea extracts of recombinant E. coli BL21 
by Sebo et at (1991), where the cyaA and cyaC  genes were co-expressed in pCACTS 
from the lac promoter to produce fully-active CyaA (enzymatically-active and 
invasive). In the present work it was demonstrated that E. coli BL21/DE3 (pGW44 and 
pGW54) produced CyaA protein that was enzymatically-active and invasive. In our 
system it was also possible to produce non-acylated, non-invasive but enzymatically- 
active 200kDa CyaA from a urea extract of E. coli BL21/DE3 (pGW44). From E. coli 
BL21/DE3 (pGW44-188) a CyaA pro-toxin can be produced that lacks AC enzymatic 
activity due to a dipeptide insertion in the ATP binding site at the N-terminal end of the 
toxin. When pGW44/188 was co-expressed with pGW54, a 200 kDa invasive CyaA 
with very low AC activity was produced. SDS-PAGE analysis demonstrated the same 
sized bands for all of these three CyaA forms (Figure 3.1.1).
4-2 Purification of CyaA from recombinant E, coli strains
The active and non-active forms of recombinant CyaA were extracted as crude urea 
extracts from inclusion bodies formed in E. coli BL21/DE3 and purified by a 
combination of two different methods. The aim of purification was to remove 
contaminating proteins and EPS. Q Sepharose column chromatography was used as an 
ion exchange method followed by Butyl Sepharose chromatography as a hydrophobic 
interaction method. Large amounts of CyaA proteins were obtained by these two
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methods of purification, with only a few lower molecular weight proteins present. The 
majority of contaminating proteins and lipopolysaccharide (LPS) were removed through 
Q Sepharose purification (Figure 3.2.1 and Table 3.1).
Recombinant proteins from E. coli BL21/DE3 are frequently contaminated with 
endotoxin due to the high quantities of LPS in the cell envelope of this gram-negative 
bacterium. In the present study, crude CyaA and CyaA"^ toxins were found to be 
contaminated with some LPS, which was visualised by silver staining (Figure 3.2.3). 
Using the two different techniques (Q Sepharose and Butyl Sepharose column 
chromatography) the majority of LPS was removed (Figure 3.2.1 and Table 3.2.2). The 
endotoxin content of each CyaA preparation is given in Table 3.1.
Ross, P et al. (2004) found that dialysis of pure CyaA against Dulbecco’s phosphate- 
buffered saline (PBS), ImM  EDTA and 1 M urea (pH 4.6) and then against Dulbecco’s- 
PBS, 1 mM CaClg and 2 M urea (pH 8.0) reduced the amount of contaminating 
endotoxin in samples to 0.220 pg/mg of protein. According to Petsch et al. (1998), 
chromatography with an endotoxin adsorbant such as polymyxin B was ineffective in 
reducing endotoxins to an acceptable level. Other studies showed that use of Triton-114 
was not suitable for removing LPS (Monison and Jacobs, 1976; Aida and Pabst, 1990; 
Petsch et ah, 1998). Czuprynski and Welch (1995) demonstrated that RTX toxins tend 
to form aggregates in aqueous solutions through hydrophobic interactions, and since 
LPS forms similar aggregates it may form complex aggregates with CyaA. It may be 
that an RTX-LPS complex is actually a biologically-active moiety.
In the present study, although a complete removal of LPS from CyaA preparations was 
not possible, a very low amount of LPS contamination (0.012 pg/mg protein) was 
obtained. As LPS is a very stable molecule at high temperatures (180-250°C), the
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destmction of CyaA toxins by heating the CyaA preparations at 100°C would reveal any 
effect due to endotoxin alone. Such experiments would not eliminate possible 
synergistic interaction between LPS and CyaA, but adding different amounts of LPS to 
pure preparations of CyaA could show any such effect. The advantage of using Q 
Sepharose and Butyl Sepharose purification methods was the capacity to obtain very 
pure proteins with acceptable LPS levels. The level of LPS contamination was low 
enough for CyaA to be acceptable as a vaccine component, as the maximum amount 
allowed is 5 lU per vaccine dose. If a vaccine dose of 25 pg CyaA were to be used, this 
would contain 3 lU  of endotoxin vaccine dose where one IU=100 pg endotoxin (Poole 
et a t,  1997).
4-3 Characterization of purified CyaA preparations 
4-3-1 Adenylate cyclase enzymic activity
Lawrence et a t  (2002) developed a conductimetric assay for determination of adenylate 
cyclase activity of CyaA. This method offers a large number of practical advantages in 
comparison with the more usual radiochemical method. The benefits of the new 
conductimetry method are in teims of cost, ease of managing data and in particular, the 
procedure is rapid. In this study, the conductimetric assay was used to measure the 
specific enzymatic activity of purified CyaA preparations and after different treatments, 
such as PCMC preparation. Both CyaA pro-toxin and CyaA were enzymatically-active, 
but the CyaA pro-toxin displayed a higher specific activity than the acylated form 
(Table 3.1.1). These results are similar to the results reported by Westrop et a t  (1996) 
and HoiTnozi et a t  (1999), who, using the conventional aP-ATP assay, found the pro­
toxin to have greater enzymatic activity. In the present investigation, the specific 
activities of CyaA and CyaA-pro toxin were 660 and 880 pmol/min/mg protein
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respectively, compared with 626, 674 and 148 and 217 pmol/min/mgprotein reported by 
Hormozi et a l  and Westrop et a l , respectively. These differences may be a reflection of 
the accuracy of the method used, or measurement of the protein concentrations or 
differences in the methods of preparation. CyaA* demonstrated very low enzymic 
activity as expected. The specific activity of 5 pmol/min/mg protein obtained for CyaA* 
was in agreement with the study of Ladant et a l  (1992).
4-3-2 Cytotoxicity assays
The acylated CyaA toxin was shown to be cytotoxic against J774.2 mouse macrophage­
like cells. The primary biological function of the toxin is presumably to deliver its 
enzymic activity into the mammalian cells, eventually resulting in their intoxication by 
the production of cyclic AMP. This occurs at low concentration of toxin, insufficient to 
cause foimation of membrane channels that would cause cell lysis, as the toxin is only 
weakly cytolytic. CyaA pro-toxin was shown to be much less toxic at the same 
concentrations as the acylated CyaA but, at higher concentrations, some cytotoxicity 
was observed. This agrees with previous findings by Rogel et a l  (1989) who showed 
that the toxin must be acylated by CyaC modification to present maximum toxicity. The 
small degree of cytotoxicity displayed by the acylated but non-enzymatic CyaA* form 
may have been due to a small amount of enzymatic activity remaining or to its pore- 
forming activity.
In addition to J774.2 mouse macrophage-like cells, different mammalian cells (sheep 
bone maiTOW mast cells, RBL-2H3 cells and U937 human monocytes) were treated with 
different concentrations of CyaA and CyaA* and their effects were compared. The 
results showed that the effects of the CyaA toxins on J774.2 and the other mammalian 
cells were different. J774.2 cells were affected by CyaA at very low concentration (50% 
killing occurred at 0.025 pg protein/ml) but activity against the other cells tested was
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much less. The reasons for these differences are not clear, but may be due to the 
absence of CyaA receptor (CD 1 lb/CD 18) on the surface of the other mammalian cells, 
as CD 1 lb/CD 18 is mainly found on the surface of monocytes, neutrophils and dendritic 
cells (Guermonprez et a l, 2001).
It can be concluded from the difference between the cytotoxicity profiles of the CyaA 
and CyaA* toxin preparations suggests that the cell killing by CyaA is due mainly to the 
intrinsic AC enzymatic activity of the protein after it has entered into the target cell. 
Without this activity, only low toxicity was observed. However, it was noted that 
addition of high concentrations of Ca^’*' in the assay with CyaA* increased to some 
extent the cytotoxic activity of this non-enzymatically-active derivative. The Ca^ '*’ may 
encourage a conformation of CyaA* that is more suited to pore formation.
The MTT dye reduction assay and the adenosine triphosphate (ATP) assay were both 
used to assess the cytotoxic effects of CyaA and CyaA* on different cell lines (J774.2, 
sheep bone marow mast cells and RBL-2H3 cells). When compared, both assays 
produced similar results, but the ATP assay apparently detected 50% cell death at lower 
concentrations of both toxins. There are a number of possible reasons for these results. 
The MTT assay assumes that the capability of cells to reduce MTT remains constant 
throughout the cell culture period. Since mitochondria are more robust than the cells 
that contain them, it is possible for injured cells to continue to reduce MTT (Petty et a l, 
1995). Several researchers have shown the ATP assay to be a sensitive and reliable 
method of quantifying viable cell numbers from eukaryotic and prokaryotic populations 
(Squatrito et al 1995; Stollenwerk et a i, 1998). Based on these data, it could be 
concluded that it is a more sensitive assay for the measurement of cytotoxicity by CyaA 
toxins. However, CyaA will deplete intracellular ATP by formation of cAMP and, as 
this assay measures ATP, this may give a false indication of the extent of cell killing.
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4-3-3 Apoptosis assays
Apoptosis is an active process of cellular suicide that is triggered by a variety of 
physiological and stress stimuli (Zychlinsky and Sansonetti 1997; Gao and Abu Kwaik, 
2000). It is now thought that interference with programmed host cell death (apoptosis) 
is a common consequence of interaction with bacterial pathogens, as a number of 
bacterial pathogens appear to be capable of manipulating host cell apoptotic pathways. 
At least three possible roles for programmed cell death in bacterial diseases have been 
reported: activation of apoptosis to destroy cells, utilisation of apoptosis to initiate 
inflammation and inhibition of host cell apoptosis. In addition, host cell apoptosis might 
represent a host defense reaction (Zychlinsky and Sansonetti, 1997). In the context of 
virus infection, apoptosis undoubtedly results in the destruction of the viral genome and 
serves as an innate defence mechanism to reduce virus replication. However, some 
viruses express anti-apoptotic proteins that efficiently block apoptosis induced by death 
receptors or in response to stress signalled through mitochondria. Viral interference 
with host cell apoptosis leads to enhanced viral replication and may promote cancer 
(Tschopp et ah, 1998; Benedict et ah, 2003). In the case of pertussis, CyaA induces 
apoptosis which, expressed early during the course of colonisation, may allow bacteria 
to survive in the initial stages of the infection. When the bacteria have successfully 
colonised the tissue Bordetella ceases to produce the toxin (Khelef et ah, 1993). B. 
pertussis is able to kill macrophages through the induction of apoptosis and CyaA 
expression is essential for the bacterium to promote cell death. It has been proposed that 
apoptosis by CyaA is induced by the increase in cAMP production, which has been 
shown to be responsible for changes in protein phosphorylation (Duprez et al., 1993; 
Khelef et al., 1993) but the mechanism for this has not yet been elucidated. As 
McConkey and Onenius (1994) noted, apoptosis could also be the consequence of the 
depletion of ATP due to the high AC enzymic activity deregulating the protein cascade.
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Khelef and Guiso (1995) suggested that apoptosis was not induced by the pore-forming 
properties of CyaA. The reason for their suggestion was that a mutant CyaA that lacks 
AC activity but retained haemolytic activity was not lethal for murine macrophages. 
However, the haemolytic property of CyaA may also be responsible for apoptosis, since 
pore formation can result in changes in intracellular calcium levels, which in turn can 
activate programmed cell death (McConkey and Orrenius 1994).
In this study, the effect of CyaA and CyaA* were investigated by two related assays, 
induction of caspase 3/7 activity and DNA fragmentation, as measures of apoptosis. 
Interestingly, among those cells treated with enzymatically-active, acylated CyaA, 
J774.2 macrophage-like cells and RBL-2H3 cells showed the greatest caspase induction 
whereas no obvious induction of caspase activity was observed in mast cells and Vero 
cells. As shown in Figs 3.5.5.1 and 3.5.5,3 none of these cells were induced by CyaA* 
to present any caspase activity. It should be noted that urea was tested at the 
concentration used in the CyaA preparations and showed no ability to induce caspase 
activity. Three possibilities for the lack of activity of CyaA on mast cells and Vero cells 
could be; 1) the lack of CyaA receptors on the surface of these cells; 2) the incubation 
time of CyaA with these cells (6 h) may not have been sufficient to induce the process; 
3) these cells may not produce caspase 3/7.
In contrast, the results obtained with the DNA fragmentation (apoptosis) assay showed 
that the CyaA induced programmed cell death in J774.2 macrophage-like cells, mast 
cells and RBL-2H3 cells. Thus, in this assay mast cells showed cleai* evidence of 
apoptosis after 12 h treatment with CyaA. However, although a clear laddering effect 
was seen in mast cells and RBL-2H3 cells, only a smear of DNA fragments was seen in 
J774.2 cells. One possibility for the differences seen in caspase induction and DNA 
laddering with J774.2 macrophage-like cells could be related to differences in the
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incubation time. During prolonged incubation, cell lysis or necrosis may set in with 
J774.2 cells as suggested by the decline in caspase activity observed with higher 
concentrations of CyaA (Figure 3.5.5.1). It was demonstrated by Khelef and Guiso 
(1995) that DNA fragmentation was induced by CyaA in J774.2 macrophage-like cells 
and that a mutant CyaA lacking AC activity but retaining haemolytic activity did not 
induce this feature of apoptosis. No apoptosis effect was seen on J774.2 macrophage­
like cells, sheep bone marrow mast cells, RBL-2H3 cells and Vero cells in the present 
study when they were treated with CyaA*. Khelef et al, (1993) reported that purified 
CyaA was the only B. pertussis vimlence factor able to induce macrophage death 
through apoptosis. They also demonstrated that mutant or non-enzymatically-active 
CyaA was ineffective in promoting programmed cell death, indicating that the AC 
activity of CyaA was required for its action. These results and the data presented here 
also suggested that DNA fragmentation or induction of caspase 3/7 activity is due to 
adenylate cyclase enzymic activity provided by CyaA. It can be concluded that cells 
infected with CyaA show a decrease in intracellular ATP, and a rise in cAMP, which 
may contribute to mitochondrial dysfunction and result in apoptosis.
4-3-4 Inhibition of phagocytosis
Phagocytosis provides a specialised mechanism for regulated ingestion and intracellular 
destruction of microbial pathogens as well as of apoptotic host cells and debris. In 
general, professional phagocytes, including neutrophils (which migrate from the blood 
to a site of infection) and macrophages (which constitutively reside in tissues and are 
less motile than neutrophils), accomplish most phagocytosis. By confining the 
mechanisms of microbial killing and digestion to distinct intracellular compartments 
(lysozomes) of these cells, damage to host cells and tissues is minimised during the 
process of killing offending microbes. In addition to disposing of microbial pathogens.
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phagocytosis (especially by macrophages and dendritic cells) initiates the process of 
antigen processing and presentation for development of adaptive immune responses 
(Ramachandra et a i,  1999).
In order to better understand the importance of this defence mechanism, a flow 
cytometry assay was developed to study phagocytosis and oxidative burst of neutrophils 
stimulated by bacteria (Lehmann et a l,  2000). A flow cytometry investigation was 
made in order to choose appropriate target cells, opsonisation conditions, and 
fluorochromes. These authors used FITC-E. coli for phagocytosis experiments and the 
extracellular fluorescence was quenched by trypan blue to differentiate it from that due 
to intracellular bacteria.
Host defence against B. pertussis relies to some extent upon phagocytosis and killing of 
the bacterial cells. The adenylate cyclase toxin appeal's to be an important virulence 
factor against phagocytosis, as evidenced by the efficient phagocytosis of mutants that 
fail to express this toxin (Weingart and Weiss, 2000). These authors also showed that 
CyaA, added separately, blocks phagocytosis even when bacteria are not expressing the 
toxin.
In this study, different concentrations of CyaA and CyaA* were used to evaluate their 
modulatory effects on phagocytosis. The results of the ingestion activity experiment 
suggested that CyaA inhibits the phagocytosis of E. coli by J774.2 macrophage-like 
cells and by human granulocytes as it caused a decrease in the mean fluorescent 
intensity (MFI) measured by flow cytometry (Figures 3.8.5 and 3.8.6). Although the 
concentration of CyaA used in the ssay caused appreciable cell killing of J774.2 cells as 
determined by the MTT assay, it should be emphasised that the effect of CyaA on 
phagocytosis was measured only in viable cells, by the flow cytometric method here. In 
contrast, no significant decrease of phagocytosis activity was noted in response to
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treatment of J774.2 macrophage-like cells or human granulocytes with various 
concentrations of CyaA*. The poor AC enzymic activity of CyaA* is presumably 
responsible for the lack of effect on phagocytosis activity in these cells, when compared 
with CyaA.
An additional experiment was performed under the same conditions on the U937 human 
monoblastic cell line in the absence or in the presence of PM A. PMA is used as a 
stimulator to differentiate this cell-line into monocyte-like cells. The effect of PMA 
shown in this study was that it potentiated the phagocytosis activity of U937 cells. 
However, the cytotoxic effect of CyaA was greater on PMA-differentiated U937 cells 
than on undifferentiated cells (see Fig 3.6 .2.3). Thus, it can be suggested that PMA at
0 .0 2 0 |Lig at final concentration could stimulate the immature cells to differentiate, which 
CyaA could, then affect. Further investigation is recommended to show how 
differentiation of U937 cells might influence their susceptibility to CyaA, for example 
by increasing the number of receptors for the toxin.
It is very clear that phagocytic functions, such as migration, ingestion and release of 
reactive oxygen intermediates (ROI), which appear to be responsible for the killing 
activity, are important host defence mechanisms against Bordetella. Evasion of these 
functions may be the principal tools by which the bacteria can persist in the sites of 
colonization and proliferate further. One obvious strategy in defence against 
phagocytosis is direct attack by the bacteria upon the professional phagocytes using 
extracellular enzymes or toxins that kill or at least block the activity of phagocytes. 
Extracellular proteins that inhibit phagocytosis include the exotoxin A of Pseudomonas 
aeruginosa, which kills macrophages, and the bacterial exotoxins that are adenylate 
cyclases e.g. anthrax toxin EF and B. pertussis CyaA which decrease phagocytic 
activity. Thus, the reduction of ingestion and oxygen-dependent killing functions is a
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predominant activity o f B. pertussis CyaA. However, the results of this study show that 
the full activity of CyaA is necessary for phagocytic inhibitory activity as CyaA* had 
little effect on phagocytosis. These results are keeping with the results reported by 
Galgiani et a l  (1988). They showed that an adenylate cyclase toxin-containing extract 
blocked neutrophil-mediated inhibition of A-acetylglucosamine incoiporation by 
arthroconidia of Coccioides immitis in a dose-dependent manner. The authors indicated 
that CyaA, rather than other virulence factors of B. pertussis, was responsible for the 
inhibitory effects on PMN. In the present study, the effect of CyaA preparations were 
examined and the interactions of human granulocytes and J774.2 mouse phagocyte-like 
cells with E. coli in vitro were compared. The results suggest that CyaA impairs the 
functions of human granulocytes and J774.2 cells phagocytosis in a dose dependent 
manner and that this activity is dependent on the AC activity of the toxin.
4-3-5 Inhibition of oxidative burst
The first line of defence against microbial infection is provided by neutrophils. Upon 
phagocytosis of bacteria, a respiratory burst occurs, initially reducing oxygen to form 
superoxide, with secondary formation of H 2O2, OH and other oxygen-derived 
molecules that participate in bacterial killing (Uhlinger et a l ,  1993). An early report 
showed that culture medium and bacterial extract from B. pertussis, containing 
adenylate cyclase of high specific activity, were able to inhibit the chemiluminescence 
(CL) response of human alveolai' macrophages and neutrophils to zymosan (Confer and 
Eaton, 1982). Others have reported the role of CyaA in the inhibition of this response. 
CyaA toxin produces high levels of intracellular cAMP in human monocytes and 
inhibits the oxidative response to a variety of particulate or soluble stimuli (Pearson et 
a l,  1987). Other researchers demonstrated that B. pertussis can survive intracellularly 
within various leukocyte cell types, including human macrophages and
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polymorphonuclear cells (Saukkonen et ah, 1991; Steed et a l ,  1991). It is possible that 
the inhibition of oxidative burst in these cells would benefit intracellular survival of the 
bacteria and may be an important evasion strategy for B. pertussis.
The results of oxidative burst experiments in the cuiTent study suggested that CyaA 
inhibits the oxidative burst of J774.2 macrophage-like cells and human granulocytes as 
it induced a decrease in mean fluorescent intensity (MFI) as measured by flow 
cytometry. Although the concentration of CyaA used in the ssay caused appreciable cell 
killing of J774.2 cells as determined by the MTT assay, it should be emphasised that the 
effect of CyaA on oxidative burst was measured only in viable cells, by the flow 
cytometric method here In contrast, CyaA* did not appear to inhibit the oxidative burst 
when it was compared with CyaA at the same concentrations. The results indicated that 
the AC enzymic activity of CyaA toxin was necessary for the inhibition of oxidative 
burst in these cells. This result is in line with Steed et a l  (1991) who indicated that 
CyaA inhibited (the phagocyte) respiratory burst activity in human PMNL.
A similar experiment, prefoimed on U937 human monocytes in the presence and in the 
absence of PMA, showed that CyaA inhibited the oxidative burst by approximately 40% 
when tested at 0.1 pg/ml final concentration on PMA-activated monocytes, but was 
ineffective on non-differentiated cells. Thus, PMA could stimulate the immature cells to 
differentiate, which CyaA then affected. These data suggest that the activity of CyaA on 
these cells is best seen when they have differentiated, possibly to express high level of 
receptor for CyaA.
Interestingly, it has been demonstrated that the leukotoxin of Mannheimia haemolytica, 
a RTX toxin with structural homology to CyaA, but without an adenylate cyclase 
domain, can stimulate the respiratory burst activity of neutrophils (Maheswaran et a l, 
1992). On the other hand, pertussis toxin (PT), another virulence factor of Bordetella
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pertussis that, like CyaA, also increases intracellular cAMP levels, could inhibit the 
respiratory burst activity of human neutrophils (Burnette, 1993). This suggests that an 
increase in cAMP levels might be responsible for the inhibition of respiratory burst 
activity by CyaA, which is borne out by the lack of activity exhibited by CyaA*.
4-4 CyaA protein- coated microcrystals (PCMCs)
PCMCs represent a novel method for the formulation of a wide range of biomolecules, 
including proteins, peptides, DNA, and vaccines. PCMCs consist of a core crystalline 
material, such as a sugar, amino acid or salt on which the biomolecules are immobilised 
(Kreiner et a l, 2001). The preparation of PCMCs is straightforward and applicable in 
any laboratory. The process involves dissolution of the appropriate crystal-forming 
carrier together with the given biomolecule in aqueous solution. Immediately, 
dehydration of the two components is facilitated by the addition of the aqueous solution 
to a water-miscible organic solvent, resulting in the rapid formation of the PCMCs with 
the biomolecule immobilised on the surface of the crystalline core carrier (via a crystal- 
lattice mediated self-assembly process). These PCMCs may be stored as a suspension or 
filter-dried to form a free-flowing powder (Ross et a l, 2002).
CyaA is a toxin and would not be used as vaccine component. However, there is a 
functional assay for the detoxified form CyaA* which is the antigen forai that would 
possibly be used in a vaccine. The reason for using CyaA in the present study was that 
available functionalassays e.g. AC activity and ctototoxic activity could be used as tools 
to examine its activity and stability before and after formolation as PCMCs.The aim of 
current work was to prepare CyaA-coated microcrystals free of urea and to improve 
stability of CyaA with a view to preparing a novel vaccine formulation. This would 
provide, on redissolving in an appropriate aqueous solution, a sample of CyaA, in the 
absence of urea, as a model antigen to be used in vitro and in vivo. Purified CyaA
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preparations are routinely stored in 8 M urea because, in aqueous solution at high 
concentration, CyaA tends to aggregate due to the hydrophobic nature of the protein. 
The crystalline core carrier material DL-valine was chosen with CyaA at an initial 
concentration of 300 pg protein/ml added to a saturated solution of 60 mg/ml DL- 
valine. This aqueous solution was slowly added into 40 ml of valine-saturated ethanol 
solution under vigorous stining. This resulted in the formation of CyaA-protein coated 
microcrystals. The solvent was then removed from the crystals using a Millipore 
filtration system (Millipore Ltd., UK) to yield upon drying, a free-flowing crystalline 
powder. Control samples of valine-PCMCs or other PCMCs without the addition of 
CyaA were also produced by this method to determine the effect of CyaA inclusion on 
crystal size and moiphology. The yield of CyaA-PCMC crystals recovered varied (50- 
90%) from the theoretical amount. The actual loading of protein on the PCMC was 
determined by Bradford assay. The recovered yield and actual protein loading of CyaA 
onto the DL-valine crystals could probably be improved by optimisation of the 
formulation strategy. The CyaA-PCMCs properties were then deteimined by dissolving 
PCMCs in 8 M urea buffer or other buffers to assess activities by conductimetry and 
cytotoxicity assay.
Scanning electron microscopy (SEM) of CyaA-PCMCs and DL-valine PCMCs, 
revealed that immobilisation of CyaA onto the valine crystal surface generally reduced 
the overall crystal size (on average to less than 10 pm), as well as the relative 
dimensions of the crystal faces particularly if CyaA was used in association with other 
proteins such as BSA or CaM. In addition, the crystal shape was less clearly defined due 
to the immobilisation of CyaA. It was clear, however, that this process could be used to 
simultaneously dehydrate and immobilise CyaA onto the surface of water-soluble 
microcrystals. However, there were differences in AC enzymic activity recovery in 
different buffers and different types of CyaA-PCMC preparations. Improvements to the
180
Discussion
process were designed to obtain a good cytotoxicity and AC activity, suggesting that the 
antigenicity of the CyaA molecule would be preserved and would be suitable for 
vaccine applications,
4-4-1 Formulation and stability of CyaA as different types of PCMCs
Different CyaA-PCMCs (prepared from cmde and pure CyaA) were made in various 
conditions e.g from 2M urea or from 8M urea for crude CyaA and with different ratios 
of CaM, BSA, CaCl2, and ATP for pure CyaA, Then, AC enzymic activity, cytotoxicity 
and the stability of PCMCs were determined. The stability of CyaA-PCMCs was 
evaluated at different temperatures after two weeks. As shown in Table 3.11.2.1.2, 
CyaA-PCMCs retained high AC activities when they were stored at -20°C, 4°C, 20°C, 
or 37°C, indicating that the CyaA-PCMCs are stable at ambient temperatures. This 
feature would have useful applications for vaccine foimulations to be used in 
developing countries where cold storage may prove difficult.
4-4-2 AC enzymic and cytotoxicity activities of different types of PCMCs
It was shown that all of the CyaA-PCMC prepaiations tested had both cytotoxic and 
enzymatic activities when crystals made from crude or pure CyaA were dissolved in 2- 
8M urea. This is evidence that the process used to make the PCMCs was working well 
to preserve the toxin activities. The problem that was encountered early on was that the 
the CyaA could not be recoverd when crystals were dissolved in aqueous buffer (20 
mM histidine alone). A urea concentration more than 1 M was required for the complete 
dissolution of the crystals and recovery of CyaA, which indicated that further 
investigation into methods of solubilising the PCMCs was required. Purified CyaA 
toxin was used for these experiments. A large range of different detergents ( non-ionic 
and zwitterionic) was used in attempts to solubilise the CyaA-PCMCs, but little AC
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activity was detected. At this stage in the investigation, urea was still the best reagent 
for solubilisation of CyaA-PCMC preparations.
Following the encouraging results on CyaA-PCMCs allowing for recovery of CyaA 
activities when PCMCs were dissolved in 2-5 M urea buffer, further investigation into 
methods of CyaA-PCMCs preparation were earned out. A range of compounds (BSA, 
CaM, CaClz and ATP) which might act as chaperones to prevent aggregation of CyaA, 
either on the PCMCs as they foimed or upon resolubilation, were selected. CaM and 
BSA were added with CyaA to DL-valine to prepare different types of CyaA-PCMCs 
for testing the CyaA properties in different aqueous buffers and at various pH values. 
BSA had been used previously as a stabiliser for CyaA. Bellalou et a l  (1990) reported 
that when B. pertussis was grown in a medium containing high levels of BSA, both the 
adenylate cyclase and haemolysin functions were maintained in the toxin whereas, 
without these additions to the growth medium, the CyaA toxin was cleaved to produce a 
45 kDa protein with AC activity only. Calmodulin is a key calcium ion sensor and 
versatile intracellular second messenger that can interact with targets via N- and C- 
terminal domains. Calcium binding to CaM induces conformational changes, from a 
mainly hydrophobic closed state to an open conformation, exposing a lai'ge hydrophobic 
binding pocket (Bhattacharya et a l,  2004). Previous work showed that the AC enzymic 
activity of CyaA is stimulated up to 1000-fold by binding of CaM to the AC domain. 
ATP and Ca^ "^  also bind to CyaA. The results obtained in this study showed that 
incoiporating BSA with CyaA in the PCMCs allowed retention of AC enzymic and 
cytotoxic activities, paiticulaiiy when combined with CaM, when the PCMCs were 
subsequently dissolved in aqueous buffer (Table 3.11.2.2.2). The AC enzymic activity 
in histidine buffer was stable for at least 7 days (Table 3.11.2.2.5). The data indicated 
that incorporating CaM into PCMC increased AC enzymic activity of CyaA but not its
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cytotoxicity activity, upon resolubilisation. It has been reported previously that CaM 
interfered with the invasive properties of CyaA (Hervekr and Ladant, 1997). The results 
showed that incorporation of ATP and Ca^ "*" had no obvious effect on the properties of 
CyaA-PCMCs.
Based on work carried out in this study it can be concluded that encouraging results 
have been obtained. The process by which the PCMCs are made has proven to be 
successful in coating the CyaA onto the valine crystals and, in addition, it seems as 
though most of the urea is removed when the CyaA coats the crystals. This is necessary 
if the PCMC preparations are to be used as a vaccine and hence the fact that there seems 
to be very little urea present in PCMC preparations is encouraging. Further work needs 
to be conducted with a range of CyaA-PCMCs, prepared with other components such 
as the inclusion of vaccine adjuvants, and a more detailed parallel investigation should 
be made into their immunological properties so as to provide a deeper understanding of 
this promising technique.
4-5 Humoral responses to CyaA-CaM-BSA-PCMCs
The aim of this part of work was to show that CyaA, after incorporation into PCMCs, 
was still immunogenic. Accordingly, BALB/c were immunised with CyaA-CaM-BSA- 
PCMCs or BSA plus CaM. Purified CyaA was used which showed in SDS-PAGE as a 
200-kDa protein with a high level of AC enzymic and cytotoxicity activities. 
Immunisation with two doses of CyaA-CaM-BSA-PCMCs gave rise to high anti-CyaA 
IgG titres (Figure 3.13.1). These results are consistent with previous studies presented 
by Hormozi et a l  (1999) and MacDonald-Fyall et a l  (2004) who reported that CyaA 
was highly immunogenic in mice and was able to stimulate serum anti-CyaA IgG 
antibody responses. The serum from PCMC-immunised mice was also able to neutralise
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the enzymic and cytotoxic activities of CyaA, which indicated that the structural 
integrity of CyaA was retained in the PCMCs such that the antibodies that were 
produced recognised the native toxin. A similar study was done by Murdan et a l  (2005) 
with diphtheria toxoid (DT) as a model antigen. DT was used to make DT-coated 
microcrystals with L-glutamine and the PCMCs were then dissolved in buffer and 
administered intramuscularly to mice following by a booster dose of the same material 
after four weeks. The DT-specific antibody in serum on day 42 was detemiined by 
ELISA, which showed a strong IgG response. However, neutralisation studies of toxin 
activity were not performed.
PCMCs offer a number of advantages for the preparation of biomolecules for vaccine 
or drug delivery as the process is straightforward to apply and does not require 
specialist laboratory equipment and, importanly, particles show good stability towards 
stress conditions of high temperature and humidity. The overall conclusion from the 
present study was that PCMCs of CyaA co-precipitated with CaM and BSA could be 
used for immunisation to induce specific antibody responses to the toxin. Further work 
needs to be conducted with the inclusion of vaccine adjuvants and more detailed 
investigation onto immunological responses after storage of PCMCs at ambient 
temperature. In addition, time did not allow an assessment as to whether immunisation 
of mice with CyaA-PCMCs allowed protection against challenge with virulent B. 
pertussis.
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Appendix A: Media composition
A .l Luria Bertani agar (LB)
Tryptone (BDH Laboratory supplies) 10 g
Yeast extract (BDH) 5 g
sodium chloride 10 g
Add 1.2% (w/v) agar for solid media 
Made up to 1 litre in distilled water
A.2 Luria Bertani broth (LB)
Tryptone (BDH Laboratory supplies) 10 g
Yeast extract (BDH) 5 g
sodium chloride
Made up to 1 litre in distilled water 10 g
A.3 Competence solution
CaClz 1.46 g
MnCL 1.384 g
sodium acetate 0.756 g
Made up to 100 ml in distilled water
A.4 TEB solution
Tris-Base 54 g
boric acid 27.5 g
EDTA (0.5M) 20 ml
Made up to 1000 ml in distilled water
Appendix B: CyaA expression and purification buffers
B .l Histidine buffer
histidine (20 mM) 0.0314 g
Made up to 100 ml in distilled water and adjusted to pH 6.0
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B.2 Urea in histidine buffer (Equilibration buffer)
urea (8  M) 48 g
histidine (20 mM) 0.0314g
Made up to 100 ml in distilled water and adjusted to pH 6.0
B.3 Washing buffer
urea (2 M) 12 g
histidine 0.0314 g
sodium chloride (0.3 M) 1.75 g
ammonium sulphate (0.8 M) 10.57 g
Made up to 100 ml in distilled water and adjusted to pH 6.0 
B.4 Eluting buffer (A)
urea (8 M) 48 g
sodium chloride 0.584 g
histidine (20 mM). 0.0314 g
Made up to 100 ml in distilled water and adjusted to pH 6.0
B.4 Eluting buffer (B)
urea (8 M) 48 g
sodium chloride 1.168 g
histidine (20 mM). 0.0314 g
Made up to 100 ml in distilled water and adjusted to pH 6.0
B.4 Eluting buffer (C)
urea (8 M) 48 g
sodium chloride 1.75  g
histidine (20 mM). 0.0314 g
Made up to 100 ml in distilled water and adjusted to pH 6.0
B.5 Dilution solution
histidine (20 mM) 0.0314
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ammonium sulphate (4M ) 52.9 g
Made up to 100 ml in distilled water and adjusted to pH 6.0
B.6 Washing buffer (D)
urea (8 M) 48 g
histidine (20 mM) 0.0314
ammonium sulphate (0.8 M) 10.57 g
sodium chloride (0.3 M) 1.75 g
Made up to 100 ml in distilled water and adjusted to pH 6.0
B.7 Washing buffer (E)
urea (8 M) 48 g
ammonium sulphate (0.8 M) 10.57 g
sodium chloride (0.2 M) 1.168 g
histidine (20 mM) 0.0314 g
Made up to 100 ml in distilled water and adjusted to pH 6.0
B.8 Washing buffer (F)
urea (2 M) 12 g
ammonium sulphate (0.6 M) 7.92 g
histidine (20 mM) 0.0314 g
Made up to 100 ml in distilled water and adjusted to pH 6.0
B.9 Eluting buffer
urea (8 M) 48 g
ammonium sulphate (0.32 M) 4.3 g
sodium chloride (0.08 M) 0.446 g
histidine (20 mM). 0.0314 g
Made up to 100 ml in distilled water and adjusted to pH 6.0
B.IO PCMCs buffer for immunisation
Naz H P 0 4 ( 1  M) 57.7 ml
Na H2PO4 (1 M) 42.3 ml
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Dilute the combined stock solution to 1000 ml with 
distilled water adjusted to pH 7.3
Appendix C: Protein analysis solutions
C.l Separating gel (7.5 % )
acrylamide/bis solution 2.5 ml
dHzO 3.8 ml
Tris-HCl (1.5 M, pH 8 ) 3.75 ml
20% (w/v) SDS 100 [il
TEMED 10 /il
10% (w/v) ammonium persulphate (APS) 100 /il
C.2 Separating gel (15%)
acrylamide/bis solution 5 ml
dHzO 1.3 ml
Tris-HCl (1.5 M, pH 8) 7.6 ml
20% (w/v) SDS 100 /il
TEMED 10 /il
10% (w/v) Ammonium persulphate (APS) 100 /il
C.3 Stacking gel
acrylamide/Bis solution 157 /il
dHzO 7 1 4 /il
Tris-HCl (0.5 M, pH 6 .8) 300 /il
20% (w/v) SDS 11.9/il
TEMED 1.18 /il
10% (w/v) Ammonium persulphate (APS) 6 /il
C.4 Protein loading buffer
glycerol 5 ml
20% (w/v) SDS 2.5 ml
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2-mercaptoethanol 
Tris (0.5 M, pH 6.8) 
bromophenol blue
C.5 Coomassie gel stain
coomassie blue 
methanol 
acetic acid
Made up to 1000 ml in distilled water
C.6 Destain buffer
methanol 
acetic acid
Made up to 1000 ml in distilled water
0.5 ml 
2.5 ml 
0.25% (w/v)
0.5 g
50 ml 
100 ml
50 ml 
100 ml
Appendix D: Silver stain buffer
D .l Fixing buffer (40% ethanol-5 % acetic acid)
absolute ethanol 400 ml
acetic acid 50 ml
Made up to 1000 ml in distilled water
D.2 Staining buffer
sodium hydroxide (O.IM) 28 ml
ammonium hydroxide 2 ml
silver nitrate 20% (w/v) e.g. (1 g silver nitrate in 5 ml of water) 5 ml
Distilled water 115 ml
D.3 Developing buffer
formaldehyde (37%) 
citric acid 
Distilled water
0.5 ml 
2ml 
200 ml
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Appendix E: Western blotting solution
E. 1 Electroblotting buffer
Tris base 7.2 g
glycine 33.4 g
dHzO 2000 ml
methanol 600 ml
Make up to 3000 ml with dHaO and adjusted to pH to 8.0
E.2 Blocking buffer
Marvel skimmed milk 6 g
Tween 20 400 fi\
dH2 0  200 ml
E.3 DAB solution
3-3’ diaminobenzidine (DAB, Sigma)) 0.05 g
PBS 98 ml
CoC12 (1%) w/v 2 ml
H2O2 (30%) 100 fil
Appendix F: CyaA enzymic assay
F .l Bicine buffer
Bicine 10 mM
magnesium acetate 1.5 mM
ATP 0.5 mM
pH to 8.0
Appendix G: Immunological assays
G .l Carbonate Coating Buffer
Na2C0 3  anhydrous 1.59 g
NaHCOs 2.95 g
NaNs 0.5 g
Made up to 1 litre in distilled water and adjusted to pH 9.5
190
Appendix
G.2 Wash Buffer (IgG)
PBS
Tween 20 0.05%
G.3 Diluent and Blocking buffer
PBS
Tween 20 0.05%
foetal calf serum (Gibco) 10%
G.4. Acetate Buffer (X 10)
sodium acetate 68.04 g
glacial acetic acid 1632 (jlI
Made up to 1 litre in distilled water
1 9 1
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Appendix H: Detergent Screen 1 Formulation-Hampton Research
Reagent number Detergent MW Type
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20 
21 
22
23
24
C12E9
C12E8
n-Dodecyi-B-D-maltoside 
Sucrose monoiaurate 
CYMAL®-6
TRITON® X-100 
CTAB
Deoxy BIgChap
n-Deoyl-B-D-maltoside
LDAO
CYMAL®-5
ZWITTERGENT®3-12
Nonyl-B-D-glucoside
1
"S-0ctyl-(3-D-
thloglucoslde
□DAO
HECAMEG
n-Octanoylsucrose
Heptyl-8-D-thioglucoside
n-Octyl-3-D-glucoside
CYMAL®-3
O-HEGA-10
ZWITTERGENT0 3-1O
MEGA-8
n-Hexyl-B-D-glucoside
583.10
539.10
510.60
524.60
508.50
631.00
364.50
862.10
482.60
229.40
494.50
335.60
306.40
308.40
201.40
335.40
468.50
274.30
292.40
466.50
377.50
307.60
321.40
264.30
N=Non Ionic Z= Zwitterionic
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